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Abstract 
Parkinson’s disease (PD) is a complex neurodegenerative disorder, the aetiology of which 
is thought to be an interaction of genetic, biological and environmental factors. Its cardinal 
motor features, tremor, muscular rigidity, bradykinesia and abnormal gait occur 
relatively late in the course of disease, as a result of over 60% loss of dopaminergic neurons 
in the substantia nigra pars compacta. While most reported PD cases are sporadic, 5-10% 
of all cases are caused by several PD-causing genes including Parkin, PINK1, LRRK2, 
SNCA, SYNJ1, DJ-1 and EIF4G1. 
These PD genes were discovered using first-generation sequencing technologies which 
were expensive and time consuming. The development of high-throughput next generation 
sequencing technologies like whole exome sequencing (WES) has fast-tracked the 
discovery of disease-causing genetic mutations in various Mendelian disorders like PD. 
WES enables the screening of only the protein coding regions of the genome, to locate 
mutations which can interrupt cellular processes and lead to diseases. To date, WES has 
identified several PD-causing genes including CHCHD2, VPS35 and LRP10, implicating 
the dysfunction of pathways regulating mitochondrial, lysosomal and synaptic function. 
The aim of the present study is to combine WES technology and functional studies to 
identify a novel pathogenic mutation in a gene that could be implicated in the autosomal 
dominant form of PD in a South African Afrikaner family. To do this, a comprehensive 
filtration strategy was applied, combining various bioinformatic tools, in a step-wise 
analysis approach to assist in the filtration, interpretation and prioritisation of the NGS 
results. The bioinformatic tools used included SIFT, PolyPhen-2, MutationTaster, CADD, 
GERP++, Allen Brain Atlas, PANTHER and SWISS-MODEL. Once a single candidate 
gene was selected from the computational prioritisation, its protein expression was 
investigated in a disease relevant cell model using Western blotting.  
WES was conducted on three affected individuals yielding over 20,000 variants each. 
Quality control (sequence alignment, alignment postprocessing, variant detection and 
quality evaluation) and filtering only the co-segregating non-synonymous variants 
through bioinformatics analysis yielded nine variants. Sanger sequencing was used to 
verify these variants, and four variants in the genes ACTN3, CDC27, POU2F1 and 
TUBB6 were found to be sequencing artefacts. Five variants in the genes RFT1, NRXN2α, 
TEP1, CCNF and CFAP65 were found to be present in all four affected PD individuals of 
the family.  
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
Only one variant, p.G849D in NRXN2α, fulfilled the various prioritisation criteria. The 
mutation was not present in the unaffected family members, in 671 South African PD 
patients and in 192 ethnically-matched controls. Multiple online population frequency 
databases also showed that the variant had not been previously reported in any 
population. Using a web-based database containing the exomes of 3000 patients with 
neurological disorders, 50 PD patients were identified with 24 other variants in the 
NRXN2α gene including indel mutations and premature stop codons. Amongst the five 
verified candidates, the p.G849D NRXN2α variant was predicted to be pathogenic across 
all four functional prediction tools with the highest Combined Annotation Dependent 
Depletion (CADD) score (29,50). It was also found to have a very high GERP++ score 
denoting that the level of evolutionary constraint acting on this site is predicted to be very 
high. The p.G849D NRXN2α amino acid change was the most severe, from a small, non-
polar, side chain free amino acid, to Aspartic acid a larger, negatively charged amino acid. 
The homology modelling of the mutant vs wild-type revealed no change in the protein 
secondary structure but biochemically the substitution could lead to unwanted 
interactions with the neighbouring residues which could possibly affect the function and 
activity of the protein.  
Also, NRXN2α was found to be highly expressed in the substantia nigra which is the main 
region of the brain affected in PD pathogenesis. It is associated with pathways related to 
calcium channel regulation, transmembrane signalling receptor activity, neuronal cell 
adhesion, synaptic organization and neuroligin family protein binding at the synapse, 
which makes it a plausible candidate gene for PD. Additionally, for functional studies, SH-
SY5Y Neuroblastoma cells which are commonly used in vitro model for PD, were utilised. 
We investigated the endogenous NRXN2α levels in the SH-SY5Y cells and found that they 
produced detectable levels of the NRXN2α protein and were stably expressing this protein.  
In summary, by integrating WES and in vitro studies, we identified p.G849D NRXN2α, a 
variant possibly associated with the autosomal dominant form of PD in a South African 
Afrikaner family. To our knowledge, this is the first report of an association between 
NRXN2α and PD. As a candidate, NRXN2α is well-suited for future functional mutant 
characterisation studies that will elucidate the impact of variants in this gene and their 
relative contribution to the disease phenotype. The further study of NRXN2α in PD may 
provide critical insight into novel disease mechanisms or genetic interactions with 
established PD mechanisms. Ultimately, this could potentially lead to development of 
improved therapeutic modalities for this debilitating disorder. 
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Opsomming 
Parkinson se siekte (PS) is 'n komplekse neurodegeneratiewe siekte, waarvan die etiologie 
'n interaksie is tussen genetiese, biologiese en omgewingsfaktore. Die kardinale motoriese 
simptome,word beskyf as spierstyfheid en bradykinesie. Hierdie abnormale gang word 
relatief laat in die verloop van die siekte waargeneem dit is as gevolg van die 60% verlies 
van dopaminerge neurone in die substantia nigra pars compacta. Terwyl die meeste PS-
gevalle sporadies is word 5-10% van alle gevalle veroorsaak deur verskeie gene, insluitend 
Parkin, PINK1, LRRK2, SNCA, SYNJ1, DJ-1 en EIF4G1. 
Hierdie familiele PS-gene is ontdek deur gebruik te maak van eerste generasie sekwensie 
tegnologieë wat duur en tydrowend was. Die ontwikkeling van hoë-deursettingsvolgorde 
(NGS)-tegnologieë, soos die heel eksoom volgordebepaling (WES), het die ontdekking van 
siekte-veroorsakende genetiese mutasies in verskeie Mendeliese afwykings soos PS 
verspoedig. WES maak sifting van slegs die proteïenkoderende streke van die genoom om 
sodoende mutasies op te spoor wat sellulêre prosesse kan onderbreek en direk tot siektes 
kan lei. Tans het WES verskeie PS-veroorsakende gene geïdentifiseer, insluitend 
CHCHD2, VPS35 en LRP10 gene, wat geïmpliseer word in die disfunksie van paaie wat 
mitochondriale, lysosomale en sinaptiese funksie reguleer. 
Die doel van die huidige studie is om WES tegnologie en funksionele studies te kombineer 
om 'n nuwe patogeniese mutasie in 'n geen te identifier wat in die outosomale dominante 
vorm van PS in 'n Suid-Afrikaanse Afrikaner-familie geïmpliseer kan word. Om dit te kan 
doen is 'n omvattende filtreertegnologie toegepas. Hierdie filtreer-tegnologieë kombineer 
doeltreffende nuwe bioinformatika-instrumente wat elkeen verskillende take aanspreek 
in 'n stap vir stap analise-benadering om te help met die filtrering, interpretasie en 
prioritering van die NGS-resultate. Die bioinformatiese gereedskap wat gebruik word 
sluit in SIFT, PolyPhen-2, MutationTaster, CADD, GERP ++, Allen Brain Atlas, 
PANTHER en SWISS-MODEL. Sodra 'n enkele kandidaat-geen uit die 
berekeningsprioritering gevind was, was ‘n funksionele analiese gedoen om die gene-
uitdrukking in 'n siekte-relevante selmodel te ondersoek.  
WES is uitgevoer op drie geaffekteerde individue wat meer as 20 000,00 variante lewer. 
Gehaltebeheer (volgordebelyning, belyningsprosessering, variantdeteksie en 
kwaliteitevaluering) en die filter van slegs die mede-segregerende, nie-sinoniem variante 
deur bioinformatika-analise het nege variante opgelewer. Sanger-volgordebepaling is 
gebruik om die nege WES-variante te bevestig, en vier variante in die gene ACTN3, 
CDC27, POU2F1 en TUBB6 was bevind as volgorde artefakte. Terwyl vyf variante in die 
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gene RFT1, NRXN2α, TEP1, CCNF en CFAP65 gevind is, was dit teenwoordig in al vier 
die betrokke PS-individue van die familie. 
Slegs een variant van die p.G849D-variant in NRXN2α het aan die verskillende 
prioritisasiekriteria voldoen. Die mutasie was nie teenwoordig in die onaangeraakte 
familielede in plaaslike pasiënte en kontroles nie. Dit is ook nie binne aanlyn 
bevolkingsfrekwensie databasisse gevind nie. Met behulp van 'n webgebaseerde databasis 
met die uitkomste van 3000 neurologiese pasiënte, is 50 PS pasiënte geïdentifiseer met 24 
ander mutasies in die NRXN2α-geen, insluitend indel mutasies en voortydige stopkodons. 
Van die vyf vasgestelde kandidate word dit voorspel dat die p.G849D NRXN2α-variant 
patogenies is oor al vier funksionele voorspellingsgereedskap met die hoogste CADD-
telling. Daar is ook gevind dat dit 'n baie hoë GERP++-telling het, wat aandui dat die vlak 
van evolusionêre beperking wat op hierdie webwerf optree, baie hoog is. Die p.G849D 
NRXN2α-aminosuurverandering was die ernstigste, 'n klein, nie-polêre, ketting vrye 
aminosuur, bewerkstellig ’n verandering tot Aspartiensuur wat 'n groter negatief gelaaide 
aminosuur is. Die homologie modellering van die mutant teenoor die wildtiepe het geen 
verandering in die proteïen sekondêre struktuur geopenbaar nie, maar biochemies kan 
die verandering lei tot ongewenste interaksies met die naburige residue wat moontlik die 
funksie en aktiwiteit van die proteïen kan beïnvloed. 
Ook, NRXN2α was hoogs uitgedruk in Pars Reticulata van die substantia nigra, die 
hoofstreek van die brein wat in PS patogenese geraak word. Dit word geassosieer met 
paaie wat verband hou met kalsiumkanaalregulering, transmembraansein, 
reseptoraktiwiteit, neuronale adhesie, sinaptiese organisasie en neuroligin-familie-
proteïenbinding. Vir funksionele studies is SH-SY5Y-selle wat 'n gevestigde en algemeen 
gebruikte in-vitro-model is vir PS , gebruik. Ons het die endogene NRXN2α-vlakke in die 
SH-SY5Y-selle ondersoek en gevind dat hulle waarneembare vlakke van die NRXN2α-
proteïen produseer en hierdie proteïen stabiel uitdruk. 
Deur integere-sekwensvolgorde en funksionele studies te integreer, het ons p.G849D 
NRXN2α geïdentifiseer in 'n variant wat moontlik met ‘ n outosomale dominante vorm 
van PS in 'n Suid-Afrikaanse Afrikaner-familie geassosieer kan word. Ons weet dit is die 
eerste verslag van 'n assosiasie tussen NRXN2α en PS. As ’n kandidaat is NRXN2α geskik 
vir toekomstige funksionele mutasie karakteriserings-studies wat die impak van variante 
in hierdie geen en hul relatiewe bydrae tot die siekte fenotipe sal verhelder. Die verdere 
studie van NRXN2α in PS kan kritiese insig gee in nuwe siekte meganismes of genetiese 
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interaksies met gevestigde PS meganismes. Dit kan moontlik lei tot die ontwikkeling van 
verbeterde terapeutiese modaliteite vir hierdie afwykende siekte. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
viii 
 
Acknowledgements 
 
"What we do for ourselves dies with us.  
What we do for others and the world remains and is immortal..." 
~ Sir Albert Bigelow Paine, 1901 
 
This thesis is a culmination of the contribution of so many people. Their thoughts, 
energy, time, financial contribution, unplanned chats, sleepless nights, tears and 
prayers. To my supervisors (Prof Bardien, Dr Williams and Dr Cloete) who patiently and 
painstakingly walked me through this journey, I am because you were, I thank you. To 
my dear mother who taught me taught me that only perseverance will be rewarded, 
thank you so much. To the amazing lab mates who kept my spirits high with humour 
and sometimes a simple smile or hug, I appreciate you all. To the admin staff of the 
division whose contribution sometimes goes unnoticed, I saw you and thank you for all 
that you did for me. To the patients and their family who made this study possible, 
thank you so very much. Lastly, to my poor husband who listened to countless hours of 
“science talk” and now claims to have enough knowledge on genetics to write a review, I 
thank you too.  
It’s almost an injustice to thank but just a few, I therefore extend my heartfelt gratitude 
to everyone who in some way or form was a part of this journey. May the work done here 
not die with me but be a stepping stone on the search for answers and relief from this 
disease. The financial assistance of the National Research Foundation towards this 
research is hereby acknowledged. Opinions expressed and conclusions arrived at, are 
those of the author and are not necessarily to be attributed to the NRF. 
 
 
 
 
 
“And whatsoever ye do in word or deed, do all in the name of the Lord Jesus, giving 
thanks to God”
Stellenbosch University  https://scholar.sun.ac.za
ix 
 
List of Abbreviations 
AAO Age at onset 
AD  Autosomal dominant  
AP Atypical Parkinsonism 
AR Autosomal recessive 
BAM Binary Alignment/Map 
BLAST Basic Local Alignment Search Tool 
BSA  Bovine Serum Albumin 
CADD Combined Annotation Dependent Depletion 
CAF  Central Analytical Facility 
cDNA Complementary Deoxyribonucleic Acid 
CLB  Cell Lysis Buffer 
CNV Copy number variation 
DBS Deep brain stimulation 
DNA Deoxyribonucleic Acid 
EGF  Epidermal growth factor 
ExAC Exome Aggregation Consortium 
gDNA Genomic Deoxyribonucleic Acid 
GMQE  Global Model Quality Estimation 
HRM High resolution DNA melting 
KEGG Kyoto Encyclopaedia of Genes and Genomes 
LB Lewy bodies 
MAF Minor allele frequency 
MLPA Multiplex Ligation-dependent Probe Amplification 
MRI Magnetic resonance imaging 
MSA Multiple System Atrophy 
NGS Next generation sequencing 
NHGRI National Human Genome Research Institute 
NMS Non-motor symptoms 
NTC  No template control 
NR Not Reported 
NTC No template control 
PBS  Phosphate Buffered Saline 
PCR Polymerase chain reaction 
PD Parkinson’s disease 
PDB  Protein Data Bank 
Stellenbosch University  https://scholar.sun.ac.za
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PS  Parkinson se siekte 
PSP Progressive Supranuclear Palsy 
QMEAN Qualitative Model Energy Analysis 
REM Rapid Eye Movement 
RNA Ribonucleic Acid 
RT Reverse transcription 
SA South Africa 
SAM Sequence alignment/map 
SDS Sodium dodecyl sulphate 
SIFT Sorts Intolerant From Tolerant 
SNP Single nucleotide polymorphisms 
SSA Sub-Saharan Africa 
TA Annealing Temperature 
TM Melting Temperature 
UPDRS Unified Parkinson's Disease Rating Scale 
UTR Untranslated Region 
WB  Western blot 
WES Whole exome sequencing 
WGS Whole genome sequencing 
Stellenbosch University  https://scholar.sun.ac.za
xi 
 
Table of Contents 
Declaration ........................................................................................................................ ii 
Abstract ............................................................................................................................ iii 
Opsomming .........................................................................................................................v 
Acknowledgements ....................................................................................................... viii 
List of Abbreviations ....................................................................................................... ix 
Table of Contents ............................................................................................................. xi 
List of Figures ................................................................................................................. xv 
List of Tables ................................................................................................................. xvii 
Outline of Thesis ......................................................................................................... xviii 
Chapter One .................................................................................................................. - 1 - 
1. Introduction and Literature Review ............................................................ - 1 - 
1.1. Introduction to Parkinson’s Disease ........................................................................... - 1 - 
1.1.1. Background .......................................................................................................... - 1 - 
1.1.2. Neuropathology of Parkinson’s Disease ............................................................. - 1 - 
1.1.3. Motor and Non-motor Features of Parkinson’s Disease ................................... - 4 - 
1.1.4. Differentiating Parkinson’s Disease from Atypical Parkinsonian Syndromes.- 5 
- 
1.1.5. Diagnosis and Treatment of Parkinson’s Disease ............................................. - 5 - 
1.1.6. Prevalence and Incidence of Parkinson’s Disease ............................................. - 7 - 
1.2. Aetiology and Risk Factors for Parkinson’s Disease ................................................. - 8 - 
1.2.1. Sporadic Versus Familial Parkinson’s Disease ................................................. - 8 - 
1.2.2. Environmental and Demographic Factors of Parkinson’s Disease .................. - 9 - 
1.2.2.1. Toxins ................................................................................................................... - 9 - 
1.2.2.2. Caffeine ................................................................................................................ - 9 - 
1.2.2.3. Cigarettes ........................................................................................................... - 10 - 
1.2.2.4. Age ...................................................................................................................... - 10 - 
1.2.2.5. Gender and Hormones ...................................................................................... - 11 - 
1.2.3. Genetic Risk Factors of Parkinson’s Disease .................................................. - 11 - 
1.3. Whole Exome Sequencing Technology and its Contribution to Parkinson’s Disease 
Genetic Research ..................................................................................................................... - 14 - 
1.3.1. Next Generation Sequencing Technology and Whole Exome Sequencing .... - 14 - 
1.3.2. Advantages of Whole Exome Sequencing ........................................................ - 17 - 
1.3.3. Disadvantages of Whole Exome Sequencing ................................................... - 17 - 
Stellenbosch University  https://scholar.sun.ac.za
xii 
 
1.3.4. Computational Tools and Variant Filtration Approaches .............................. - 18 - 
1.3.5. Bioinformatic In-silico Tools to Assess Pathogenicity .................................... - 20 - 
1.3.6. Whole Exome Sequencing Approaches to Identify Parkinson’s Disease-causing 
Genes - 21 - 
1.4. History of Molecular Research of Parkinson’s Disease in South Africa ................. - 24 - 
1.5. The Present Study ..................................................................................................... - 26 - 
1.6. Aims and Objectives .................................................................................................. - 28 - 
Chapter Two ................................................................................................................ - 29 - 
2. Materials and Methods .................................................................................. - 29 - 
A. Whole Exome Sequencing Analysis and Prioritisation ............................... - 29 - 
2.1. Participant Recruitment ............................................................................................ - 29 - 
2.1.1. Ethical Considerations ...................................................................................... - 29 - 
2.1.2. Study Participants and Selection Criteria ...................................................... - 29 - 
2.1.3. Extraction of gDNA from whole blood ............................................................. - 29 - 
2.2. Whole Exome Sequencing ......................................................................................... - 30 - 
2.3. Polymerase Chain Reaction Primer Design ............................................................. - 31 - 
2.4. Polymerase Chain Reaction ...................................................................................... - 33 - 
2.5. Gel Electrophoresis .................................................................................................... - 33 - 
2.6. Post-Polymerase Chain Reaction Purification for Sanger Sequencing .................. - 33 - 
2.7. Bioinformatic In-silico Analysis of Variants ............................................................ - 34 - 
2.8. Population Frequency Evaluation ............................................................................ - 35 - 
2.8.1. High Resolution Melt Analysis ......................................................................... - 35 - 
2.8.2. Online Population Frequency Databases ........................................................ - 36 - 
2.9. Pathway and Expression Analysis............................................................................ - 36 - 
B. Investigating the Prioritised Gene .................................................................. - 36 - 
2.10. Frequency of NRXN2α Variant in Patient Group ................................................... - 36 - 
2.11. Protein Structure Homology Modelling .................................................................... - 37 - 
2.12. Prioritised Gene Primers ........................................................................................... - 38 - 
2.13. cDNA Synthesis ......................................................................................................... - 41 - 
2.14. cDNA Quantification and Quality Assessment by Absorbance .............................. - 42 - 
2.15. cDNA Quality Assessment by Polymerase Chain Reaction .................................... - 42 - 
2.15.1. Amplification of Exon 1 To Exon 2 of HBB from cDNA .................................. - 42 - 
2.15.2. Amplification of Exon 2 To Exon 5 of PARK2 from cDNA ............................. - 43 - 
2.16. Culturing SH-SY5Y Cells for Protein Expression Studies ...................................... - 44 - 
2.16.1. Thawing of SH-SY5Y Cells from Frozen Stocks ............................................. - 44 - 
2.16.2. Removing Freezing Media from Frozen Stocks ............................................... - 44 - 
2.16.3. Sub-culturing of SH-SY5Y Cells ...................................................................... - 45 - 
Stellenbosch University  https://scholar.sun.ac.za
xiii 
 
2.16.4. Lysis of SH-SY5Y Cells ..................................................................................... - 45 - 
2.16.5. Bradford Assay for Determination of Protein Concentration in Cell Lysates- 45 
- 
2.17. Western Blot Analysis of Endogenous NRXN2α Expression .................................. - 46 - 
2.17.1. Membrane Blocking and Antibody Binding .................................................... - 46 - 
2.17.2. Chemiluminescent Detection ........................................................................... - 46 - 
2.17.3. Optimisation of Primary Antibody Dilution .................................................... - 47 - 
2.17.4. Quantification of Western Blot Signal ............................................................. - 47 - 
Chapter Three ............................................................................................................. - 49 - 
3. Results .............................................................................................................. - 49 - 
A. Whole Exome Sequencing Results and Prioritisation ................................. - 49 - 
3.1. Identifying the Family ............................................................................................... - 49 - 
3.2. Whole Exome Sequencing ......................................................................................... - 52 - 
3.3. Sanger Sequencing Validation of Variants .............................................................. - 54 - 
3.4. Bioinformatic In-silico Analysis Using Functional Prediction Tools...................... - 59 - 
3.5. Frequency of Variants in Controls ............................................................................ - 61 - 
3.5.1. Screening Online Frequency Databases .......................................................... - 61 - 
3.5.2. Screening the Local Population ........................................................................ - 61 - 
3.6. Pathway and Expression Analysis............................................................................ - 64 - 
3.7. Selection of Functional Candidate from Gene List ...................................................... 67 
B. Results of Prioritised Gene Studies ..................................................................... 67 
3.8. Frequency of NRXN2α Variant in South African Parkinson’s Disease Patients ...... 67 
3.8.1. South African Parkinson’s Disease Patients ....................................................... 67 
3.8.2. International Cohort of Patients with Parkinson’s Disease ............................... 68 
3.9. Structural Analysis of NRXN2α Protein with and Without Mutation ....................... 71 
3.10. Generation of cDNA from Foetal Brain RNA Library ................................................. 72 
3.10.1. cDNA Quality Assessment by Spectrophotometry and Gel Electrophoresis .... 72 
3.10.2. cDNA Quality Assessment by Polymerase Chain Reaction ............................... 74 
3.11. Polymerase Chain Reaction of NRXN2α from cDNA .................................................. 78 
3.11.1. Amplification of Full-Length NRXN2α Inserts for Cloning ............................... 78 
3.11.2. Assessment of Polymerase Chain Reaction Using Large Products ................... 80 
3.11.3. Polymerase Chain Reaction of NRXN2α Using Internal Primers to Generate 
Full-length CDNA................................................................................................................... 81 
3.11.4. cDNA Synthesis Using a NRXN2α Specific Reverse Transcription Gene Primers
 82 
3.11.5. Intron Spanning Primers to Generate Smaller Fragments of NRXN2α cDNA 83 
3.12. NRXN2α Protein Analysis ......................................................................................... - 87 - 
Stellenbosch University  https://scholar.sun.ac.za
xiv 
 
3.12.1. Determining the NRXN2α Protein Concentration in Neuroblastoma Cells . - 87 - 
3.12.2. Western Blot Analysis of Endogenous NRXN2α Expression ......................... - 88 - 
Chapter Four ............................................................................................................... - 92 - 
4. Discussion ........................................................................................................ - 92 - 
4.1. WES Results and the Prioritisation Process ............................................................ - 92 - 
4.2. Neurexin Protein Family ........................................................................................... - 96 - 
4.3. Involvement of Neurexins in Human Disorders and Animal Studies .................... - 98 - 
4.4. Possible Effect of the Missense Variant in NRXN2α ............................................... - 99 - 
4.5. Study Limitations .................................................................................................... - 101 - 
4.6. Future Work ............................................................................................................. - 102 - 
4.7. Conclusion ................................................................................................................ - 102 - 
Reference List ............................................................................................................ - 104 - 
URL List ..................................................................................................................... - 140 - 
Appendices ................................................................................................................. - 142 - 
1. Appendix I ...................................................................................................... - 142 - 
1. Supplementary Tables ................................................................................................. - 142 - 
2. Appendix II .................................................................................................... - 161 - 
2. Supplementary Figures ............................................................................................... - 161 - 
 
Stellenbosch University  https://scholar.sun.ac.za
xv 
 
List of Figures 
Chapter 1 Page 
Figure 1.1 Transverse section of midbrain showing the difference in the 
substantia nigra of a healthy control and a PD patient. 
2 
Figure 1.2 Histological section of the substantia nigra zona compacta of a 
healthy control and a PD patient. 
2 
Figure 1.3 Stages in the evolution of PD-related pathology.  4 
Figure 1.4 Cost of sequencing a human genome over a 17-year period. 15 
Figure 1.5 Schematic representation of the NGS workflow. 16 
Chapter 2 
Figure 2.1 HRM curve analysis. 35 
Figure 2.2 NRXN2α Primer binding sites schematic diagram. 41 
Figure 2.3 HBB PCR cDNA and gDNA schematic diagram. 43 
Figure 2.4 PARK2 PCR cDNA and gDNA schematic diagram. 44 
Chapter 3 
Figure 3.1 Pedigree of family ZA253 49 
Figure 3.2 Sanger sequencing validation of WES co-segregating variants. 55 
Figure 3.3 HRM analysis performed on the G849D variant in NRXN2α 62 
Figure 3.4 NRXN2α G849D amino acid residues. 71 
Figure 3.5 Superimposition of the predicted NRXN2α G849D model onto the 
homologous template structure 
72 
Figure 3.6 Agarose gel electrophoresis to distinguish between genomic DNA 
and complementary DNA.  
74 
Figure 3.7 Visualisation of HBB products on a 1% agarose gel. 75 
Figure 3.8 Visualisation of PARK2 PCR amplification products on a 1% 
agarose gel. 
76 
Figure 3.9 Partial sequence chromatograph and alignment of the HBB cDNA 
fragments with an HBB cDNA reference. 
77 
Figure 3.10 Alignment of PARK2 cDNA fragment 77 
Figure 3.11 Visualisation of PCR products generated using full-length 
NRXN2α primers 
78 
Figure 3.12 NRXN2α optimised PCR products on a 1% agarose gel. 79 
Figure 3.13 The amplification of NRXN2α using Phusion® High-Fidelity DNA 
Polymerase Taq, on a 1% agarose gel. 
80 
Stellenbosch University  https://scholar.sun.ac.za
xvi 
 
Figure 3.14 The amplification of the p2Nsm3125LS plasmid product shown on 
a 1% agarose gel. 
80 
Figure 3.15 PCR amplification of shorter NRXN2α primers on a 1 % agarose 
gel. A. 
81 
Figure 3.16 NRXN2α gene specific primers cDNA synthesis. 82 
Figure 3.17 Gel electrophoresis of PCR products using the primers to generate 
smaller fragments of NRXN2α 
84 
Figure 3.18 Sequence chromatograph and alignment exon 2 to exon 7 cDNA 
product. 
85 
Figure 3.19 Sequence chromatograph and alignment of exon 19 to exon 22 
cDNA product. 
86 
Figure 3.20 SH-SY5Y cell line proliferation 88 
Figure 3.21 Protein assay standard curve 89 
Figure 3.22 Western blot showing endogenous NRXN2α expression in 
proliferating in SH-SY5Y cells. 
90 
Chapter 4 
Figure 4.1 Schematic structure of the two major isoforms (alpha and beta) of 
the NRXN2 proteins. 
97 
Figure 4.2 Schematic representation of NRXN(NX) and NLGN(NL) complex 
formation at the synaptic cleft. 
97 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
xvii 
 
List of Tables 
Chapter 1 Page 
Table 1.1 List of genes conclusively implicated in Mendelian forms of PD. 12 
Chapter 2 
Table 2.1 WES co-segregating variant primers for amplification and HRM 32 
Table 2.2 NRXN2α Gene amplification primers and PCR conditions 38 
Table 2.3 NRXN2α specific 3’ UTR reverse transcription primers 39 
Table 2.4 NRXN2α intron flanking primers 40 
Table 2.5 Primer sequences for HBB reference gene 42 
Table 2.6 Primer sequences for PARK2, exon 2 to exon 5. 43 
Table 2.7 Characteristics of the relevant antibodies used in western blot 
analysis 
47 
Chapter 3 
Table 3.1 Clinical information of multiplex Afrikaner South African Family 51 
Table 3.2 Summary of metrics of WES in the three affected individuals 52 
Table 3.3 Rare and novel exonic variants shared between individuals 12.726, 
11.844 and 92.32 after variant filtering. 
53 
Table 3.4 Genotyping of the five validated variants in the family. 58 
Table 3.5 Computational tool scores and predictions for validated variants 60 
Table 3.6 Allele frequencies for the five variants in multiple control 
populations. 
63 
Table 3.7 Summary of the expression and pathway analysis for the five 
proteins 
65 
Table 3.8 The screening results of exome data base Annex for NRXN2α 
variants 
69 
Table 3.9 cDNA concentration and purity results obtained from NanoDrop 73 
 
 
Stellenbosch University  https://scholar.sun.ac.za
xviii 
 
Outline of Thesis 
Chapter 1 provides background information on PD with emphasis on the advances in sequencing 
technologies and the PD genetics research that has been conducted in South Africa to date. The present 
study describes the scientific value of the work and it is followed by the main objectives of the project.  
Chapter 2 is the Materials and Methods which describes how the experiments were conducted. It is 
written in two sections; the first section is of the investigation of the whole exome sequencing data using 
bioinformatics tools to estimate the impact of the detected single nucleotide variants. This is followed 
by filtration based on set criteria and the resulting process of candidate gene prioritisation. Sanger 
sequencing was used to validate the presence of WES variants discovered in the PD patients. Then last 
to be described is the determination of the variant frequencies in multiple control populations. 
The second section was of the Methods and Materials is the investigation of the prioritised gene. This 
included determining the variant frequency in the local PD population as well as an international cohort 
of PD patients. The structural homology modelling of the wild-type and mutant protein were done, to 
determine the impact of the variant on protein folding and amino acid interactions. Multiple attempts of 
generating cloning inserts ensued, before functionally determination the endogenous protein levels of 
the prioritised gene in a neuroblastoma cell line. 
Chapter 3 is the results section, it contains the findings of the study in the same sequential order as the 
methodologies. Documenting the WES analysis results, filtration criteria and the candidate 
prioritisation. And the following section having the results of all that was done to characterise the 
prioritised gene.  
To conclude is Chapter 4, which has a detailed discussion on the findings of the study, the potential 
implications of these results, study limitations, and recommendations regarding further research. 
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Chapter One 
1. Introduction and Literature Review 
1.1. Introduction to Parkinson’s Disease 
1.1.1. Background 
The clinical syndrome described as Parkinson’s disease (PD) [OMIM #168600] was first 
documented in western medical literature by a London-based doctor, James Parkinson, in 
1817. Dr. Parkinson wrote a medical case report entitled “An Essay on the Shaking Palsy” 
(Parkinson, 1817), and in his report he often referred to older findings of this “shaking 
palsy” by scholars before his time including the Italian artist, engineer and scientist 
Leonardo da Vinci (1489-1506) and the late Roman physician Claudius Galenus (1200 - 
1350 Anno Domini) (Forno, 1996). 
Preceding this account, PD as a disorder had been identified and treated in different parts 
of the world since ancient times. One clear description of this can be found as early as 300 
BC in the ancient Indian system of medicine of Ayurveda, where a disorder named 
Kampavata is described that is consistent with parkinsonism in all of its components 
(Ovallath and Deepa, 2013). Since then PD has become the second most common 
neurodegenerative disorder, affecting 1-2% of the global population above the age of 65 
years (de Rijk et al., 2000). Research has uncovered much about PD, but the underlying 
disease mechanisms remains a mystery.  
1.1.2. Neuropathology of Parkinson’s Disease 
The major neuropathological symptoms of PD include, but are not restricted to, 
dopaminergic neuronal degeneration, demyelination, gliosis and depigmentation of the 
substantia nigra (Jankovic, 2008; Hauser et al., 2016). The substantia nigra is responsible 
for muscle tone, ease of movement and learned muscle patterns (LaRocco, 2015) and its 
depigmentation is due to the loss of neuromelanin in the dopaminergic neurons of the 
locus coeruleus (Figure 1.1). It is estimated that when the motor symptoms of PD emerge, 
approximately 50-70% of dopaminergic neurons have already been lost from the 
substantia nigra (Cheng et al., 2010). 
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Figure 1.1 Transverse section of midbrain showing the difference in the 
substantia nigra of a healthy control and a PD patient. Shown on the far-left is the 
location of the substantia nigra in a transverse cross section of the brain A. Visibly dark 
normally distributed dopaminergic neurons in the substantia nigra of a healthy control. 
B. Severe depigmentation of the substantia nigra due to loss of neuromelaninated 
dopaminergic neurons of a PD patient. (Adapted with permission from A.D.A.M. 
https://medlineplus.gov/ency/imagepages/19515.htm ) 
Another major neuropathological symptom of PD is the presence of intracellular 
proteinaceous inclusions called Lewy bodies (LBs) and accumulations of alpha-synuclein 
filaments with granular material referred to as Lewy neurites (Figure 1.2) (Spillantini et 
al., 1998). Both these inclusions are found in brain regions such as the brainstem, cortical 
areas and locus ceruleus (Wakabayashi et al., 2007; Belin and Westerlund, 2008). Lewy 
pathology occurs in about 8–17% of neurologically normal people above the age of 60 (Gibb 
and Lees, 1988; Frigerio et al., 2011), this finding is termed incidental LBs. However, in 
PD patients the prevalence of these incidental LBs has been shown to increase 
aggressively with age (Gibb and Lees, 1988). It has been hypothesised that LB aggregation 
represents the pre-symptomatic phase of PD (Lacono et al., 2015). 
Figure 1.2 Histological section of the substantia nigra zona compacta of a 
healthy control and a PD patient. A. Immunohistochemical hematoxylin and eosin 
staining of zona compacta in a healthy control. B. Staining of the same region in a PD 
A. Normal substantia nigra B. Diminished substantia nigra in PD 
B. A. C. 
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patient shows the loss of pigmented neurons and neurons with the eosinophilic spherical 
LB. C. A magnified view of the pigmented neuron in the PD patient, containing 
eosinophilic cytoplasmic inclusions with a halo (Adapted with permission from 
http://neuropathology-web.org/chapter9/chapter9dPD.html ). 
Braak and colleagues investigated the neuropathology of PD in 41 patients (19 females, 
22 males, aged 75,7 ±7,2 years) who had all been clinically diagnosed with PD and all had 
accumulations of alpha-synuclein filaments (they exhibited nigral LBs and severe loss of 
nigral dopaminergic neurons). From this study they proposed that, within the central 
nervous system PD begins as a synuclein pathology in non-dopaminergic structures of the 
lower brainstem or in the olfactory bulb (Braak et al., 2002). They noted and demonstrated 
that the varying degrees of synuclein pathology depicted a sequence of events that 
progressed to affect the substantia nigra and ultimately caused parkinsonism (Braak et 
al., 2003). This concept was further investigated and developed into a staging of the 
pathology of PD and has become widely accepted with its observations now required for a 
definitive diagnosis of PD (Braak et al., 2007) (Moore et al., 2005). 
The Braak staging (Figure 1.3) proposes that in the earliest stage of PD, stage one, there 
is abnormal α-synuclein accumulation in either the medulla oblongata or the olfactory 
bulb. In stage two the LB pathology develops in the locus coeruleus in the pontine 
tegmentum of the brainstem. Stages three and four involves the development and increase 
of LBs as well as the severe loss of dopaminergic neurons in the substantia 
nigra/amygdala. It is at this stage of the pathology that the clinical signs of PD are visible, 
and it is then possible to diagnose PD by current clinical criteria. In stages five and six 
the synuclein pathology invades the neocortex and spreads into other the structures of the 
brain. Cell death occurs in the substantia nigra, both the motor and sensory areas of the 
brain are affected and the disease is at its most severe (Braak et al., 2002; Burke et al., 
2008; Halliday et al., 2011). 
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Figure 1.3 Stages in the evolution of PD-related pathology. Stylized representation 
of the Braak staging for Parkinson's disease showing the initiation sites in the medulla 
oblongata and olfactory bulb through to the later infiltration of Lewy pathology into the 
cortical regions (Halliday et al., 2011). Used with permission from John Wiley and Sons, 
Inc. 
1.1.3. Motor and Non-motor Features of Parkinson’s Disease 
The motor features of PD typically begin subtly, becoming prominent over time with 
tremor being the initial symptom that is most widely recognised (Hauser et al., 2016). In 
his clinical report Dr. Parkinson described the motor symptoms that define PD as: 
“Involuntary tremulous motion, with lessened muscular power in parts not in action, and 
even supported, with a propensity to bend the trunk forward, and to pass from a walking 
to a running pace, the senses and intellect being uninjured.”(Parkinson, 1817). 
Sixty years after the publication of this report, a French neurologist, Dr. Jean Martin 
Charcot, recognised the importance of Parkinson's observations and justly named the 
disease after Dr. Parkinson. Charcot further refined and expanded this early description 
of the disease by adding rigidity to what is now recognised as the four cardinal motor 
symptoms of PD; bradykinesia (slowness of movement), tremor (unintentional shaking), 
rigidity (muscular stiffness) and postural instability (balance impairment) (Kapur et al., 
2012). Over time more motor features have been identified though classified as minor 
because they only occur in a small fraction of all PD patients. These include reduction in 
dexterity (fine motor skills), coordination, and decreased arm swing on the first-involved 
side (Antonini et al., 2015). 
 
Dr. Parkinson also noted an array of symptoms that did not involve movement, 
coordination and physical tasks. These were later coined as non-motor symptoms (NMS) 
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and have become a hallmark of disease manifestation with some NMS preceding the motor 
symptoms by up to ten years. The most common being olfactory impairment, excessive 
production of saliva, sleep disturbances, dysphagia and autonomic dysfunction 
(constipation, bladder dysfunction and orthostatic hypotension) (Hauser et al., 2016).  
In advanced PD, patients experience NMS related to mild cognitive impairment which 
range from dementia, psychosis, bradyphrenia (slowing in cognitive abilities), 
hallucinations and depression (Meireles and Massano, 2012). The recognition of NMS and 
their impact on the patient’s quality of life has led to a significant shift in diagnostic and 
therapeutic approaches to the disease. 
1.1.4. Differentiating Parkinson’s Disease from Atypical 
Parkinsonian Syndromes. 
Atypical Parkinsonism (AP) is a term describing a spectrum of neurodegenerative 
disorders that have some of the classic features of PD but have additional symptoms that 
are not typically present in PD and have a different pathology. AP disorders include 
Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and Corticobasal 
Degeneration (CBD) (Behnke et al., 2005). It is vital to differentiate PD from AP as the 
treatment, symptoms and prognosis for each disease is different. The phenotypic 
symptoms present in AP but absent in PD are the onset of motor symptoms occurring on 
both sides of the body, experiencing falls early in disease manifestation, dementia 
accompanied by early cognitive decline and significant visual complications (Colosimo et 
al., 2010). 
The clinical differences between the two are that PD motor symptoms are typically 
alleviated by dopamine replacement in the form of Levodopa (LD) while AP patients 
exhibit poor or no response to LD (Hughes et al., 1992). This is because in PD the dopamine 
producing nerve cells in the substantia nigra are lost, however the nerve cells in the basal 
ganglia with dopamine receptors are preserved and capable of responding to treatment. 
Also, 5% to 10% of AP patients have lesions in other systems and a worse prognosis from 
disease onset (Trenkwalder et al., 2017). 
1.1.5. Diagnosis and Treatment of Parkinson’s Disease 
Currently, the commonly accepted method of PD diagnosis is the application of the 
stringent United Kingdom PD Society Brain Bank criteria by a trained neurologist 
(Hughes et al., 1992). This criteria states that the patient must have bradykinesia and at 
least one of the following; muscular rigidity, rest tremor (4–6 Hz) or postural instability 
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(Alfred Goldscheider, 1898; Clarke et al., 2016). This diagnostic screening criteria can be 
accompanied by an array of ancillary tests, such as genetic testing, olfactory testing, 
magnetic resonance imaging (MRI), and dopamine-transporter single-photon-emission 
computed-tomography imaging, to solidify diagnostic accuracy (Tolosa et al., 2006). 
There is currently no cure for PD nor is there any treatment that has definitively been 
shown to slow the progression of the disease. As a result, the treatments that have been 
developed are predominantly used to treat the various symptoms (Antonini et al., 2015). 
Most of the available medications are designed to help replace the dopamine deficiency 
that occurs in PD (Booker, 2012).  
The gold standard or primary medication dispensed is LD. It acts directly on the brain 
replenishing depleted dopamine stores as it is a precursor to dopamine with the unique 
ability of crossing the blood-brain barrier. Although it is the most effective medication for 
symptomatic treatment of the motor symptoms, this motor symptom suppressive effect 
will eventually wear off with chronic LD administration and disease progression (LeWitt 
et al., 2016). 
High frequency deep brain stimulation (DBS) is a surgical procedure for PD treatment 
that does not cure PD, but has been proven to diminish symptoms (Benabid et al., 2009). 
It involves implanting a small metal electrode into either the subthalamic nucleus, globus 
pallidus interna, or ventral lateral nucleus of the thalamus (Weaver, 2009). The 
advantages of DBS are that it improves symptoms like tremor, rigidity, and bradykinesia 
significantly, resulting in the decrease of prescribed LD doses by an average of 60% 
(Limousin et al., 1998; Groiss et al., 2009). The procedure is reversible and does not cause 
damage to brain tissue.  
A disadvantage of the DBS surgery is the risk of developing a postoperative stroke caused 
by bleeding in the brain. This can result in permanent brain damage or death, though it 
is reported that fewer than one percent of PD patients who have undergone DBS surgery 
have experienced a stroke (Stefani et al., 2007; Zrinzo et al., 2011). Other complications of 
DBS surgery include infection, malfunction of the neurostimulator and movement of the 
electrode (Limousin et al., 1998; Follett et al., 2010). 
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1.1.6. Prevalence and Incidence of Parkinson’s Disease 
Prevalence and incidence are epidemiological measures of disease frequency in 
populations. The prevalence is a ratio of the number of existing cases of a disease in a 
population of a defined size (de Lau and Breteler, 2006). In contrast, incidence is a rate of 
the number of new reported cases of disease in a population of a defined size, during 
specific time period (de Lau and Breteler, 2006).  
Globally, the prevalence of PD is predicted to be within the range of 41 per 100,000 people 
in the fourth decade of life (Pringsheim et al., 2014). In individuals aged 80 years and 
older it is predicted to be more than 1,900 people per 100,000 (Pringsheim et al., 2014; 
Cacabelos, 2017). Approximately 60,000 people were diagnosed with PD in the United 
States of America in 2002, and eight years later this number increased ten times to 
630,000 (Obeso et al., 2000, Kowal et al., 2013). In 2000, Europe had a prevalence of 1,803 
per 100,000 people above the age of 65 years, and this increased significantly with age to 
2599 per 100,000 people between 85 to 89 years (de Rijk et al., 2000). A review published 
by Dorsey et al., (2007) estimated the number of individuals suffering from PD in ten of 
the most populated countries in the world. This was reported to be between 4,1 and 4,6 
million people in 2005 and they also projected that the global PD prevalence is expected 
to increase twofold by the year 2030 (Dorsey et al., 2007). 
Compared to other regions, there is a lack of epidemiological studies in Sub-Saharan 
Africa (SSA) and the studies that have been conducted are either very old or have a very 
small sample size. The prevalence of PD in the countries of SSA is perceived to be 
considerably lower than that reported in the more developed countries. Previously Africa 
as a continent had been estimated to have similar rates of prevalence as those of China 
and Japan ranging between 88 to 133 per 100,000 people (Zhang and Román, 1993). A 
review of SSA prevalence studies conducted in 2013 estimated an even lower prevalence 
of PD in SSA, between 7 to 20 per 100,000 people (Blanckenberg et al., 2013). To date, 
there have only been 12 prevalence studies conducted in SSA (Cosnett, 1973; Lombard 
and Gelfand, 1978; Osuntokun et al., 1987; Schoenberg et al., 1988; Haimanot et al., 1990; 
Benamer et al., 2008; Dotchin et al., 2008; Winkler et al., 2010; Akinyemi, 2012; Femi et 
al., 2012; Cubo et al., 2014; Kisoli et al., 2015) which is composed of 51 countries with a 
population of a billion citizens (Department of Economic and Social Affairs, 2016).  
In SA, it has been 45 years since the first and only prevalence study was conducted in a 
neurology unit of a Durban public hospital cohort in 1973. The calculated prevalence of 
PD in the black SA population was 150 per 100,000 people, in the SA Indian population it 
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was 1,260 per 100,000 people, while the prevalence of PD in the Caucasian SA population 
was 2,310 per 100,000 people (Cosnett, 1973).  
The annual incidence rate of PD globally differs greatly between populations ranging from 
5 per 100,000 to 346 per 100,000 people per year in European countries (Campenhausen 
et al., 2005) versus in China where it is between 1,5 per 100,000 to 8,7 per 100,000 people 
per year (Zou et al., 2015).The only reported incidence rate estimate for PD in a SSA 
population came from a study done in North Africa that had included the Arabs of Eritrea 
as part of the North African patient cohort (Benamer et al., 2008). The calculated annual 
incidence rates of PD in the North African Arabs between 1982 and 1984 was reported to 
range from 4,5 per 100,000 people, to 20 per 100,000 people per year (Benamer et al., 
2008). Multiple studies have inferred that PD might be more common in the Northern 
African Arabic population than the rest of SSA, and therefore this may not reflect the 
overall incidence. More data is required to confirm this (Okubadejo, 2008; Bardien et al., 
2010; Blanckenberg et al., 2013). 
1.2. Aetiology and Risk Factors for Parkinson’s Disease 
1.2.1. Sporadic Versus Familial Parkinson’s Disease 
PD can present in two forms, namely sporadic PD and familial PD. Familial PD is less 
prevalent as approximately only 10% of patients report a positive family history (Klein 
and Westenberger, 2012), but its causation is better understood when compared to 
sporadic PD. The discovery during the last two decades of gene mutations that are directly 
linked to acquiring heritable forms of PD [autosomal dominant (AD), autosomal recessive 
(AR), and sex chromosome linked] has confirmed the role of genetics in the development 
of PD. These mutations have also provided vital clues in understanding the molecular 
pathogenesis of PD (Klein and Westenberger, 2012). 
Sporadic PD is thought to be an interaction between genetic factors, environmental toxins, 
and oxidative stress which together ultimately impact neuronal loss (Lesage et al., 2006). 
The mechanisms believed to be involved in the development of sporadic PD include the 
aggregation of abnormal proteins (Langston, 2006), damage to cellular membranes, 
mitochondrial dysfunction (Winklhofer and Haass, 2010), impaired transportation in 
neural synaptic clefts (Belin and Westerlund, 2008), and ultimately programmed cell 
death (Perier et al., 2011). 
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1.2.2. Environmental and Demographic Factors of Parkinson’s 
Disease 
In the absence of a clear genetic cause for the majority of cases, environmental influences 
are thought to play an important role in the development of PD (Di Monte et al., 2002). 
These environmental risk factors include pesticides, organic solvents, metals, and air 
pollutants (Dick et al., 2007). There have also been environmental influences that have 
been found to exert beneficial effects against PD development, these include polyphenols, 
curcumin, green tea, coffee and nicotine (Abdel-Salam, 2019).  
1.2.2.1. Toxins 
A study by Langston and colleagues reported parkinsonism in a group of drug addicts 
following injection of self-produced drugs containing N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) (Langston et al., 1983). This toxin has been found to 
selectively damage cells in the substantia nigra by inhibiting Complex I (NADPH-
ubiquinone oxidoreductase I) of the electron transport chain, which leads to impaired ATP 
production, elevated intracellular calcium concentrations an increase in reactive oxygen 
species, and ultimately results in cell death (Watanabe et al., 2005).  
A well-researched form of toxin exposure is farming or rural living, which are both 
associated with a greater risk of PD (Seidler et al., 1996; Liou et al., 1997). Two toxins 
that has become evident through farming practices are the herbicide paraquat and the 
pesticide rotenone. Paraquat causes oxidative stress and rotenone inhibits mitochondrial 
complex I (Langston et al., 1983; Sherer et al., 2007). In multiple experimental models of 
PD, both toxins have been shown to induce the loss of dopaminergic neurons in the 
substantia nigra(Cacabelos, 2017). Over the years, other neurotoxins have emerged from 
the agricultural occupation including organophosphates, organochlorine, metals and 
carbamate (Hertzman et al., 1990; Semchuk et al., 1991, 1992, 1993; Di Monte et al., 2002; 
Dick et al., 2007). 
1.2.2.2. Caffeine 
The effect of caffeine on PD risk is well studied and it has been found that the consumption 
of caffeine rich beverages like green tea amongst Chinese or coffee amongst Caucasians 
results in a protective effect against PD (Ross et al., 2000). This finding is consistent with 
the results of studies conducted in Germany and Sweden (Ascherio, et al., 2001). Caffeine 
is a known antagonist to adenosine, which is a signalling molecule that binds to receptors 
specifically found on dopaminergic neurons of the basil ganglia to reduce the release of 
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dopamine. By inhibiting adenosine binding, caffeine temporarily induces the release of 
dopamine (Muñoz and Fujioka, 2018). This is one mechanism caffeine may employ to 
prevent neurodegeneration damage and decrease bradykinesia and rigidity in PD patients 
(Postuma et al., 2012).  
1.2.2.3. Cigarettes 
Despite the adverse health effects of cigarette smoking, a large number of studies have 
consistently found that smokers have a lower incidence of PD than non-smokers 
(Baumann et al., 1980; Grandinetti et al., 1994; Di Monte et al., 2002). This implies that 
smoking could be a protective factor for PD. It was found that the more years of smoking, 
rather than increased number of cigarettes smoked per day, was linked closely to lowering 
the risk of PD amongst smokers (Gorell et al., 1999; Hellenbrand et al., 1997). 
It is not clear why this occurs, but it has been found experimentally that in animal models 
nicotine interacts with receptors to protect dopaminergic neurons (Quik and Kulak, 2002). 
A number of studies has even shown the protective effects of nicotine against toxin, MPTP, 
further strengthening the nicotine neuroprotective hypothesis (Group, 2006, Muñoz and 
Fujioka, 2018). 
There have been other findings regarding cigarette smoking and PD. In case-control 
studies researchers observed a significantly lower risk of PD for smoking as early as 15 to 
20 years before symptom onset, but not for smoking 25 years before onset (Hernán et al., 
2001, Thacker et al., 2007). This suggests a temporal relationship between cigarette 
smoking and PD risk, with a lower risk amongst current smokers, than in former smokers. 
1.2.2.4. Age 
PD occurrence has been shown to directly increase with advancing age, making age the 
strongest risk factor for disease development (Driver et al., 2009; Reeve et al., 2014; 
Cacabelos, 2017). The mean age at onset of PD is approximately 60 years, with only 4% of 
all patients developing the early-onset form of PD before the age of 50 (Bower et al., 1999). 
It has been established that with advancing age there is naturally a decline in dopamine 
neuron function and an accumulation of dysfunctional cell organelles of neurons (Müller 
and Pedigo, 1994; Thal et al., 2004). However, in PD it is thought that the normal course 
of ageing is disrupted to such an extent that it results in a significant loss of dopamine 
producing neurons and thereafter PD symptoms (Calne and Langston, 1983). As 
populations grow older than before, due to advances in medicine and the abundance of 
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food, age-related illnesses like PD will become more common (Campbell and Tishkoff, 
2008; Ramsay et al., 2011).  
1.2.2.5. Gender and Hormones 
Studies have reported a higher occurrence of PD in men than in women. The overall 
annual incidence rate of PD in females 40 years of age and older is 37,55/100,000 compared 
to 61,21/100,000 people in males within the same age range (Hirsch et al., 2016). One 
study has suggested that observable higher risk of PD in males than in females is a result 
of the hormone oestrogen. It is highly expressed in females and thought to exert 
neuroprotective benefits (Saunders-Pullman, 2003). 
A study by Haaxma et al., (2007) conducted on 253 PD patients found several gender 
differences between patients. The female patients tended to be older than males at the 
age at onset. They more often presented a tremor dominant form of PD which has been 
associated with a slower disease progression. Also at onset, female PD patients had higher 
levels of striatal dopamine binding than men suggesting a more benign PD phenotype in 
females when compared to males (Haaxma et al., 2007). 
1.2.3. Genetic Risk Factors of Parkinson’s Disease 
Research on the genetic causes of PD over the past two decades has led to the discovery of 
several PD-causing or associated genes. Summarised in Table 1.1 are the established PD 
genes with mutations proven to be pathogenic. 
The AD PD genes identified include SNCA (PARK1,4), LRRK2 (PARK8), VPS35 
(PARK17), EIF4G1 (PARK18) and LRP10. The characteristics shared by these AD PD 
genes are typical PD, a good response to LD in the early stages of disease progression, LB 
formation and majority of these genes result in late-onset PD. The differences in 
associated disease phenotypes includes dementia, cognitive decline and sleep 
abnormalities in PD patients with SNCA mutations (Zarranz et al., 2004; Zarranz et al., 
2005), while patients with LRRK2 mutations show amyotrophy and/or severe dystonia 
(Zimprich et al., 2004; Gilks et al., 2005). VPS35 patients tend to have tremor dominant 
parkinsonism accompanied by muscle spasms and depression (Wider et al., 2008; Vilariño-
Güell et al., 2011),while PD patients with EIF4G1 mutations tend to exhibit mild disease 
with a few having dementia (Chartier-Harlin et al., 2011; Schulte et al., 2012). Patients 
who have mutations in the recently discovered LRP10 gene exhibited typical PD with 
dementia and in a small number of cases there were unique features observed such as 
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supranuclear gaze palsy and ideomotor apraxia (an inability to perform a gesture using a 
limb upon verbal command or by imitation) (Quadri et al., 2018). 
The AR PD genes include DJ-1 (PARK7), FBXO7 (PARK15), Parkin (PARK2), PINK1 
(PARK6) and SYNJ1 (PARK20) (Table 1.1). The characteristics shared by these AR PD 
genes are typical PD, majorly juvenile to early disease onset and LB pathology is generally 
absent. The differences in phenotype between these genes are that PARK2 and PINK1 
patients exhibit very similar disease phenotype with lower limb dystonia and no cognitive 
NMS (Ahlskog, 2009; Samaranch et al., 2010), whereas DJ-1 patients, although similar 
in phenotype to PARK2 and PINK1 patients, also exhibit early dementia and amyotrophy 
(Lesage and Brice, 2009). Patients with SYNJ1 mutations tend to have dystonia with 
rapid cognitive decline and seizures (Krebs et al., 2013). FBXO7 patients exhibit typical 
PD with pyramidal signs such as hyperreflexia, limb atrophy and spasticity (Di Fonzo et 
al., 2009). 
Table 1.1 List of genes conclusively implicated in Mendelian forms of PD. 
Gene (locus) Typical symptoms Mutations Average 
age at 
onset 
(Years) 
Reference 
Autosomal dominant 
EIF4G1 (PARK18) Late-onset 
Lewy bodies present 
 
p.R1205H ≥50 Chartier-Harlin 
et al. 2011 
Nichols - 2015 
Tucci et al 2012 
LRRK2 
(PARK8) 
Late-onset 
Good response to 
Levodopa 
Lewy bodies present 
Slow progression 
p.G2019S 
p.R1441G 
p.R1441C 
p.R1441H 
p.I2020T 
p.Y1699C 
p.R1437H 
≥50 Zimprich et al. 
 2004 
Ozelius et al. 2006 
Ujiie et al. 
2012 
LRP10 
(No PARK locus) 
Late-onset 
Lewy bodies present 
Progression 
p.G603R 
p.P699S 
p.Y307N 
p.R533L 
p.R235C 
p.1424+5delG 
(intronic) 
p.N517del 
n.A212Sfs17 
≥60 (Quadri et al., 
2018a) 
SNCA (PARK1,4) Variable onset 
Good response to 
Levodopa 
Dementia 
Cognitive decline 
p.A53T 
p.A30P 
p.E46K 
p.H50Q 
p.G51D 
Variable 
onset 
Polymeropoulos et 
al. 1996 
Klein et al.2009 
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Gene (locus) Typical symptoms Mutations Average 
age at 
onset 
(Years) 
Reference 
Lewy bodies present 
Fast progression 
p.A53E 
VPS35 (PARK17) Late-onset 
Good response to 
Levodopa 
Slow progression 
p.D620N 
p.P316S 
≥50 Vilariño-Güell et 
al. 2011 
Autosomal recessive 
DJ-1 
(PARK7) 
Early-onset 
Lewy bodies absent 
Slow progression 
Psychiatric features 
p.A39S 
p.E64D 
p.D149A 
p.Q163L 
p.L166P 
p.M261I 
dup168-185 
≥35 Bonifati et al 2003 
FBXO7 (PARK15) Juvenile or early-
onset 
Pyramidal signs 
Fast progression 
p.T22M 
p.R378G 
p.R498X 
≤20 Di Fonzo et al. 
2009 
Parkin 
(PARK2) 
Early-onset 
Lewy bodies absent 
Good response to 
Levodopa 
Slow progression 
Various point 
mutations 
Exonic 
rearrangements  
≥30  Kitada et al. 1998 
Lucking et al. 
2000 
Brüggemann, and 
Klein, 2013 
PINK1 
(PARK6) 
Early-onset 
Lewy bodies absent 
Good response to 
Levodopa 
Slow progression 
Various point 
mutations 
Exonic 
rearrangements 
≤50 Valente et al 2004 
Cazeneuve et al. 
2009 
Li et al. 2005 
SYNJ1 
(PARK20) 
Early-onset 
Cognitive decline 
Fast progression 
p.R258Q 
p.A320V 
p.A551V 
p.S1422R 
≤50 Krebs CE et al. 
2013 
(Quadri et al., 
2013) 
(Drouet and 
Lesage, 2014) 
Chen et al. 2015 
 
Several other genes associated with PD, have been identified (Appendix I, Table 1). 
However, most of these genes have only been found in a single family and to date there is 
no reported experimental studies on the impact of protein dysfunction leading to PD 
pathology. Further investigation is needed to elucidate their role in PD pathogenicity or 
their contribution to disease risk (Golbe et al., 2001). 
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1.3. Whole Exome Sequencing Technology and its Contribution to 
Parkinson’s Disease Genetic Research 
1.3.1. Next Generation Sequencing Technology and Whole Exome 
Sequencing 
The modern history of DNA sequencing technology began in 1977, when two methods 
namely chemical cleavage DNA sequencing and chain-terminating DNA sequencing were 
introduced (Maxam and Gilbert, 1977; Sanger et al., 1977). These first-generation 
sequencing technologies relied on the separation of DNA fragments of various sizes on 
polyacrylamide gels to determine the sequence of nucleic acids. Over time the Gilbert and 
Maxam method was replaced by Sanger sequencing because it was less complex and 
involved the use of less hazardous chemicals. The Sanger sequencing method has 
remained the “gold standard” of DNA sequencing for decades and was the core technology 
of the Human Genome Project. This project aimed to determine all three billion base pairs 
making up the human genome (International Human Genome Sequencing Consortium, 
2001). In 2001, after 15 years of effort the first human genome was sequenced by the 
Human Genome Project at an estimated cost of $2,7 billion (Lander et al., 2001; Venter et 
al., 2001).  
Over the years, DNA sequencing has advanced with the development of parallel 
sequencing high-throughput technology known as next generation sequencing (NGS). It 
is now a large-scale industry with specialised infrastructure of robotics, instruments, 
bioinformatics and computer databases. These technologies are different to Sanger 
sequencing where one run only produces a single forward or reverse sequencing read, 
whereas NGS allows millions of sequencing reactions to be carried out in parallel 
(Baudhuin et al., 2015). NGS presently enables researchers to sequence the entire human 
genome in under two weeks for approximately US $ 1506,00 (Figure 1.4) and the entire 
human exome (protein coding regions of DNA) of an individual for US $555,00 in under 
48 hours. This represents remarkable progress in reducing the cost and time of DNA 
sequencing by several orders of magnitude relative to first-generation sequencing 
technologies (Schwarze et al., 2018). 
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Figure 1.4 Cost of sequencing a human genome over a 17-year period. Since 2001 
the National Human Genome Research Institute (NHGRI) has tracked the costs 
associated with DNA sequencing of human-sized genomes. On the y-axis is the cost of 
sequencing in US Dollars and on the x-axis is time in years. The sudden and profound 
drop in cost observed between 2007 and 2008 represents the time when most sequencing 
centres transitioned from first-generation sequencing to NGS technologies (Used with 
permission from the NHGRI https://www.genome.gov/27565109/the-cost-of-sequencing-a-
human-genome/ ). 
The NGS workflow is typically made up of five main steps (Figure 1.5), first the sample 
collection phase where DNA isolation and purification from the samples of interest is 
performed. The DNA (for humans) may originate from a variety of sources and ideally 
between 10 and 20 μg of DNA is needed to produce a library (Mardis, 2008; Metzker, 2010). 
The second phase is library construction, where the DNA template is converted into a 
library of sequencing reaction templates. Each sequencing platform uses a slightly 
modified library preparation process, but in essence the DNA is randomly sheared into 
specific sizes suitable for sequencing by sonification, nebulisation or enzyme digestion 
(Mardis, 2008).  
The resulting DNA fragments are then ligated to platform specific adaptor oligos at both 
ends. If the sequencing is targeted at a specific region of the genome like the exome or at 
a certain group of genes, then enrichment of the target fragments for that region is done. 
Enrichment can be done using variable capture strategies such as hybrid capture, 
microdroplet PCR, or array capture techniques (Schuster, 2008; Mardis, 2008). 
The third phase of NGS is the library immobilization phase. This involves the DNA 
templates being separated into single strands and then attached by the already bound 
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oligo onto beads (Emulsion PCR) or a solid surface (Bridge PCR) before extension and 
amplification (Schuster, 2008; Mardis, 2008). This immobilization of the template strands 
allows for the millions of reactions to be carried out in parallel on each template. 
The fourth step of the NGS workflow is sequencing, this step greatly varies according to 
the platforms sequencing chemistry. The most commonly used sequencing chemistries are 
cyclic reversible termination, real-time sequencing, pyrosequencing, semiconductor 
sequencing and sequencing by ligation. This step results in the sequence of each template 
strand being read out after the incorporation of each base through fluorescence or 
chemiluminescence (Metzker, 2010). 
The final step of the NGS work flow is the data analysis, where bioinformatics programs 
convert the generated raw output to interpretable information. The detected read data is 
aligned to a reference or assembled de novo, then primary filtering removes duplicate 
reads and those that have low quality scores. Lastly single nucleotide polymorphisms 
(SNPs) and inversion-deletions can be identified before downstream interpretation of their 
impact (Mardis, 2008). 
 
Figure 1.5 Schematic representation of the NGS workflow. Sample collection, 
library construction, template immobilization, sequencing and detection. After the signal 
detection step, data interpretation begins with alignment, mapping, filtering and SNP 
calling using bioinformatic computational tools (Pillai et al., 2017) . Used with permission 
from Elsevier.  
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Whole genome sequencing (WGS), the most comprehensive NGS method, sequences the 
non-coding regions of the genome in addition to the exons. It has already proven its 
usefulness however, the large output of data obtained and the complexity in interpreting 
it remains a computationally intensive challenge (Meynert et al., 2014). WES another 
NGS approach, extracts only the protein coding fragments of the genome. The 
commercially available WES kits target all of the genes documented in Refseq (Pruitt et 
al., 2014). This typically will yield between 20,000 to 25,000 variants per individual 
(Bamshad et al., 2011).This constitutes approximately ~1,2% of the genome which 
provides the advantage of producing more manageable sequencing data output than WGS 
(Bamshad et al., 2011).  
1.3.2. Advantages of Whole Exome Sequencing 
The greatest benefit of WES has been the exponential increase in the rate of discovery of 
Mendelian disease genes (Bamshad et al., 2011). Previously, screening for mutations was 
conducted in known regions of interest. Currently, exomes which are predicted to harbour 
~85% of the mutations, can all be simultaneously screened (Botstein and Risch, 2003). 
This has been of great benefit in genetically heterogeneous conditions (single disease being 
caused by any one of a multiple number of alleles) like PD. It is cost effective and quicker 
than both Sanger sequencing and targeted gene panels, which lag behind in integrating 
newly associated disease genes (Ng et al., 2010). Apart from gene discovery, WES has also 
been useful in genetic diagnostic settings. Using WES Yang et al., (2013) correctly 
diagnosed 62 out of 250 children with neurological phenotypes, which is a higher 
diagnostic yield than the other genetic tests (karyotype, chromosomal microarray and 
Sanger sequencing) in a fraction of the time (Yang et al., 2013). 
Compared to WGS, WES yields greater sequencing accuracy in a fraction of the time. The 
amount of data generated from WES at 100X depth is ±5 gigabyte which is significantly 
less than WGS at the same depth yielding ±90 gigabyte (Cherukuri et al., 2015). Therefore, 
the data storage costs of WES are lower, data analysis is rapid and more manageable. For 
example, it is currently possible to sequence the exomes of three different individuals at a 
target coverage of 40X for the same cost as a single human genome at 30X coverage 
(Robert et al., 2014). 
1.3.3. Disadvantages of Whole Exome Sequencing 
In spite of the many successes, there are technological limitations to WES. One 
disadvantage is its inability to accurately detect structural variants such as inversions 
and translocations, as well as other types of variants such as non-coding variants, indels, 
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copy number variations and repeat expansions (Botstein and Risch, 2003; Krumm et al., 
2012). As the field is advancing this can be to some degree overcome by a number of tools 
that have been proposed in the literature, that detect structural variant signatures which 
are diagnostic of different rearrangements with high sensitivity and specificity when used 
in combination (Tattini et al., 2015). Some non-coding variants may be overlooked despite 
their importance for controlling gene transcriptional regulation or splicing (Fromer et al., 
2012). Although WES yields on average a higher coverage than WGS, the target coverage 
along the length of exons in WES is usually uneven. This causes errors in downstream 
analysis such as false-positive calls in variant calling analysis. Factors that affect 
coverage in WES include the size of the exon, the presence or absence of repeat elements, 
GC content and segmental duplications (Kozarewa et al., 2009; Belkadi et al., 2015). Other 
errors can occur during WES due to hybridisation not being stringent enough to 
differentiate between exons belonging either to genes with very similar sequences such as 
paralogues, pseudogenes, and gene family members (Gnirke et al., 2009).  
1.3.4. Computational Tools and Variant Filtration Approaches 
The approach of filtering through NGS data typically consists of the following steps: raw 
data quality assessment, alignment, variant calling, annotation, and then prioritisation 
(Bao et al., 2014). The quality of the raw data is first assessed using several tools such as 
FastQC (Andrews, 2016) (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), 
FastQ (http://homer.ucsd.edu/homer/basicTutorial/fastqFiles.html) and FASTX-Toolkit 
(Gordon and Hannon, 2010) (http://hannonlab.cshl.edu/fastx_toolkit/) to determine 
whether pre-processing steps such as base trimming, read filtering, or adaptor clipping 
are necessary. The sequences are then mapped/aligned, and this entails the cross-
referencing of the 20,000–25,000 SNPs to the reference genome using tools such as 
Sequence Alignment/Map (SAM) (Li et al., 2009) 
(http://software.broadinstitute.org/software/igv/sam), Binary Alignment/Map (BAM) (Li 
et al., 2009) (https://software.broadinstitute.org/software/igv/BAM), Bowtie2 (Langmead 
and Salzberg, 2012) (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml) and 
Novoalign (http://www.novocraft.com/products/novoalign/). 
Variant calling involves producing meta-information for each variant relative to the 
reference genome sequence, as well as quality metrics, like the overall number of reads at 
each position and the number and depth of alleles detected (Liu et al., 2013). Popular 
variant calling tools include SAMtools (Li et al., 2009) (https://samtools.github.io), GATK 
(McKenna et al., 2010) (https://software.broadinstitute.org/gatk/) and Atlas2 (Challis et 
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al., 2012) (https://www.hgsc.bcm.edu/software/atlas-2). After variants are called, 
annotation adds attributes such as genomic feature, gene symbol, exonic number, amino 
acid change and the effect of the variant on the gene product (non-sense, missense, splice-
site SNPs, insertion, deletion or inversion, etc.) (Rabbani et al., 2014). 
Prioritisation is the part of filtration that reduces the total number variants to a workable 
list of candidates. This process is versatile and varies across studies according to the 
methods and tools that are most informative and relevant. The ultimate purpose of 
prioritising, regardless of the combination of tools, is to remove any unreliable variant 
calls, to determine the frequency of variants in various populations and to assign priority 
to variants most relevant to that specific disease (Bao et al., 2014). 
A common step in filtration is to determine the population frequency of the variants. It is 
expected that Mendelian disease-causing alleles are extremely rare, if not absent, in the 
general population due to negative selection (Wong et al., 2003). The minor allele 
frequency (MAF) is the frequency of the less frequent allele at a given locus and in a given 
population. In AD alleles, the MAF would be expected to be low as the variants would not 
be commonly found in the general population, variants would be either novel or extremely 
rare. While the alleles responsible for causing AR diseases can be found in the general 
population (Wong et al., 2003). The MAF threshold of ≤1% is typically used to filter out 
polymorphisms. 
Publicly available online databases can be used to determine the frequency of the variant 
in different populations. The commonly used databases include the Exome Aggregation 
Consortium (ExAC) Database (Karczewski et al., 2017), the 1000 Genomes Project (Siva, 
2008, The 1000 Genomes Project Consortium, 2015), dbSNP (Sherry et al., 2001) and 
NHLBI Exome Sequencing Project (https://esp.gs.washington.edu/drupal/). Populations 
represented in these databases include, but are not limited to, the European (Non-
Finnish), African, East Asian, Latino and South Asian populations. The MAF threshold 
of ≤1% though useful, should be varied depending on the frequency of the disease in the 
population of interest and according to the expected penetrance of the candidate variant. 
Since the frequency of benign and pathogenic variants can differ between ethnicities, the 
variant might be absent in one population but commonly found in another (Wong et al., 
2003). Therefore, when determining the population frequency of variants, it is essential 
to also screen ethnically-matched populations. 
The degree of amino acid conservation can also be used to prioritise variants. Conservation 
prediction programs like GERP (Davydov et al., 2010), PhastCons (Siepel, 2005) and 
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PhyloP (Pollard et al., 2010) determine conservation by aligning human protein sequences 
to homologous protein sequences from other organisms. The rationale behind this is that 
the more conserved a region is within the multiple alignment, the more damaging an 
amino acid-changing variant at that position will be. Alternatively the less conserved the 
region is predicted to be, the more likely change will be tolerated (Davydov et al., 2010). 
The final step of variant prioritisation is usually the predicting of effects of protein coding 
sequence changes. To do this bioinformatic in-silico approaches have been developed to 
predict the functional impact of a SNP on the protein’s structure and function (Patel et 
al., 2014). Each tool is unique in incorporating different information to make its prediction 
this includes evolutionary conservation, biochemical properties, statistical significance 
and what is commonly known from literature.  
1.3.5. Bioinformatic In-silico Tools to Assess Pathogenicity 
Numerous tools, capable of classifying both non-synonymous and structural variants are 
publicly available such as Provean (Protein Variation Effect Analyser) (Choi and Chan, 
2015), CADD (Kircher et al., 2014), FATHMM-MLK (Functional Analysis through Hidden 
Markov Models) (Shihab et al., 2015), GWAVA (Genome Wide Annotation of VAriants) 
(Ritchie et al., 2014) and MutationTaster (Schwarz et al., 2014).  
The most popularly used tools for pathogenicity prediction since their advent have been 
SIFT (Sorts Intolerant From Tolerant) (Ng and Henikoff, 2003) and PolyPhen-2 
(polymorphism phenotyping version 2) (Adzhubei et al., 2013). Both tools give probabilistic 
estimates based on conservation of protein sequence between species. Polyphen-2 
additionally incorporates the physicochemical features of amino acids, and structural 
features of protein to generate the predictions in a Bayesian fashion. These tools differ not 
just in their inference algorithms but also in composition of predictive features which 
explains their occasional contrasting predictions (Flanagan et al., 2010). Comparable 
performance tests can be found in their original reports (Ng and Henikoff, 2003;Kumar et 
al., 2009; Adzhubei et al., 2013), as well as in recent independent assessment studies (Li 
et al., 2013; Ghosh et al., 2017). Nonetheless, in terms of overall performance across the 
independent assessments conducted using known mutations, SIFT and PolyPhen-2 fare 
similarly on prediction accuracy. 
New meta-tools have been proposed that appear to achieve better performance, by 
combining prediction scores from multiple tools. CADD uses a unified score for the 
potential deleteriousness of all 8,6 billion possible human mutations by comparing 
variants that survived natural selection, with simulated mutations. The tool integrates 
Stellenbosch University  https://scholar.sun.ac.za
- 21 - 
 
63 predictive features in total, including SIFT, GERP++, PolyPhen-2 scores, as well as 
CPG distance and GC content. It measures deleteriousness, a property said to encompass 
both molecular functionality and pathogenicity, compensating for the incompleteness and 
bias of the existing predictive tools (Kircher et al., 2014). 
Multiple studies have assessed the utility of CADD to prioritise functional and disease 
relevant mutations. One such study was conducted by Bandaru et al., (2015) on previously 
been annotated and functionally validated WES data from a male of Chinese descent. As 
the variants impact outcomes were known the CADD C-scores predictions could be 
compared to the existing prediction tools for accuracy. The CADD C-score and predictions 
outperformed both the missense-only predictive tools and the conservation tools in 
predicting variant impact. Another study by Mather et al., (2016) had conducted germline 
cancer susceptibility testing on 624 patient samples that had generated 12,391 novel 
SNPs. Although accurate in the prediction of the missense variants, they concluded that 
the algorithm calculating the CADD score was limited in magnitude to effectively classify 
the significance of non-exonic variants. This sentiment had been previously expressed for 
the existing predictive tools and therefore none of them should be independently used to 
prioritise candidates (exonic and intronic) (Mather et al., 2016). 
Although they are greatly useful, functional prediction tools should not be the sole method 
of prioritisation, as each tool is based on certain assumptions and therefore have their 
own limitations. The groups that have produced these tools have emphasised that the 
terms damaging or deleterious should never be logically equated with causal for a disease 
phenotype. As a variant that damages a gene is not necessarily damaging to the overall 
health of an individual. These tools merely seek to improve filtration accuracy and should 
be used in combination where possible and in conjunction with additional sources of 
information such as knowledge about the molecular and cellular mechanisms involved in 
a disease or phenotype. 
1.3.6. Whole Exome Sequencing Approaches to Identify 
Parkinson’s Disease-causing Genes 
Before 2011, many of the earlier genetic studies on PD involved genetic linkage analysis 
which brought about the discovery of SNCA, LRRK2, PARK2, PINK1 and DJ-1 
(Polymeropoulos et al., 1997; Kitada et al., 1998; Bonifati et al., 2003; Valente et al., 2004; 
Paisán-Ruíz et al., 2004). However, this approach was labour intensive and expensive due 
to the large number of genes to be sequenced by Sanger sequencing. It also requires large 
pedigrees with both affected and unaffected individuals. WES presented the opportunity 
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to investigate all the known genes simultaneously. This has contributed to the discovery 
of new PD associated genes CHCHD2 (Coiled-Coil-Helix-Coiled-Coil-Helix Domain 
Containing 2), VPS35 (Vascular Protein Sorting 35) and LRP10 (Low-density lipoprotein 
receptor-related protein 10) all found in familial PD (Zimprich et al., 2011; Vilariño-Güell 
et al., 2011; Funayama et al., 2015; Quadri et al., 2018). 
The first studies that used WES to discover the PD associated gene VPS35 were conducted 
by Vilariño-Güell et al., (2011) and Zimprich et al., (2011). The study by Vilariño-Güell et 
al., (2011) was conducted on a multi-incident Swiss family with AD, late-onset PD. The 
affected family members had a mean age at onset of 50,6 ± 7,3 years and were tremor-
predominant with a good response to LD. They had been previously screened for the 
known PD mutations which were absent, and WES was applied to interrogate co-
segregating variants amongst the affected family members (Vilariño-Güell et al., 2011), 
identified 4,256 novel variants. 
Authors assumed AD inheritance of disease, and therefore excluded variants on the X-
chromosome and homozygous changes. Removal of the non-coding variants, synonymous 
changes, and variants present in dbSNP identified 69 variants. Sanger sequencing of the 
69 variants in one previously whole exome sequenced affected member, two additional 
affected family members and one unaffected family member, validated 33 variants, six of 
which co-segregated exclusively in family members with PD. Screening 184 randomly US 
control subjects of European descent for the six variants revealed that only two were not 
in the control population, namely one within the VPS35 gene and one in Integrin Subunit 
Alpha X (ITGAX). 
Both variants were subsequently genotyped in a multi-ethnic case-control series 
consisting of 4,326 patients and 3,309 controls. Nine affected individuals and none of the 
controls had the VPS35 Asp620Asn (c.1858G>A) variant. The VPS35 gene was found to 
be highly conserved and the p.Asp620Asn substitution was predicted to be a deleterious 
substitution (SIFT score = 0). Together, this information implicated the VPS35 
Asp620Asn (c.1858G>A) variant in being a strong candidate variant for PD. The second 
variant ITGAX p.Ala1012Val mutation was found in one control (61 years) and one 
affected individual (42 years at onset). The ITGAX gene was predicted to not be 
evolutionarily conserved, and p.Ala1012Val was not predicted to be deleterious (SIFT 
score = 0,16), and was authors concluded that ITGAX p.Ala1012Val was a rare variant 
(Vilariño-Güell et al., 2011). 
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Another study by Zimprich et al., (2011) performed WES on an Austrian family with 16 
affected individuals with late-onset PD. They discovered the p. Asp620Asn (c.1858G>A) 
mutation in VPS35 which co-segregated in seven out of the 16 affected family members. 
This variant was not found in the 860 sporadic PD cases and in the 1014 controls. Two 
additional families, with five and ten affected members with late-onset PD, were further 
screened and the p. Asp620Asn mutation in VPS35 co-segregated in both families with 
incomplete penetrance in an AD fashion. Additionally, sequence-based and molecular-
dynamics based predictive tools PolyPhen2, SNAP and SIFT were utilised and all the tools 
predicted the VPS35 p. Asp620Asn to be deleterious. A second variant in VPS35 was 
detected in a single sporadic PD case p.Arg524Trp (c.1570C>T) and was also predicted to 
be damaging by sequence-based and molecular-dynamics analyses (Zimprich et al., 2011). 
VPS35 is a protein critical for endosome-trans-Golgi trafficking and membrane-protein 
recycling (Vilariño-Güell et al., 2011).  
A study by Funayama et al., (2015) performed WES on a Japanese family with eight 
affected members who had an average age of onset of 55,5 ± 4,8 onset with AD PD. Four 
of the eight affected individuals were WES and a heterozygous variant p.T61I (c.C182T) 
in CHCHD2 was identified. The variant co-segregated variant in all eight affected 
individuals and was not present in five unaffected family members. The mutation was 
further screened and found in two out of 340 familial PD patients but not found in 517 
sporadic PD patients or 559 ethnically-matched controls. The variant was not found in 
online population databases 1000 genome and Human Genetic Variation Database 
(Funayama et al., 2015). CHCHD2 is known to regulate mitochondrial crista structure 
and maintaining the integrity of the mitochondrial respiratory complexes. The 
dysfunction of the gene has been shown to impair mitochondrial function significantly, 
this could be the mechanism by which it contributes to the PD pathology (Meng et al., 
2017) . 
A recent study used genome wide linkage analysis in an Italian family with ten affected 
individuals with an average age at onset of 59,8 years (± 8,7) to identify a novel locus on 
chromosome 14 (Quadri et al., 2018). WES was then performed on the index patient to 
identify candidate variants within that specific locus. The resulting variants were then 
filtered based on being non-synonymous variants in a heterozygous state, having a MAF 
of less than·1% in four online population frequency databases and lastly being predicted 
as pathogenic by at least five of 11 in-silico tools. The prioritised candidate LRP10 
p.G603R (c.G1807A) was present in all the affected individuals, absent the unaffected 
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family members and eight of the 11 functional prediction tools classified it as deleterious. 
All the exons of LRP10 were then screened for variants in 938 unrelated PD patients from 
seven different countries. This yielded an additional seven rare and potentially pathogenic 
LRP10 variants (p.G603R, p.P699S, p.Y307N, p.R533L, p.R235C, p.1424+5delG, 
p.N517del and n.A212Sfs17), present in multiple affected PD patients. Control screening 
was performed on 553 unrelated controls and 92 relatives of PD patients, using WES. Only 
one individual out of the 645 screened controls was found to have a variant (p.R151C) in 
LRP10 (Quadri et al., 2018). LRP10 has been shown to function as a shuttle between the 
Golgi network, endosomes, and plasma membrane similar and in pathways related to PD 
gene VPS35 (Steinberg et al., 2013).  
1.4. History of Molecular Research of Parkinson’s Disease in South Africa 
In comparison to the global advances in understanding the genetics of PD, studies on SSA 
populations have been scarce. The majority of genetic PD research in this region was 
conducted in SA and has focussed on candidate gene studies (all studies found 
summarised in Appendix I, Table 2). Autosomal dominant PD genes EIF4G1, GBA, 
GCH1, LRRK2, SNCA, VPS35 and autosomal recessive PD genes ATP13A2, DJ-1, Parkin 
and PINK1 have been assessed in SA PD patients using various assays, including KASP 
genotyping assay, dosage analysis MLPA (Multiplex Ligation-dependent Probe 
Amplification), HRM and Sanger sequencing.  
Of the five studies that screened for LRRK2 mutations in SA PD patients, only two studies 
identified SNPs (Bardien et al., 2010), (Keyser et al., 2010), (Blanckenberg et al., 2014), 
(Mahne et al., 2016), (Barkhuizen et al., 2017). The first study, involving 205 PD patients, 
found that four patients harbour the G2019S mutation in a heterozygous state (Bardien 
et al., 2010). Another study conducted by Trinh et al., (2015) screened all 51 exons of 
LRRK2 in four SA PD patients, and identified four rare non-synonymous variants that 
were unique to this population. Keyser et al. (2009), investigated SNCA in 88 patients, 
and only one affected individual was found to have three copies of the gene (Keyser et al., 
2009). None of the other AD mutations in known PD genes were found by various studies 
that were conducted on the SA population. (Keyser et al., 2010, Blanckenberg et al., 2014, 
Barkhuizen et al., 2017),. 
A study screening exon two and exon nine of ATP13A2 in 88 SA PD patients yielded none 
of the known mutations (Keyser et al., 2009). In DJ-1, a novel 16 bp deletion variant (g.-
6_+10del) was found in the 5’ untranslated region of the gene by two separate studies. The 
first study identified the g.-6_+10del variant in two out of 150 SA PD patients, however 
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screening of an additional 30 PD patients did not identify other individuals with this 
variant (Keyser et al., 2009). Subsequent screening of a larger cohort (402 SA individuals) 
for the g.-6_+10del variant identified in the same individual as the Keyser et al. (2009) 
study, representing an allele frequency of 0,1 % (1/804). This study also found another 
deletion g.168_185del present with an allele frequency of 0,6 % (5/804) using the KASP 
genotyping assay (Glanzmann et al., 2013). Variant g.168_185del was proposed to 
interfere in the role of DJ-1 in alleviating oxidative stress, however because it was present 
in both cases and controls, it was concluded that it was unlikely that it had a significant 
role in the development of PD in this population (Glanzmann et al., 2013). A luciferase 
assay was used to show that the g.-6_+10del variant reduces DJ-1 expression in the 
response to oxidative insults (Keyser et al., 2009). 
Mutations in the coding regions of the Parkin gene are the most common cause of early-
onset PD cases. These include heterozygous and homozygous point mutations, non-sense 
mutations and exonic deletions (Myhre et al., 2008). In SA PD patients, known mutations 
in PARK2 were found in four separate studies, in both heterozygous and homozygous 
forms (Keyser et al., 2009, Haylett et al., 2012, Mahne et al., 2016 ,Carr et al., 2016). A 
WES approach in an affected family identified two mutations, namely p.R275W and 
p.M432V, in homozygous forms in three PD patients, and in heterozygous form in three 
unaffected family members (Carr et al., 2016). Population screening on the ExAC database 
showed that the R275W variant had an allele frequency of 0,2%, whereas the M432V 
variant's frequency is 0,00096%. Bioinformatic tools PolyPhen2, MutationTaster and 
FATHMM predicted M432V as pathogenic with a CADD score of 20,6 (Carr et al., 2016). 
A separate study using MLPA and real-time PCR techniques identified the polymorphism 
p.M192L in 13 out of the 210 affected individuals (van der Merwe et al., 2016). The study 
also found that one patient out of the 210 had a heterozygous PARK2 exon 4 deletion. 
They concluded that the PARK2 mutations previously discovered in other populations 
were not a major contributor to PD pathology in the SA population (van der Merwe et al., 
2016). 
The screening for PINK1 variants in 154 SA PD patients using the HRM curve analysis 
and direct sequencing yielded a total of 16 sequence variants (Keyser et al., 2010). 
Thirteen of these were previously known polymorphisms, while five were novel. Two of 
the three remaining variants (p.Y258X and p.E476K) had been previously reported 
(Valente et al., 2004; Rogaeva et al., 2004; Bonifati et al., 2005; Abou-Sleiman et al., 2006; 
Keyser et al., 2009; Tan et al., 2006). The p.Y258X mutation was found in homozygous 
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form, and p.P305A and p.E476K were in heterozygous form (Keyser et al., 2010). The 
p.P305A variant, which was novel, was found in a black female patient who had a positive 
family history for PD with an age at onset of 30 years. The variant was predicted to be 
probably damaging by PolyPhen and was found to have an allele frequency of 1,9% (2/108) 
amongst the controls. Structural protein analysis showed the potential to modulate 
enzymatic activity due to its location in the kinase domain. (Keyser et al., 2010). Two other 
CNV studies that also screened the eight exons of PINK1 using MLPA and CNV but did 
not find any pathogenic mutations (Keyser et al., 2009, van der Merwe et al., 2016). 
A study conducted by van der Merwe et al., (2016) aimed to determine the CNV of multiple 
PD genes on 210 SA PD patients using MLPA (van der Merwe et al., 2016). The genes 
screened were SNCA, PINK1, LRRK2 (exons 1, 2, 8, 10, 15, 27, 49) and DJ-1 (exons 1, 3,5, 
7). The study calculated the combined frequency of exonic rearrangements in the known 
PD genes by including results from a previous study on 229 SA PD patients. The frequency 
of exonic rearrangements was reported to be 1,8% (8/439 patients) in SA PD patients 
(Keyser et al., 2009; van der Merwe et al., 2016; Haylett et al., 2012). This means that 
although CNV has been implicated in PD pathogenesis in other populations, in SA 
patients it is very rare and not a major contributing factor to PD pathogenesis.  
Lastly a large collaborative study performed by the Consortium of Genetic Epidemiology 
of Parkinson’s Disease (http://geopd.can.ubc.ca) combined PD patient populations from 
multiple countries, including 398 unrelated SA PD patients. These individuals were 
screened for polyglutamine repeat expansions in the Spinocerebellar Ataxia genes, but the 
study did not find any pathogenic repeat expansions in CACNA1A, TBP, ATXN2 or 
ATXN3 in the SA PD patients (Wang et al., 2015). 
1.5. The Present Study 
There is a clear disparity in the number of PD genetic studies conducted on SSA 
populations, in comparison to the studies conducted in Caucasian and Asian populations. 
This is thought to be due to extrinsic factors such as the lack of resources and skilled 
personnel, and the shorter life expectancy of SSA populations (Okubadejo, 2006, 
Blanckenberg et al., 2013). However, as the number of older people in SSA is growing 
faster than the rest of the world, there is an increasing need to study age-related diseases 
like PD in the SSA population (Velkoff et al., 2007).  
It is well established that the known PD mutations are minor contributors to disease 
aetiology in SSA populations (Bardien et al., 2009; Blanckenberg et al., 2013; Cilia et al., 
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2011; Glanzmann et al., 2013; Haylett et al., 2012; Keyser et al., 2009a, 2009b, 2010b; 
Okubadejo et al., 2008; Okubadejo, 2008; van der Merwe et al., 2016; Wang et al., 2015; 
Yonova-Doing et al., 2012). This further highlights the need to bridge the knowledge gap 
in the genetics of PD in SSA, by using new technologies to discover novel PD-causing genes 
or novel mutations in the known genes. Ultimately, this knowledge could make an 
important contribution to the current understanding of PD genetic aetiology both locally 
and globally. 
The present study investigated the potential genetic cause of PD in a SA Afrikaner family 
with multiple affected individuals. Given the uniqueness of this ethnic group, we 
undertook WES as an approach to identify a possible novel PD-causing gene in the family. 
The Afrikaner Caucasian population is unique to SA (Greeff, 2007) and is derived from 
settlers that arrived in SA thought to have mainly originated from the Netherlands, 
Germany and France (Heese, 1971). Initially, the settlers lived in isolated communities in 
relatively small communities, with very little admixture with the surrounding 
populations. This is thought to have contributed to the relatively high frequency of founder 
effects in this ethnic group. Some of the common Mendelian disorders in this population 
can even be traced back to specific founder couples. This includes progressive familial 
heart block (Brink et al., 1977), Huntington's disease (Hayden et al., 1980) osteogenesis 
imperfecta (Knoll et al., 1988), pseudoxanthoma elasticum (Saux et al., 2002), 
schizophrenia (Karayiorgou et al., 2004), long QT syndrome (Brink et al., 2005) and 
Fanconi's anaemia (Tipping et al., 2001).  
Notably, in a previous study conducted by our research group genealogical analysis 
revealed that six unrelated Afrikaner PD patients were related to a single founder couple 
that immigrated to SA in the 1600s, suggesting a possible founder effect for the disease 
(Glanzmann, 2013; Geldenhuys et al., 2014). The same study also aimed to identify novel 
PD-causing gene using WES, 21 variants were found to be shared by three unrelated 
Afrikaner PD patients (Glanzmann, 2013). This present study is different in that we will 
investigate the cause of PD in a single Afrikaner family. It is anticipated that studying a 
familial form of PD will increase the likelihood of discovering a novel PD-causing gene. 
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1.6. Aims and Objectives 
The aim of this study was to investigate the genetic aetiology underlying PD in a multiplex 
SA Afrikaner family. The aim was achieved through the following objectives: 
i. To perform WES on three PD affected family members. 
ii. To apply a comprehensive filtration strategy to prioritise only co-segregating variants 
(using bioinformatic tools) found in the three PD patients. 
iii. To validate the presence of variants discovered with WES and screen the unaffected 
family members for the variants by Sanger sequencing. 
iv. To perform high resolution melt (HRM) analysis to determine the frequency of the 
variants in ethnically-matched controls. 
v. To perform functional studies on a single prioritised candidate variant, to assess its 
potential functional effect. 
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Chapter Two 
2. Materials and Methods 
A. Whole Exome Sequencing Analysis and Prioritisation 
In this section we use WES to screen a multiplex family with PD, then validate the list of 
variants using Sanger sequencing. Computational analysis is then performed on the 
validated variants to predict the pathogenicity before prioritising the list of candidates to 
a single gene. 
2.1. Participant Recruitment  
2.1.1. Ethical Considerations 
Ethical approval was obtained from the Health Research Ethics Committee of 
Stellenbosch University, Cape Town, SA (Protocol number 2002/C059) (see Appendix II, 
Figure 2). Written informed consent was obtained from all study participants. 
2.1.2. Study Participants and Selection Criteria 
In the context of this study, the term ‘Afrikaner’ refers to the Afrikaner Caucasian 
population that is unique to SA. The selected family (labelled as ZA 253) was of Afrikaner 
ethnicity and consisted of four affected PD patients and five unaffected individuals .The 
five affected patients were examined by a specialist and diagnosed according to the UK 
Parkinson's Disease Society Brain Bank Research criteria (Gibb and Lees, 1988). The age 
at onset (AAO), lifestyle information and family history were obtained from the patients 
by a trained research nurse using a questionnaire. The average AAO of the affected 
individuals was 50,8 years (ranging from 37 to 77 years).  
A total of 192 healthy, unrelated individuals were recruited as controls though these 
individuals were not clinically assessed for PD. Of the 192 controls, 96 were self-identified 
as SA Afrikaner Caucasians and 96 were self-identified as SA ‘non-Afrikaner’ Caucasians. 
Males made up 51,6% of the controls, and the average age was 64,5 (±19,9) years.  
2.1.3. Extraction of gDNA from whole blood  
Peripheral blood samples were collected from the study participants and genomic DNA 
(gDNA) was extracted from whole blood using the NucleoSpin® Blood XL kit (Macherey-
Nagel™ GmbH and Co., Germany), according to manufacturer instructions. 
In brief, 10 ml of whole blood is mixed with 500μl of Proteinase K and 10 mL Buffer BQ1, 
which lyses the cells. The sample enters a mixing and incubation cycle where it is vortexed 
for 10 seconds and then it is incubated at 56 ˚C for 10 minutes, this occurs three times 
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before cooling the lysate to room temperature. Once cooled, 10 ml of Ethanol (96–100 %) 
is added before mixing by inversion allowing the DNA to precipitate. The 15 ml of lysate 
is then transferred to a collection tube with a NucleoSpin® Blood XL Column. The sealed 
collection tube is then centrifuged 3000 rpm for 3 minutes and the flow through is 
discarded. This is repeated with the remaining 15 ml lysate in the same column. Once the 
second flow through has been discarded the column still in the collection tube is washed 
with 7.5 ml of Buffer BQ2 and centrifuged for two minutes at 3000 rpm. The wash step is 
repeated however it is now centrifuged for 10 minutes at 3000 rpm. After placing the 
washed column in a new collection tube, the DNA is then dissolved by pouring 1000 μl of 
preheated Buffer BE (70 °C) directly onto the membrane and centrifuging at 3000 rpm for 
two min. The elution collected contains an ultra-pure, high-yield DNA which will be stored 
at 4°C, ready to use for downstream analysis. DNA concentration was estimated by 
measuring the absorbance at 260nm on the NanoDrop spectrophotometer. 
2.2. Whole Exome Sequencing 
At the time when the sequencing was performed only three of the five affected individuals 
were analysed (12.726, 11.844 and 92.32) because individuals 92.33 and 11.902 had not 
yet been diagnosed with PD. WES was performed using an Illumina HiSeq 2000 platform 
by a collaborator, Prof. Matt Farrer (University of British Columbia, Canada).  
Genomic DNA samples were constructed into Illumina PairEnd pre-capture libraries 
according to the Illumina Multiplexing Sample Prep Guide 1005361 protocol 
(https://support.illumina.com/downloads/multiplexing_sample_prep_guide_1005361.html
). Library templates were prepared for sequencing using Illumina's cBot cluster 
generation system with the corresponding TruSeq PE Cluster Kits (Illumina© Inc, United 
States) for the HiSeq. Briefly, the library was denatured with sodium hydroxide and 
diluted to 3 to 6 pM in hybridisation buffer in order to achieve a load density of 700 to 900 
k clusters/mm2 on the HiSeq 2000. Each sample was pooled (in a set of three) for loading 
onto a single lane of a HiSeq flowcell and then deconvoluted for analysis based on barcode 
sequence. All lanes were spiked with 2% phage phiX DNA control library for run quality 
control. After loading onto the flow cell, sample libraries underwent bridge amplification 
to form clonal clusters, and the sequencing primer was hybridised. 
Sequencing runs were performed in paired-end mode using the HiSeq 2000 platform. 
Using the TruSeq SBS Kit, sequencing-by-synthesis reactions were extended for 101 
cycles from each end, with an additional seven cycles for the index read for runs that 
included pooled samples. Real-time analysis software was used to process the image 
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analysis and base calling. Sequencing runs generated approximately 100 to 140 million 
successful reads per lane. With these run yields, each sample library achieved 10 to 12 Gb 
of raw DNA sequence data, which enabled a minimum of 20x coverage for 85% to 90% of 
the bases targeted in the exome.  
Burrows-Wheeler Aligner (BWA-MEM) (Li, 2013) was used to align sequence reads or 
assembly contigs against the Genome Reference Consortium Human NCBI build 37 
(GRCh37/hg19). BWA-MEM was also used for the removal of read duplicates, SNP calling 
and indel detection. ANNOVAR Software (Wang et al., 2010) was used to annotate the 
variants using GRCh37/hg19 as the reference genome.  
The Genome Analysis Toolkit (GATK) was used for variant calling, and to describe 
variants as either exonic, intronic, in the UTR or splice-site region by comparison with a 
reference sequence (Wang, Li, and Hakonarson 2010). To provide a summary of the 
coverage of mapped reads on a reference sequence at a single base pair resolution 
SAMtools mpileup was used with a Minimum variant QUAL score of 30. The co-
segregating variants of the three PD patients that met the filtration criteria amongst the 
remaining WES data were then pooled to make the list of candidate variants for further 
filtering and study. The post processing of the raw sequence data and the filtration up to 
generating the list of co-segregating variants was conducted by our collaborator at the 
University of British Columbia, Canada. 
 
2.3. Polymerase Chain Reaction Primer Design 
Oligonucleotide primers were designed using sequence data obtained from the Ensembl 
Genome Browser database (http://www.ensembl.org). Primer3 software version 4.0.0 
(http://primer3.ut.ee) (Koressaar and Remm, 2007), and Primer-Basic Local Alignment 
Search Tool (BLAST) (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to 
confirm the specificity of the primer binding sites, identify primer-primer 
complementarity and self-complementarity and calculate the primer melting 
temperatures. Forward and reverse PCR primer sequences, annealing temperatures and 
the expected sizes of the PCR products are recorded in Tables 2.1 to 2.6. The primers 
were synthesised by Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, SA.  
The primers designed to validate the WES variants by Sanger sequencing and used to 
screen populations for the variant frequencies are recorded in Table 2.1.  
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Table 2.1 WES co-segregating variant primers for amplification and HRM 
Chr, chromosome; Tm, melting temperature; Ta, annealing temperature; POU2F1,POU 
class 2 homeobox 1; CFAP65,cilia and flagella associated protein 65; CDC27, Cell Division 
Cycle 27; RFT1, requiring fifty-three one homolog; NRXN2α, neurexin alpha 2; ACTN3, 
Alpha-actinin-3; CCNF, Cyclin F; TEP1, telomerase-associated protein 1; TUBB6, 
Tubulin Beta 6 Class V. 
 
 
 
Chr Gene Primer Sequence (5’-3’) Tm (˚C) 
Ta 
(˚C) 
Product 
size(bp) 
1 POU2F1 
Forward AGTGAAGTTGGGTAGCTGGG 59,31 
56,0 407 
Reverse AGGCCCCACACTAACAATCA 58,93 
2 CFAP65 
Forward CCAAACTTGCCCTTCCTTGG 59,32 
56,0 382 
Reverse CTCCCACCTCAGCTTCTTGA 59,02 
3 RFT1 
Forward TTTTCCTGTCTCCTCCCCAG 58,64 
55,6 368 
Reverse GGGACAGGAGGAGGCAAAA 59,23 
11 NRXN2 
Forward TTTATCTCCGTGGTGCCCTC 59,46 
56,2 388 
Reverse AGCCAGGAGAGCTGTATGTG 59,17 
11 ACTN3 
Forward GCTGAGCTGAGACTTGAATCC 58,72 
55,8 385 
Reverse AAAGGTCATGAGAGGCAGCT 59,01 
14 
TEP1 
Forward AGTCAGAGAAATGCAGGGGA 58,34 
55,3 394 
Reverse CCTTTCCCAGTGCTCTCAGA 59,02 
16 
CCNF 
Forward AGTTCCCACGTGCTTCTCTT 59,24 
56,0 154 
Reverse AGCACATGAAGGGCAGGTGAC 58,87 
17 
CDC27 
Forward 
GCAAACCGTTTCTCCATAATTC
A 
57,95 
55,0 418 
Reverse TGGAAAACAGGGAAGAAAGGG 58,04 
18 
TUBB6 
Forward CCTTCATCGGCAACAGCAC 59,50 
55,3 250 
Reverse TCCGACTATCCATCGATCTCC 58,29 
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2.4. Polymerase Chain Reaction  
The fragments of interest were amplified from either gDNA or complementary DNA 
(cDNA) in a 25μl PCR reaction containing 30 – 100 ng of template genomic DNA, 20 
pmoles of both the forward and reverse primer, 75 μM dNTPs (Promega, Madison, 
Wisconsin, U.S.A), 1,5 mM MgCl2, 1X Green GoTaq® Reaction Buffer (Promega, Madison, 
Wisconsin, U.S.A) and 0,5 U GoTaq® G2 Flexi DNA Polymerase (Promega, Madison, 
Wisconsin, U.S.A). All PCR reactions performed included a non-template negative control 
to identify any PCR contamination. Amplification was performed in an ABI 2720 Thermal 
Cycler (Applied Biosystems Inc., Foster City, California, U.S.A). PCR conditions 
comprised of a denaturation step of 94°C, between 25 to 35 cycles of denaturation at 94°C, 
annealing at the primer’s optimum temperature (Table 2.1 to Table 2.6) followed by an 
extension step at 72°C. A final extension step of 72°C was performed for seven minutes 
before a cooling step at 4°C for 10 minutes. For lengthy fragments the extension time was 
dependent on amplicon length and complexity, generally an extension time of 60 seconds 
per 1000 bases was used.  
2.5. Gel Electrophoresis 
To visualise the PCR amplicons and to investigate if non-specific primer binding or 
contamination was present, gel electrophoresis was performed as follows: A 1% (w/v) 
agarose gel with 1μg/ml ethidium bromide (Sigma-Aldrich., United States) and 1X sodium 
borate (SB) buffer ( was cast and immersed in 1X Sodium Tetraborate (SB) buffer (give 
buffer components i.e. final concentration). Multiple molecular size markers were used for 
the duration of the study to determine the size of the fragment size and 5 to 8 μl of PCR 
product was loaded into the gel wells. Electrophoresis, was performed at 10 V/cm for 25 to 
30 min. To visualise the DNA fragment, the SynGene UV gel documentation system 
(Synoptics Ltd., Cambridge, UK) was utilised with GeneTools software version 3.0.6 
(Synoptics Ltd., Cambridge, UK). 
 
2.6. Post-Polymerase Chain Reaction Purification for Sanger Sequencing 
Enzymatic PCR clean-up was done to remove the remaining primers and dNTPs from the 
reaction. Products were purified by mixing 8 µl of the PCR reaction, with one unit of 
Shrimp alkaline phosphatase (Sap I) (Cleveland, Ohio, USA) and 0,1 units of Exonuclease 
(Exo I) (Promega, USA). The reaction was then incubated in an ABI 2720 Thermal Cycler 
at 37 °C for 15 minutes and 80 °C for 15 minutes to inactivate the enzymes (Applied 
Stellenbosch University  https://scholar.sun.ac.za
- 34 - 
 
Biosystems Inc., Foster City, California, U.S.A). The DNA concentration was 
subsequently determined using the NanoDrop™ 2000 (Thermo Scientific, MA, U.S.A) and 
the product was diluted to a concentration of 30 ng/μl.  
Samples were sequenced at the Central Analytical Facility (CAF) (Stellenbosch 
University, Stellenbosch, South Africa). Capillary electrophoresis was done on a 3130 x1 
Genetic Analyser (Applied Biosystems, CA, U.S.A) using The BigDye Terminator 
Sequence Ready Reaction kit version 3.1 (Applied Biosystems, CA, U.S.A) following in 
house optimised reaction conditions. Analysis of data was carried out using BioEdit v7.2.0 
software (Hall, 1999). Sequencing data was aligned with reference sequences generated 
from Ensembl Genome Browser database (http://www.ensembl.org).  
2.7. Bioinformatic In-silico Analysis of Variants 
To investigate the genetic variants identified, comprehensive computational analysis was 
performed. Functional prediction was determined from sequence homology–based 
programs namely SIFT; (http://sift.jcvi.org/), PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/), MutationTaster 
(http://www.mutationtaster.org/) and CADD (http://cadd.gs.washington.edu/). To 
determine evolutionary constraint acting on genomic sites GERP++ was used 
(http://mendel.stanford.edu/SidowLab/downloads/gerp/). 
SIFT and PolyPhen-2 both reports result in terms of pathogenic scores accompanied by 
the prediction, for readability only the predictions are reported. MutationTaster reports 
the amino acid change impact as one of two predictions of either neutral or pathogenic 
based on its disease-causing threshold. CADD reports phred-like scores (“scaled C-scores”) 
ranging from zero to 50.Variants predicted to be amongst the 10 %, 1 % or 0,1 % most 
deleterious substitutions that can occur in the human genome, at that specific base 
position, are assigned a score of between 10 and 19, 20 and 29 or 30 and 50 respectively. 
Thus, the higher the CADD score the more likely it is that the variant is highly pathogenic. 
GERP++ uses maximum likelihood evolutionary rate estimation for position-specific 
scoring, and the score ranges from -12,3 to 6,17. The closer the score is to 6,17(representing 
the most conserved a region can be), the greater the level of evolutionary constraint 
inferred to be acting on that site.  
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2.8. Population Frequency Evaluation  
2.8.1. High Resolution Melt Analysis 
High resolutions melt (HRM) analysis was used to screen ethnic matched controls for the 
variants identified. For detection a 1/100 dilution of SYTO® 9 (Thermo Fisher, Waltham, 
MA, U.S.A), a green fluorescent nucleic acid stain was added to the standard PCR protocol 
as described in section 2.4. HRM analysis detects the change in fluorescence as a double 
stranded PCR product dissociates to single-stranded DNA with increasing temperature. 
Initially, the fluorescence will be high, but reduces gradually as the double stranded DNA 
intercalating dye is released. The resulting thermal denaturation profile is unique to that 
specific PCR product, because DNA strand melting depends on sequence length, bases and 
GC content (HRM Assay Design and Analysis Booklet; 
http://www.corbettlifescience.com/shared/RotorGene%206000/hrm_corprotocol.pdf). This 
enables visual discrimination between homozygous and heterozygote genotypes (Figure 
2.1). The melt temperature conditions are from 65°C to 95°C rising by 0,1°C increments 
on a Rotor-Gene 6000 analyser (Corbett Life Science, Australia).  
In the population screening experiments, the proband sample with the known variants 
was included as a reference for comparison. For every variant, any sample exhibiting 
altered thermal denaturation profiles on HRM was selected for Sanger sequencing to 
characterise the sequence variation. In a validation step samples would be randomly 
selected from each variant run for sequencing. In total for each screened variant 20 control 
samples were sequenced (10,4 % of total controls). A non-template control was included in 
each run to monitor contamination. 
  
Figure 2.1 HRM curve analysis. It is possible to differentiate between variants in 
human ACTN3 (R577X) SNP genotypes using HRM. Homozygous wild-type (C allele), 
mutation (T allele) and heterozygote samples are shown on a standard normalised melt 
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curve (A) and a difference plot normalised to mutant samples (B). Amplification and HRM 
analysis were done using a Rotor-Gene 6000 instrument and genotypes were 
automatically assigned by the Rotor-Gene software (Adapted with public domain rights 
from http://hrm.gene-quantification.info). 
 
2.8.2. Online Population Frequency Databases 
The frequency of genetic variants in other populations was determined by searching public 
mutation databases. Each database comprises of reported sequencing data from multiple 
populations, the frequency at which alleles occur in any given population can then be 
determined. This is referred to as the population specific MAF, and it enables us to 
differentiate between common and rare variants in populations. Variants with a MAF 
greater than or equal to 0,01 are considered to be polymorphisms, being found at a 
frequency greater than 1 % in the general population. The population frequency databases 
examined included the ExAC database (http://exac.broadinstitute.org/), the 1000 Genomes 
Project (http://browser.1000genomes.org/index.html) and dbSNP 
(https://www.ncbi.nlm.nih.gov/snp). Populations examined were the European (Non-
Finnish), African, East Asian, Latino and South Asian. 
2.9. Pathway and Expression Analysis 
To further prioritise the variants according to gene function and interactions, pathway 
analysis was performed using Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
Pathways Analyser (http://www.genome.jp/kegg/pathway.html) and PANTHER Pathway 
Analyser (http://www.pantherdb.org/pathway/). The publicly available expression 
databases accessed were the Allen Brain Atlas (www.brain-map.org/) and Human Protein 
Atlas (https://www.proteinatlas.org/). Both databases record human mRNA expression 
data, but Allen Brain Atlas gives only brain regional whole-transcriptome gene expression 
data. 
B. Investigating the Prioritised Gene 
Although computational analysis predicted the pathogenicity of the candidate variant in 
NRXN2α, characterisation of the variant and its protein is necessary to validate the in-
silico predictions. 
2.10. Frequency of NRXN2α Variant in Patient Group 
The HRM analysis was performed on the Rotor-Gene 6000 analyser (Corbett Life Science, 
Australia) to screen 671 SA PD patients for the NRXN2 c.G3008A (p.G849D) variant. The 
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same NRXN2α primers that were used to screen the controls were used for the patient 
screening. PCR reactions were prepared according to the standard PCR protocol as 
described in section 2.4. For detection 1 µl (1/100 dilution) of SYTO® 9 (Thermo Fisher, 
Waltham, MA, U.S.A), was added to reaction mix. The melt temperature conditions 
ranged from 65°C to 95°C rising by 0,1°C increments. 
 A proband sample with the known variants was included as a reference for comparison 
in each run to determine the samples that could be exhibiting altered thermal 
denaturation profiles. Thereafter, these sample would be sent for Sanger sequencing to 
characterise the observed sequence variation. As with the control screening, samples were 
randomly elected from each run for sequencing. In total 30 patient samples were Sanger 
sequenced (5 % of the total screened patients). A non-template control was included in 
each run to monitor contamination. Patient samples that were unsuccessfully amplified 
or that exhibited abnormal thermal denaturation profiles were repeated. 
To screen the prioritised gene in PD patients from other populations Annex 
(https://annex.can.ubc.ca/about), a web-based private database (from our collaborator 
Prof. Farrer) was searched. The database comprises of over 3000 exomes of patients with 
different neurological diseases from all over the world. Access to the database was granted 
by the system administrator and a user account was provided. The data contained has 
been deidentified and each user can search the database but there is no option to download 
the exome data files. The database was searched for NRXN2α variants that were 
specifically found in diagnosed PD patients. The repository has an inbuilt frequency 
database called Genome Aggregation Database (GnomAD ) (gnomad.broadinstitute.org/) 
and also reports CADD scores for each variant. 
2.11. Protein Structure Homology Modelling 
The initial step of the homology modelling was to identify templates of protein structures 
evolutionary related to the target sequence. This was accomplished using the SWISS-
MODEL Webserver (https://swissmodel.expasy.org/) (Bordoli and Schwede, 2012) which 
identifies suitable templates through a BLASTP (Basic Local Alignment Search Tool) 
search. BLASTP (https://blast.ncbi.nlm.nih.gov/BLAST.cgi?PAGE=Proteins), is an 
algorithm used for computing primary biological sequence information, such as the amino 
acid sequences of different proteins (Altschul et al., 1997). The search enables a researcher 
to compare a query sequence with a library or database to identify sequences that 
resemble the query sequence above a certain threshold. The sequence search was 
performed in SWISS-MODEL using default parameters with the NRXN2α target 
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sequence (Uniprot ID number Q9P2S2, Transcript ENST00000265459.10) as the search 
query.  
The selection of a template from the available files was based on properties like sequence 
identity, structural similarity, Global Model Quality Estimation (GMQE) score and the 
Qualitative Model Energy Analysis (QMEAN) score. A NRXN2α protein PDB (Protein 
Data Bank) structure file was found and selected based on its properties for further 
analysis. The model was evaluated against its respective template using standalone 
application PyMol (Schrödinger L, 2015) and the SWISS-MODEL inbuilt sequence to 
structure workbench SWISS-PDB Viewer (Guex and Peitsch, 1997) to ensure the quality 
of the model. These programs allow for the superimposing of two structures to find the 
differences in the backbone atoms, stereochemistry, spatial distribution of small charged 
groups and main chain hydrogen bonding (Moreland et al., 2005).  
2.12. Prioritised Gene Primers 
Initially a gene amplification primer pair (Table 2.2 A) was designed to bind to the 5’ and 
3’ ends of NRXN2α (Figure 2.2 A). The primer set was designed on the basis of the 
following criteria: 50-60 % GC content, 25-35 nucleotides long and an annealing 
temperature below 60ºC. Due to the initial primer set not amplifying full-length NRXN2α 
from cDNA, shorter gene primers that would bind to the 5’ and 3’ ends of the gene were 
designed to improve the specificity of binding. Overlapping internal primers that were 20 
nucleotides long, with melting temperatures of 56ºC and GC contents of 55 % were also 
designed to use with the shorter gene primers (Table 2.2 B). We expected that the two 
separate fragments amplified from the cDNA library could be ligated to form full-length 
NRXN2α cDNA. The primer binding sites are illustrated in Figure 2.2 A and Figure B. 
Table 2.2 NRXN2α Gene amplification primers and PCR conditions 
A. NRXN2α Gene Primers with Restriction sites 
Gene Primer Sequence (5’-3’) Tm (˚C) 
Ta 
(˚C) 
Product 
size(bp) 
NRXN2α 
EcoR1 5’A 
Forward 
ACTGCAGAAGAATTCATGGCGTCC
GGGAG 
54,06* 
51,0 5139 
NRXN2α  
SalI 3’A 
Reverse 
ACTGCAGAAGTCGACTCAGACATA
ATACTCCTTGTCTTTG 
56,62* 
B. Shortened NRXN2α Gene Primers and internal primers 
Gene Primer Sequence (5’-3’) Tm (˚C) 
Ta 
(˚C) 
Product 
size(bp) 
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Turquoise, universal seat sequence, purple, EcoRI restriction enzyme site; yellow, SalI 
restriction enzyme site, red, start codon; green, stop codon; Ta, annealing temperature, Tm, 
melting temperature; ˚C, Degrees Celsius, Nucleobases - A, adenine; G, guanine; C, 
cytosine; T, tyrosine. 
In an effort to increase the reverse transcription (RT) efficiency and specifically target the 
NRXN2α gene in cDNA synthesis from the Human Foetal Brain RNA library, we decided 
to use NRXN2α-specific primers in the initial step of RT (Table 2.3). A combination of 
four primers were designed that would bind to the 3´untranslated region (UTR) of the 
NRXN2α RNA, and these would be used instead of the random hexamers that were 
supplied with the QuantiNova™ Reverse Transcription kit, for cDNA synthesis. The 
resulting cDNA would be used to generate the full-length gene using the primers in Table 
2.2.  
Table 2.3 NRXN2α specific 3’ UTR reverse transcription primers  
NRXN2α, neurexin alpha 2; UTR, Untranslated Region; Ta, annealing temperature, Tm, 
melting temperature; ˚C, Degrees Celsius, Nucleobases - A, adenine; G, guanine; C, 
cytosine; T, tyrosine. 
As neither of the previously described primer pairs were able to amplify the full-length 
NRXN2α, intron flanking primers (Table 2.4) were designed to amplify short PCR 
products (size ± 500 base pairs) from the cDNA. This was to check if there was complete 
NRXN2α in cDNA generated from the gene specific RT. If a PCR product was produced it 
would mean that the synthesised cDNA library contained NRXN2α gene DNA fragments 
spanning multiple exons. The first primer set designed spanned from exon 2 to exon 7 and 
would produce a product of 475bp. The second primer set spanned from exon 19 to exon 
NRXN2α 
EcoR1 5’B  
Forward 
CAGAAGAATTCATGGCGTCCGGGA
G 
54,06* 
51,0 2594 
NRXN2α 
Internal 
Primer 
Rev 
Reverse ATGATGCCCGTCTCAATGTT 55,5 
NRXN2α 
Internal 
primer 
Fwd 
Forward AGCTGTCTGTGGACAACGTG 60,53 
53,6 2633 
NRXN2α  
SalI 3’B 
Reverse  
GACGTCGACTCAGACATAATACTCC
TTGTCTTTG 
56,62* 
Gene Primer Sequence (5’-3’) 
NRXN2α 3’ UTR 1 Rev 
Reverse TGAGGCAGCCAGGGAGAG 
NRXN2α 3’ UTR 2 Rev 
Reverse TTTTTGCGTTTCCTCTTCGT 
NRXN2α 3’ UTR 3 Rev 
Reverse GTGGACGGCAGGAGGAAG 
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22 and would produce a PCR product of 515bp. The primer binding sites are shown in 
Figure 2.2 C. 
Table 2.4 NRXN2α intron flanking primers 
Tm, melting temperature; Ta, annealing temperature; NRXN2α, neurexin alpha 2; UTR, 
Untranslated Region; *, Tm calculated without restriction sites or enzyme seat; 
Nucleobases - A, adenine; G, guanine; C, cytosine; T, tyrosine. 
Figure 2.2 is a schematic representation showing the NRXN2α gene with the multiple 
PCR amplification primers and their corresponding binding sites. This is to illustrate the 
different ways in which we attempted to amplify the full-length NRXN2α gene. 
Gene Primer Sequence (5’-3’) Tm (˚C) Ta (˚C) 
Product 
size(bp) 
NRXN2α 
Exon 2 For 
Forward GCTTCGGCGGCAAGTTCT 
61,05 
55,9 475 
NRXN2α 
Exon 7 Rev 
Reverse ACCATAGCGTGTCCAATCCC 
58,92 
NRXN2α 
Exon 19 For 
Forward 
TGGTGCGCTTCACTCGAA 58,9 
55,9 505 NRXN2α 
Exon 22 
Rev 
Reverse 
CCTCCAGGTCCTCATCATCG 59,0 
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Figure 2.2 NRXN2α primer binding sites schematic diagram. The relative locations of 
primer binding sites are indicated by the red arrows, the full-length gene is illustrated by 
the blue and the untranslated region is shown by the turquoise. 
2.13. cDNA Synthesis 
An expression vector containing the prioritised gene was required to perform functional 
studies. To generate this expression vector, full-length cDNA of the prioritised gene was 
synthesised using the QuantiNova™ Reverse Transcription kit (Qiagen, Hilden, 
Germany). Before cDNA synthesis, 1 μg total RNA from a commercially available Human 
Foetal Brain RNA library (CLO- 636526, Takara Bio Europe, Saint-Germain-en-Laye, 
France) was treated with 1x gDNA wipeout buffer and RNase free water on the 2720 
Thermal Cycler (Applied Biosystems, CA, USA) according to the manufacturer's 
instructions, to ensure no DNA contamination. cDNA synthesis was carried out with the 
purified RNA following the manufacturer’s instructions. The RT reaction was performed 
C. NRXN2α intron flanking primers 
NRXN2α SalI 3’B 
NRXN2α Internal primer Fwd 
Exon 7 
Exon 2 Exon 19 
B. Shortened NRXN2α gene primers with internal primers 
NRXN2α SalI 3’A 
NRXN2α EcoR1 5’A 
NRXN2α Internal Primer Rev 
Exon 22 
NRXN2α EcoR1 5’B 
A. NRXN2α full length gene primers 
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using 2720 Thermal Cycler (Applied Biosystems, CA, U.S.A). A volume of 14 μl of purified 
RNA was added to 1 μl RT Primer Mix, 4 μl 5 × Quantiscript RT Buffer and Quantiscript 
reverse transcriptase (100 units/μl) before incubating at 42°C for 30 min. The RT reaction 
was terminated by incubating at 95°C for three min, the synthesised cDNA was then used 
as the template for PCR amplification. An internal control supplied with the RT kit was 
also included in the run as a positive control for synthesis. 
2.14. cDNA Quantification and Quality Assessment by Absorbance  
cDNA quantity and quality were determined by a NanoDrop spectrophotometer 2000 
(Thermo Fisher Scientific, United States) using the DNA mode. The quantity of the 
sample is reported ng/ul, the quality is determined using the ratio of absorbance at 260nm 
and 280nm and 230nm. It is generally accepted that a 260/280 ratio that is greater than 
1,80 indicates adequate purity and integrity of DNA. The cDNA was stored at -20°C until 
required for PCR amplification reactions. 
2.15. cDNA Quality Assessment by Polymerase Chain Reaction  
2.15.1. Amplification of Exon 1 To Exon 2 of HBB from cDNA 
To further verify the purity of the cDNA and detect possible gDNA contamination, the 
Haemoglobin subunit beta (HBB) gene was amplified. The HBB s primer pair was 
previously designed to span a small intron (130 bp) between exon 1 and exon 2 (Table 2.5 
and Figure 2.3). This PCR therefore allows discrimination between cDNA and gDNA on 
the basis of product size. 
Table 2.5 Primer sequences for HBB reference gene 
Name of 
Primer 
Primer Sequence (5’-3’) 
Tm 
(˚C) 
%GC 
Ta 
(˚C) 
Size of 
PCR 
Product 
(bp) 
HBB-F ACACAACTGTGTTCACTAGC 58 45 
55 
gDNA: 377 
cDNA: 247 HBB-R ACCGAGCACTTTCTTGCCAT 60 50 
F, Forward; R, Reverse; Ta, annealing temperature, Tm, melting temperature; ˚ C, Degrees 
Celsius, Nucleobases - A, adenine; G, guanine; C, cytosine; T, tyrosine. 
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Figure 2.3 Schematic diagram of the amplification of HBB from cDNA and gDNA. 
Forward and reverse primers are highlighted in red. Intron 1 to 2 is 130 bp in size. After 
PCR the gDNA product will be 377 bp in size and the cDNA PCR product will be 247 bp 
because the intron is spliced out. 
2.15.2. Amplification of Exon 2 To Exon 5 of PARK2 from 
cDNA 
PARK2 is considered to be one of the largest genes in the human genome, this is due to 
its large introns (Asakawa et al., 2001). The primers which had been previously designed, 
amplify a region spanning from exon 2 to exon 5, flanking three introns with a combined 
total size of 389,151bp (Figure 2.4). The primer sequences are shown in Table 2.6. Due 
to the splicing of introns in RNA these primers are expected to produce a cDNA PCR 
product of 419bp whereas it there should be no PCR product from gDNA as amplifying the 
389,151 bp product would not be feasible.  
Table 2.6: Primer sequences for PARK2, exon 2 to exon 5.  
Name of 
Primer 
Primer Sequence (5’-3’) Tm (˚C) %GC 
Ta 
(˚C) 
Size of 
PCR 
Product 
(bp) 
PARK2 
Exon 2 For 
CACCATTTAAGGGCTTCGAG 60 50 
55 
gDNA: 
389,151 
cDNA: 419 
PARK2 
Exon 5 Rev 
TTCCTGGCAAACAGTGAAGA 
 
58 45 
For, Forward; Rev, Reverse; Ta, annealing temperature, Tm, melting temperature; ˚C, 
Degrees Celsius, Nucleobases - A, adenine; G, guanine; C, cytosine; T, tyrosine. 
cDNA: 
Exon 2 
223 bp 
Intron 1 
130 bp 
Exon 3 
263 bp 
Exon 2 
223 bp 
Exon 1 
268 bp 
 
A. HBB Primers spanning intron 
 
gDNA: 
Exon 1 
268 bp 
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Figure 2.4 PARK2 PCR cDNA and gDNA schematic diagram. Forward and reverse 
primers are in red. After PCR the cDNA product will be 419 bp in size and there should 
not be any PCR amplification in gDNA possible due to extremely large introns. 
2.16. Culturing SH-SY5Y Cells for Protein Expression Studies 
2.16.1. Thawing of SH-SY5Y Cells from Frozen Stocks 
The human Neuroblastoma SH-SY5Y adherent/suspension cell line (Cellonex, 
Johannesburg, RSA) (passage 12) originally derived from metastatic bone marrow, were 
rapidly thawed from long-term storage of frozen aliquots at -80°C. The vial containing the 
frozen stock was immersed for three to five minutes in a 37°C water bath. Thereafter, the 
outside of the vial was immediately sterilized with 70% Ethanol and placed in the Esco 
Airstream® Class II Biohazard Safety cabinet (Esco Technologies Inc., United States). 
2.16.2. Removing Freezing Media from Frozen Stocks 
Culture media was prepared using Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12 (DMEM/F-12) in a ratio of 1:1 (Lonza, Walkersville, MD, USA), supplemented with 
20% Foetal Bovine Serum (Lonza, Walkersville, MD, USA) and 1% of the antibiotic 
Penicillin-Streptomycin (Lonza, Walkersville, MD, USA). The antibiotic mixture is added 
to prevent contamination by gram-positive and gram-negative bacteria (Kohanski et al., 
2010). The culture media was then prewarmed to 37°C and 5 ml of prewarmed culture 
media was added to the thawed cells in a 15 ml Eppendorf tube. Cells were spun at 1500 
rpm for 5 minutes and the supernatant was discarded. The pelleted cells were 
resuspended in 5 ml of culture media and seeded in a 25 cm2 flask (Corning Inc., United 
States) with an additional 10 ml of culture media. Thereafter, the flask was gently swirled 
to distribute the cells evenly over the growth surface of the flask and incubated at 37°C in 
a 5% carbon dioxide humidified incubator (Farma International, Miami, Florida, U.S.A). 
Exon 5 
116 bp 
cDNA: 
Intron 3 
61,272 bp 
A. PARK2 primers spanning introns 
 
gDNA: 
Intron 2 
180,544 bp 
Exon 5 
Exon 1 
 
Exon 2 
164 bp 
Exon 4 
122 bp 
Exon 3 
241 bp 
Intron 4 
146,956 bp 
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For growth and maintenance of the cells, the culture media was changed when the cells 
became adherent and cell debris was evident. 
2.16.3. Sub-culturing of SH-SY5Y Cells 
The cells were sub-cultured when 80 to 90% confluency was reached, and this typically 
took 3 to 4 days. As a majority of the SH-SY5Y cells were adherent to the growth surface, 
the culture media was removed from the flask and the cells were gently rinsed with 2 to 
3ml of sterile Phosphate Buffered Saline (PBS) (Lonza, Walkersville, MD, U.S.A), at room 
temperature. The cells were treated with 3ml Trypsin (0,5g/L Trypsin) (Lonza, 
Walkersville, MD, U.S.A) for 5 minutes to facilitate the detachment of cells from the 
growth surface of the flask. Culture media (5ml) was then added to the cell suspension, 
this was then transferred to a 15 ml Eppendorf tube. The cells were spun at 1500 rpm for 
5 minutes and the supernatant was discarded. The pelleted cells were resuspended in 6 
ml of culture media and 3ml of the resuspended cells was seeded into each 25cm2 flask 
(Corning Inc., United States) with an additional 12 ml of prewarmed culture media. 
2.16.4. Lysis of SH-SY5Y Cells 
To prepare whole cell protein extracts from the SH-SY5Y cells, 1X Cell Lysis Buffer (CLB) 
was prepared using 1M Tris- HCl at pH 7,4, 5M NaCl, 1% of the total volume of Triton™ 
X-100 (Sigma-Aldrich, United States), 1M MgCl2 and ddH2O to a final volume of 1L. The 
cOmplete™ EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich, United States) was 
added immediately before using the CLB. To harvest the cells the culture media was 
removed, and the flasks were washed once with 4ml ice-cold PBS. A volume of 1,5 ml ice-
cold PBS was added to each flask, and a cell scraper was used to scrape the cells off the 
growth surface. The detached cell suspension was transferred to 2ml Eppendorf® LoBind 
microcentrifuge tubes (Eppendorf, United States). The tubes were centrifuged at 15,000 
rpm for 5 minutes, and the supernatant was gently removed with a pipette. The pellet 
was resuspended in 200 μl ice-cold CLB containing the Protease Inhibitor Cocktail and 
~0,5 ml of sterile 0,1 mm glass beads before incubating on ice for 30 minutes. Subsequently 
the lysates were homogenized at 4°C using a Precellys ® 24 tissue homogenizer (Bertin 
Instruments, Amsterdam, Netherlands) three times for 30 seconds with 5 minutes 
intervals on ice. The lysates were the centrifuged at 15,000rpm at 4°C in a bench top 
centrifuge (Labnet International Inc., United States) for 30 minutes. The supernatant was 
carefully transferred to a new 2 ml LoBind microcentrifuge tube and stored at -80°C. 
2.16.5. Bradford Assay for Determination of Protein 
Concentration in Cell Lysates  
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The protein concentration of cell lysates was determined using the Bradford assay to 
enable the loading of equal amounts of protein per well for western blot (WB) experiments. 
Bovine Serum Albumin (BSA) (Biolabs, New England) standards ranging from 0-1000 
ng/ml were prepared and 10μl of each BSA standard was pipetted in duplicate in a 
microtiter plate. Volumes of 1/20, 1/10 and 1/3 of lysate samples were then pipetted in 
duplicate and a lysis buffer control was added. Next, 200μl Bradford reagent was added 
to the BSA standards and lysate samples with a five-minute incubation step before the 
plate was read at 595nm absorbance on a Synergy HT luminometer (BioTek Instruments 
Inc., Vermont, U.S.A) using the KC4™ v3.4 software (BioTek Instruments Inc., Vermont, 
U.S.A). The BSA standard curve was generated and the average lysate concentration was 
determined from the technical duplicates for each sample. 
2.17. Western Blot Analysis of Endogenous NRXN2α Expression 
2.17.1. Membrane Blocking and Antibody Binding 
After running the precast sodium dodecyl sulphate (SDS) gel in a polyacrylamide gel 
electrophoresis (PAGE) system, the proteins were transferred to nitrocellulose membrane. 
The automated IBLOT™ transfer system (Invitrogen™, United States) was used, with 
iBlot™ Transfer Stacks containing integrated nitrocellulose transfer membranes. 
Transfer of protein was carried out using the default transfer parameters of 7 minutes at 
20-25 Volts. Once completed the membranes were removed and washed in Tris-buffered 
saline with Tween 20 (TBS-T) buffer (20 mM Tris at pH 7,4, 150 mM NaCl, 0,1% Tween 
20) for five minutes. The membrane was then incubated for an hour in 5% BSA to ensure 
the blockage of all non-specific binding sites. The membrane was rinsed in TBS-T, cut 
appropriately and incubated overnight at 4°C in 5 ml of the appropriate antibody diluted 
in TBS-T on a Stuart® orbital shaker SSL1 (Barloworld Scientific Ltd., United Kingdom). 
Following overnight incubation, the membrane was rinsed four times with TBS-T for a 
total wash time of 45 minutes, while shaking at room temperature on a rotating shaker 
(Labcon Pty, Ltd, Maraisburg, RSA). Next, the membrane was incubated for 1 hour at 
room temperature with the relevant horseradish peroxidase (HRP) conjugated secondary 
antibody. Thereafter, the membrane was again washed three times in TBS-T for a total 
wash time of 30 minutes. 
 
2.17.2. Chemiluminescent Detection 
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Detection of the membranes was done in the dark room. The reagents of the Clarity™ 
Western Enhanced Chemi-Luminescence Blotting Substrate (Bio-Rad Laboratories, 
United States) were mixed as follows; 5 ml of Clarity western luminol/enhancer reagent 
and 5 ml Clarity western peroxide reagent to make a 1:1 working solution. The antibody 
treated membranes were incubated in the solution for 5 minutes. The membranes were 
then placed in an autoradiography cassette, covered with a transparent plastic sheet 
avoiding bubbles. A CL-Xposure™ autoradiography film (Thermo Fisher Scientific, 
United States) was placed in the cassette and the exposure time varied between 10 
seconds and 10 minutes, depending on the strength of the signal. The exposed films were 
developed using a Hyperprocessor™ automatic autoradiography film processor 
(Amersham Pharmacia Biotech Ltd., United Kingdom) and the protein bands were 
visualised. 
2.17.3. Optimisation of Primary Antibody Dilution 
The Anti-Neurexin II alpha (NRXN2α) antibody (rabbit, polyclonal), Anti-Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) antibody (Goat, Polyclonal) and HRP-conjugated 
secondary antibodies were all obtained from Abcam (BIOCOM Biotech, South Africa). The 
optimal dilution of each of the antibodies was experimentally determined. For the Anti- 
NRXN2α antibody 1/400, 1/500 and 1/1000 dilutions were tested (Table 2.7),while for the 
Anti-GAPDH antibody 1/1000 and 1/3000 dilutions were tested.  
Table 2.7 Characteristics of the relevant antibodies used in WB analysis 
Target 
Protein 
Antibody Recommended 
Primary Ab 
dilution 
Optimised 
Primary 
Ab 
dilution 
Secondary 
Ab 
dilution  
Expected 
size (kDa) 
NRXN2α 
(ab34245) 
Rabbit/polyclonal 1:400 1:500 1:5000 185 
GAPDH* 
(ab9483) 
Goat/polyclonal 1:1000 1:3000 1:5000 37 
Abbreviations: Ab: antibody, kDa –kilodalton, *represent the loading control 
2.17.4. Quantification of Western Blot Signal 
All Western blots were quantified using the open source platform, ImageJ 
(http://imagej.nih.gov/ij/) developed by the National Institute of Health. The exposed 
western blotting films were digitalized by scanning and saved as .jpg files. Before 
quantification the jpg images need to be reduced from a 24-bit to an 8-bit images using 
the jPOR custom palette provided by ImageJ. Each band is converted to a peak in which 
the intensity of the signal is proportional to the peak area. The protein band intensity can 
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now be measured by highlighting the area of each peak and drawing a baseline across the 
bottom of the peaks, thereby excluding the underlying area from the measurement. 
ImageJ employs the pixel intensity of the bands and to quantify the relative abundance of 
the protein on the WB. All blots were performed in biological triplicates and GAPDH was 
used as the internal control protein. This was necessary to verify that the samples were 
loaded uniformly on the gel and to enable normalisation of the relative protein 
concentrations amongst the samples.  
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Chapter Three 
3. Results 
A. Whole Exome Sequencing Results and Prioritisation 
In this section we use WES to screen a multiplex family with PD, then validate the list of 
variants using Sanger sequencing. Computational analysis is then performed on the 
validated variants to predict the pathogenicity before prioritising the list of candidates to 
a single gene. 
3.1. Identifying the Family 
This study used a WES approach to screen a multiplex family with PD for candidate PD-
causing genes. Identification of the family and the expansion of the pedigree was done by 
the consulting neurologist, Prof. Jonathan Carr (Tygerberg Academic Hospital, Cape 
Town, SA). The full pedigree of this family, which is denoted as family ZA253, contains 57 
individuals (Appendix II, Figure 1). In total, 11 members were reported to have been 
affected by PD. A simplified version of the pedigree indicating the family members who 
took part in this study, is shown in Figure 3.1. 
 
Figure 3.1 Pedigree of family ZA253. Circles denote females and squares depict males. 
The filled in symbols indicate affected individuals. The intersecting diagonal lines indicate 
that the person is deceased. The numbers below each individual is the laboratory ID 
number. For readability and confidentiality, the pedigree is greatly simplified. Branches 
without medically confirmed PD or without DNA samples were omitted, but all known 
living family members with PD diagnoses are included in the pedigree. AAO, Age at onset, 
the black arrow shows the proband.  
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Patient 11.844 (Proband) was the first individual to be formally diagnosed with PD at the 
age of 51 years. He presented with typical PD with some of the classical motor symptoms 
including tremor, rigidity and balance problems. Shortly after the diagnosis, his siblings 
were assessed, and individual 12.726 was also diagnosed with PD, and his age of onset is 
estimated to be 43 years. The typical PD motor symptoms were noted without any NMS, 
and the cognitive assessment showed no cognitive decline. Patient 92.32, the nephew of 
the two affected siblings was later examined by Prof. Carr and diagnosed with early-onset 
PD at the age of 37 years. His most prominent motor symptom was early dystonia. His 
mother (individual 92.33) was examined by Prof. Carr and diagnosed with PD with an 
AAO of 72 years.  
Patient 11.902 was diagnosed with PD in 2017, Prof. Carr noted that this individual 
developed a slowly progressive form of the disease. She had an AAO of 75 years and the 
predominant symptoms at the time of diagnosis were tremor and REM sleep behaviour 
disorder. A summary of the clinical characteristics of each family member is recorded in 
Table 3.1.  
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Table 3.1 Clinical information of multiplex Afrikaner SA Family 
M, male; F, female; AAO, age at onset; NR, not relevant; PD, Parkinson’s disease; ^; denotes potential phenocopy of disease; *; individuals 
WES was conducted on. 
 Affected Unaffected 
Individual 
ID 
11.844* 
(proband) 
12.726* 
(sibling) 
92.32* 
(nephew) 
92.33 
(sibling) 
11.902^ 
(cousin) 
94.06 
(cousin) 
94.05 
(nephew) 
11.901 
(cousin) 
10.202 
(spouse of 
sibling) 
Gender M M M F F M M F M 
Age in 
2018 
63 69 44 72 80 69 43 71 73 
Disease 
Diagnosis 
PD PD PD PD PD* Unaffected Unaffected Unaffected Unaffected 
AAO 51 43 37 72 78 NR NR NR NR 
Clinical 
Signs 
Typical PD Slow 
Duration 
dystonia, 
minimal 
autonomic 
and 
cognitive 
decline 
Early 
Dystonia 
Late-onset 
Mild PD 
Tremor, 
Rapid eye 
movement 
sleep 
behaviour 
disorder 
NR NR NR NR 
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3.2. Whole Exome Sequencing 
WES was performed on three of the affected family members (12.726, 11.844 and 92.32). 
The WES metrics, reported in Table 3.2, revealed good overall coverage of the sequencing 
in all three individuals. Individuals 92.33 and 11.902 had not yet been diagnosed with PD 
at the time that WES was performed. For the data analysis, we made the following 
assumptions that the three affected individuals had the same genetic cause of disease and 
the mode of inheritance was AD. Importantly, none of the known causal mutations 
associated with PD were found in any of the affected individuals. This indicates that it is 
plausible that there is a novel PD-causing mutation in this family.  
Table 3.2 Summary of metrics of WES in the three affected individuals 
 
All synonymous co-segregating variants were excluded. This left a total of nine novel or 
rare non-synonymous variants that were shared between the three affected individuals 
(Table 3.3). The genes in no particular order are NRXN2α (Neurexin 2 alpha), ACTN3 
(Actinin Alpha 3), POU2F1 (POU Class 1 Homeobox 1), CFAP65 (Cilia and Flagella 
Associated Protein 65), RFT1 (Requiring Fifty-Three 1), TEP1 (Telomerase-Associated 
Protein 1), CCNF (Cyclin F), CDC27 (Cell Division Cycle 27), and TUBB6 (Tubulin Beta 
6 Class V) . 
Metrics 
WES Individuals 
12.726 11.844 92.32 
Total number of 
reads 
136,048,746 127,298,302 114,750,902 
Non-duplicated 
reads 
90,255,052 97,195,484 85,612,771 
Reads aligned to 
target 
82,045,320 
(90,9%) 
83,570,035 
(86,0%) 
74,665,623 
(87,2%) 
Mean target 
coverage (%) 
88,12 79,88 71,04 
Total number of 
variants 
22,318 22,566 22,531 
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Table 3.3 Rare and novel exonic variants shared between individuals 12.726, 11.844 and 92.32 after variant filtering. 
Chr Gene 
Genomic 
coordinate 
Ref Alt Exon 
Variant 
Type 
Amino Acid 
position 
dbSNP 
Accession ID 
1 POU2F1 167343435 G C 6 
Non 
synonymous 
p.A154P rs774001310 
2 CFAP65 219886565 A G 18 
Non 
synonymous 
p.T1023A rs748008106 
3 RFT1 53126455 C G 12 
Non 
synonymous 
p.A463G novel 
11 NRXN2α 64418979 G A 13 
Non 
synonymous 
p.G849D novel 
11 ACTN3 66319116 A C 2 
Non 
synonymous 
p.E127A rs569022261 
14 TEP1 20871567 A G 7 
Non 
synonymous 
p.Y412C novel 
16 CCNF 2495617 G C 10 
Non 
synonymous 
p.C363S novel 
17 CDC27 45249391 A C 3 
Non 
synonymous 
p.Y48S rs62077270 
18 TUBB6 12326073 A C 4 
Non 
synonymous 
p.T429P rs745469423 
Chr, chromosome; p., protein codon position; rs, reference SNP ID number, Nucleobases - A, adenine; G, guanine; C, cytosine; Amino 
acids – A, Alanine; C, Cysteine; D, Aspartic acid; E, Glutamic acid; G, Glycine; P, Proline; S, Serine; T, Threonine; Y, Tyrosine. The 
genomic coordinates are from the GRCh37/hg19 reference genome, Nucleobases - A, adenine; G, guanine; C, cytosine; T, tyrosine. 
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NRXN2α is thought to be involved in neuronal cell adhesion and in calcium channel 
activity regulation (Futai and Hayashi, 2008; Reissner et al., 2008). ACTN3 functions as 
a structural component of sarcomere Z line regulating calcium ion binding and actin 
binding (Quinlan et al., 2010). CDC27 forms a part of an essential ubiquitin-protein ligase 
called the anaphase-promoting complex without which the cell division cycle in 
mammalian cells stops at Metaphase (Topper et al., 2002). 
POU2F1 mainly regulates transcription of specific genes in the nucleus as a ubiquitous 
protein (Ng M. C. Y. et al., 2010). TEP1 has been previously found to be a component of 
the telomerase complex, maintaining chromosome termini and shown to interact 
specifically with telomerase reverse transcriptase (Harrington et al., 1997; Weinrich et 
al., 1997). CFAP65 is reported to be involved in regulating spermatogenesis and flagellar 
development (Tang et al., 2017). 
RFT1 has been shown to encode an enzyme that catalyses the translocation of 
intermediate substrates from the cytosolic to the luminal side of the endoplasmic 
reticulum membrane (Haeuptle et al., 2008; Helenius et al., 2002). CCNF forms a part of 
a F-box motif which is an E3 ubiquitin-protein ligase complex mediating the 
ubiquitination of cellular substrates (Williams et al., 2016). The last of the nine genes 
TUBB6 encodes a Tubulin polymer, which forms protofilaments, the major constituent of 
microtubules in the cytoskeleton (Sun et al., 2007). 
3.3. Sanger Sequencing Validation of Variants 
To ensure that the nine variants found using WES in the three affected individuals are 
not sequencing artefacts, Sanger sequencing was performed. The two newly diagnosed 
individuals and the unaffected family members whose samples were available, were also 
Sanger sequenced for co-segregation analysis. PCR was used to amplify the region around 
each variant from gDNA, and Sanger sequencing was performed in both the forward and 
reverse directions. The Sanger sequencing chromatograms generated from the screening 
of the nine variants in individual 11.844 (Proband) are shown in Figure 3.2. The variant 
genotyping results of the entire family are summarised in Table 3.4. The four WES 
variants that were found to be sequencing artefacts in the three affected individuals were 
subsequently excluded from the co-segregation analysis.  
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Gene Sequence around variant Chromatogram 
Validated Variants 
CFAP65 CAACTGC[A]CCCTCT 
 
RFT1 CTGG[C]TGGCC 
 
NRXN2α AATG[G]CCAG 
 
TEP1 AGGT[A]CATA 
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Gene Sequence around variant Chromatogram 
CCNF ATCT[G]CACC 
 
Non-Validated Variants 
POU2F1 CTCC[G]CCAG 
 
ACTN3 CTGG[A]GGTC 
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Gene Sequence around variant Chromatogram 
CDC27 TGTT[A]TTAC 
 
TUBB6 GCCA[C]CGCCA 
 
Figure 3.2 Sanger sequencing validation of WES co-segregating variants. Chr, chromosome; Nucleobases - A, Adenine; G, Guanine; C, 
Cytosine, T, Tyrosine . Variants of interest are indicated by [ ] in the sequence column, and by a solid line through the variant base on the 
chromatograph.  
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Table 3.4 Genotyping of the five validated variants in the family. 
 
Gene 
CFAP65 RFT1 NRXN2α TEP1 CCNF 
Affected 
individuals 
11.844 
(proband) 
Yes Yes Yes Yes Yes 
12.726 
(sibling of 
proband) 
Yes Yes Yes Yes Yes 
92.32 
(nephew) 
Yes Yes Yes Yes Yes 
92.33 
(sibling) 
Yes Yes Yes Yes Yes 
11.902 
(cousin) 
Yes No No No No 
Unaffected 
individuals 
94.06 
(cousin) 
No No No No Yes 
94.05 
(nephew) 
No No No No Yes 
11.901 
(cousin) 
No No No No Yes 
10.202 
(spouse of 
sibling) 
No No No No No 
The relationships that are shown for each family member are in reference to the proband; 
Yes, Variant is Present; No, Variant is Absent. 
 
Of the nine prioritised variants, five (CFAP65, RFT1, NRXN2α, TEP1 and CCNF) were 
validated by Sanger sequencing and four (POU2F1, ACTN3, CDC27 and TUBB6) were 
considered sequencing artefacts. The five validated variants were all present in four of the 
affected individuals, one affected individual (11.902) had only one of the five validated 
sequence variants, in the CFAP65 gene. The unaffected family members only shared one 
co-segregating variant with the affected individuals, in the CCNF gene, which indicates 
that this variant might be a rare polymorphism. 
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3.4. Bioinformatic In-silico Analysis Using Functional Prediction Tools 
The amino acid changes for each variant are recorded in Table 3.5. None of the base 
changes reported occurred in the interchangeable third base position (wobble base) and 
therefore all resulted in non-synonymous exonic changes in the proteins. The RFT1 A463G 
variant causes a transition from Alanine, a small non-polar, aliphatic amino acid to 
glycine which is also a small non-essential, non-polar amino acid. TEP1 and CCNF both 
had the substitution from one polar group to another. The TEP1 Y412C variant changes 
tyrosine, an aromatic amino acid with a polar side chain to Cysteine which is a smaller, 
non-charged, polar amino acid. The variant occurring in CCNF C363S changes Cysteine, 
a polar, non-charged amino acid to Serine which is a much smaller, polar amino acid with 
a hydroxymethyl side chain. The exchange of a polar group for a non-polar one was 
observed in both CFAP65 and NRXN2α. The CFAP65 T1023A variant causes Threonine 
which is a polar, uncharged amino acid to be substituted by an Alanine, a smaller non-
polar, aliphatic amino acid. The NRXN2α G849D amino acid change was from glycine a 
small, non-polar, side chain free amino acid, to Aspartic acid a larger, negatively charged 
amino acid. 
 Various functional prediction tools were used to further prioritise the sequence variants. 
The results of the computational analysis performed are summarised in Table 3.5 with 
the functional scores and predictions from SIFT, PolyPhen-2, MutationTaster, GERP++ 
and CADD indicated. The TEP1 variant was predicted to be benign across all the different 
prediction tools with a CADD score of zero and with a gene GERP++ score of - 8,29. The 
conservation score indicates that in the region of the genome where this variant occurs, 
more substitutions occur than for the average neutral site, thus indicating that this region 
may not be under evolutionary constraint.  
The variant occurring in RFT1 was also predicted to be benign by all four tools, although 
though its conservation score implies that it occurs in a region under evolutionary 
constraint. The CFAP65 and CCNF variants both had three out of the four different 
computational tools predicting them to be pathogenic, and the gene conservation scores 
were positive indicating that they both occurred in regions of the genome under 
evolutionary constraint. The only variant that was predicted to be pathogenic across all 
four functional prediction tools was NRXN2α, which had a CADD score of 29,50 and a 
conservation score of 4,93 showing that the level of evolutionary constraint inferred to be 
acting on this site is rather high.  
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Table 3.5 Computational tool scores and predictions for validated variants. 
Chr Gene 
cDNA 
Pos 
Amino 
Acid 
Pos 
Codon 
Change 
Gene 
Pos 
Exon 
SIFT 
Pred 
PolyPhen2 
Pred 
Mut 
Taster 
Pred 
GERP CADD 
2 
CFAP65 
c.A3151G p.T1023A ACC⇒GCC exonic 18 Deleterious Benign 
Disease-
causing 
2,38 18,70 
3 RFT1 c.C1450G p.A463G GCT⇒GGT exonic 12 Tolerated Benign Neutral 2,53 4,96 
11 NRXN2α c.G3008A p.G849D GGC⇒GAC exonic 13 Deleterious 
Probably 
Damaging 
Disease-
causing 
4,93 29,50 
14 TEP1 c.A1276G p.Y412C TAC⇒TGC exonic 7 Tolerated Benign Neutral -8,29 0,00 
16 CCNF c.G1176C p.C363S TGC⇒TCC exonic 10 Tolerated 
Probably 
Damaging 
Disease-
causing 
5,43 27,30 
Chr, chromosome; Pos, position, p., protein codon position, Nucleobases - A, adenine; G, guanine; C, cytosine; Amino acids – A, Alanine; C, 
Cysteine; D, Aspartic acid; E, Glutamic acid; G, Glycine; P, Proline; S, Serine; T, Threonine; Y, Tyrosine. 
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3.5. Frequency of Variants in Controls  
3.5.1. Screening Online Frequency Databases 
To determine the frequency of the validated variants in multiple control populations an 
extensive search was performed in publicly available databases including the ExAC 
database and the 1000 Genomes Project (Table 3.6). Results from the databases revealed 
that four of the five validated variants had not been previously reported. This could mean 
they are either extremely rare or novel variants in the screened African American, 
American, East Asian, South Asian, Finnish and Non-Finnish European population 
exome data. The CFAP65 variant had been previously reported and was found to be 
present in the ExAC Aggregated Population at a MAF frequency of 17 out of 2 100 000 
individuals. In assessing the allele frequency of these variants, it is important to consider 
not just the publicly available online databases, but also to screen the appropriate 
ethnically-matched control individuals. 
3.5.2. Screening the Local Population 
To determine the allele frequency in ethnically-matched control samples, HRM analysis 
was performed on 192 SA Caucasian controls, 96 of which self-identified as Afrikaner. The 
HRM results for the NRXN2α variant are shown in Figure 3.3. For this variant, the 
reference allele is a guanine and the variant allele is an adenine residue. Both the melt 
curve (Figure 3.3 A) and the difference graph (Figure 3.3 B) distinguish the variant in 
the positive control (individual 11.844) from the wild-type allele in healthy controls. None 
of the 192 ethnically-matched controls had any of the five variants (Appendix; Table 3). 
The absence of the validated variants in the local control population means that the 
variants are rare. 
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Figure 3.3 HRM analysis performed on the G849D variant in NRXN2α, showing 
that the positive control sample melts differently from all the wild-type controls. A, Melt 
curve showing the that the different genetic sequences melt at slightly different rates. B, 
The Difference graph shows the normalised fluorescence of all the samples subtracted 
from a selected reference sample at different temperatures. The positive control was 
selected as the reference in this difference graph. Fluorescence is plotted on the y-axis and 
temperature in degrees Celsius is plotted on the x-axis. 
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Table 3.6 Allele frequencies for the five variants in multiple control populations. 
Chr, chromosome; ExAC, Exome Aggregation Consortium; AFR, African; AFR AMR, African American, AGG, Aggregated population, 
AMR, American; EAS, East Asian; EUR, European; SA, South African. Amino acids – A, Alanine; C, Cysteine; D, Aspartic acid; E, Glutamic 
acid; G, Glycine; P, Proline; S, Serine; T, Threonine; Y, Tyrosine. 
 Online databases 
Present 
Study 
Chr Gene 
Amino 
acid 
Pos 
1000 
Gen 
AFR 
AMR 
1000 
Gen 
AMR 
1000 
Gen 
EAS 
1000 
Gen 
EUR 
ExAC 
AFR 
AMR 
ExAC 
AMR 
ExAC 
EAS 
ExAC  
Finnish 
ExAC 
Non-
Finnish 
EUR 
ExAC 
AGG 
HRM 
Results 
2 CFAP65 p.T1023A 0 0 0 0 0 0 0 0 0 
34/4 
200000 
0/384 
3 RFT1 p.A463G 0 0 0 0 0 0 0 0 0 0 0/384 
11 NRXN2α p.G849D 0 0 0 0 0 0 0 0 0 0 0/384 
14 TEP1 p.Y412C 0 0 0 0 0 0 0 0 0 0 0/384 
16 CCNF p.C363S 0 0 0 0 0 0 0 0 0 0 0/384 
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3.6. Pathway and Expression Analysis 
To add further information about the possible causal role of the variants, gene expression 
profiles across the human body and various human brain regions were assessed using 
publicly available databases, namely the Allen Brain Atlas (Sunkin et al., 2013) and the 
Human Protein Atlas (Pontén F. et al., 2011). Pathway analysis was also performed using 
KEGG Pathways Analysis (Kanehisa and Goto, 2000) and PANTHER Pathway Analysis 
(Mi and Thomas, 2009) to determine if any of the genes containing the five of variants are 
co-expressed, co-regulated or co- localize with each other or any of the known PD genes. 
This analysis also shows if the genes containing the variants and any of the known PD 
genes are functionally related or impact a pathway of interest such as neuronal 
development, regulation and functioning. 
The results in Table 3.7 show that none of the five variants interacted with any of the 
known PD genes. NRXN2α was noted by both the Allen Brain Atlas and the Human 
Protein Atlas to be highly expressed in the brain and selectively in the substantia nigra, 
a key brain region in PD pathogenesis. Pathway analysis showed that NRXN2α was 
involved in pathways that regulate synaptic functioning, neurotransmitter secretion and 
neuronal cell to cell adhesion. RFT1 was the only other gene to be reported as highly 
expressed in the brain, it was implicated in pathways of protein metabolism and of the 
endoplasmic reticulum membrane network. 
CFAP65 expression was highest in the ciliac processes in the testis, fallopian tube and 
lungs, and it was associated with motile cilia pathway. TEP1 is expressed in all tissues of 
the body with expression reported to be low in the brain. It is reported to be involved in 
apoptotic pathways and in assembling telomerase components in cell signalling. Lastly 
CCNF, which was had low expression in the brain, was highly expressed in immunological 
tissues such as the lymph nodes, skin, appendix and bone marrow. It was associated with 
pathways of ubiquitination and cell cycle regulation. 
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Table 3.7 Summary of the expression and pathway analysis for the five proteins 
Protein 
Amino Acid 
Pos 
Allen Brain Atlas Human Protein Atlas 
KEGG Pathways 
Analysis 
PANTHER 
Pathway Analysis 
CFAP65  p.T1023A o NR o Testis 
o Fallopian Tube 
o Lung 
o Nonhomologous 
End Joining 
o Cyano-Amino 
Acid Metabolism 
o Motile Cilium 
RFT1 p.A463G o Expressed in all 
brain cells 
o Cardiac Muscle 
o Skeletal Muscle 
o Cerebral cortex 
o Hippocampus 
o Caudate 
o Cerebellum 
o Placenta 
o Endoplasmic 
Reticulum 
Membrane 
Network 
o N-Glycan 
Biosynthesis 
o Metabolism of 
proteins 
o Endoplasmic 
Reticulum 
Membrane 
Network 
NRXN2α p.G849D o Paravermis 
o Substantia Nigra 
(Pars Reticulata) 
o Exclusively expressed 
in the brain 
o Highest in the 
Cerebral Cortex 
o Cell adhesion 
molecules 
o Tight junction 
o Synaptic 
regulation 
o Neuron cell-cell 
adhesion 
o Chemical 
synaptic 
transmission 
o Neurotransmitter 
secretion 
o Regulation of 
molecular 
function 
o Synapse 
assembly 
o Postsynaptic 
membrane 
assembly 
TEP1 p.Y412C o Paravermis 
o Left, Lateral 
Hemisphere 
o Expressed in all 
tissues 
o Apoptotic 
Pathways 
o CCKR signalling 
map 
o p53 pathway 
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Chr, chromosome; Pos, position; KEGG, Kyoto Encyclopaedia of Genes and Genomes, NR, not reported 
o Highest in 
Parathyroid gland 
and Duodenum 
o Telomerase 
Components in 
Cell Signalling 
o Inflammation 
mediated 
Cytokine 
Signalling 
Pathway 
CCNF p.C363S o Cingulate Gyrus 
o Left, Lateral 
Hemisphere 
o Tonsil 
o Lymph node 
o Skin 
o Appendix 
o Bone marrow 
o Cerebral cortex 
o Ubiquitin 
mediated 
proteolysis 
o Cell cycle 
o Ubiquitination 
and Proteasome 
degradation 
o Cell cycle 
regulation 
o Regulation of 
phosphate 
metabolic process 
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3.7. Selection of Functional Candidate from Gene List 
Of all five prioritised genes, NRXN2α is the strongest candidate based on the following 
evidence. It was shared by the four affected individuals with a similar disease phenotype. 
All four of the sequence-based computational tools correlated in their prediction of this 
variant being a pathogenic mutation with CADD classifying it within 0,1% of the most 
possible pathogenic substitutions that could have occurred at that specific locus (Table 
3.5). The genome region where this variant occurs was reported to be highly conserved by 
GERP++ and it had the most severe codon change from a non-polar amino acid to a polar 
one. The NRXN2α variant was absent in the unaffected family members (Table 3.4), the 
ethnicity-matched matched neurologically normal controls and the populations screened 
on the online databases (Table 3.6). NRXN2α protein was reported by the pathway and 
expression databases to function in neuronal cell-cell adhesion, neurotransmitter 
secretion regulation and synaptic regulation (Table 3.7) and found to be highly expressed 
in the Pars Reticulata of the substantia nigra, a key brain region in PD pathogenesis. This 
makes it an ideal candidate for further analysis. 
Based on meeting the requirements of the prioritisation criteria in all aspects, NRXN2α 
was the top candidate gene to be considered for further study. Although in-silico tools 
have enabled efficient, informative and reliable filtration strategies to filter candidate 
genes for disease, it is vital to functionally validate the prioritised novel candidate gene 
to validate the biological significance of the genes in a relevant disease model.  
B. Results of Prioritised Gene Studies 
Although computational analysis predicted the pathogenicity of the candidate variant in 
NRXN2α, characterisation of the variant and its protein is necessary to validate the in-
silico predictions. 
3.8. Frequency of NRXN2α Variant in South African Parkinson’s Disease 
Patients 
3.8.1. South African Parkinson’s Disease Patients 
To determine if the NRXN2α c.G3008A (p.G849D) variant is present in unrelated PD 
patients, HRM analysis was performed on 671 SA PD patients of various ethnicities 
(Afrikaner Caucasian 192, non-Afrikaner Caucasian 96, Black 192, Mixed Ancestry 96 
and Indian 75). As previously shown by the HRM screening of this variant in ethnically- 
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matched controls, the variant allele (A) can clearly be distinguished from the wild-type 
allele (G) in the melt curve and the difference graph (Figure 3.3 A and B).  
As with the control screening experiments, the positive control was the patient, individual 
11.844, in whom the variant was validated by Sanger sequencing. The HRM screening 
showed that the variant was not found in any of the 671 patient samples. For validation, 
one sample was selected from each run (30 samples in total) to be Sanger sequenced. The 
Sanger results confirmed the HRM analysis results, that none of the PD patients had the 
NRXN2α c.G3008A variant allele. 
3.8.2. International Cohort of Patients with Parkinson’s Disease 
To further screen a different subset of PD patients for other variants in the NRXN2α, 
Annex (https://annex.can.ubc.ca/about) was searched. The search for NRXN2α variants 
that were specifically found in diagnosed PD patients on this database yielded 24 genetic 
variants that were shared amongst 50 patients (Table 3.8). The only individuals who had 
the p.G849D variant in the database, are the affected individuals from our family who 
were sequenced by Prof. Farrer. All 24 variants are exonic and a total of 12 variants of 
the 24 were indels of various lengths. Majority of the variants were novel and not present 
on the inbuilt frequency database GnomAD with most CADD scores above 20. 
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Table 3.8 The screening results of exome data base Annex for NRXN2α variants 
Genome 
Position 
Ref/Alt Variant Zygosity 
No. of 
PD 
patients 
Unaffected 
(Non-PD) 
dbSNP CADD GnomAD 
64374723 G/T p.A649D Het 1 0 Novel 12,6 NA 
64375161 AC/GA c.1507_1508TC Het 1 0 Novel NA NA 
64375171 C/CCG c.1498_1498delinsCGG Het/Hom 3 0 Novel NA NA 
64375212 G/T p.P486H Het 1 0 Novel 9,56 NA 
64375283 C/CA c.1386_1386delinsTG Hom 1 0 Novel NA NA 
64375321 C/G p.A450P Het 1 0 Novel 21,7 NA 
64375390 /AG c.1279_1279delinsCT Hom 2 0 Novel NA NA 
64375473 G/C p.P399R Het 4 0 Novel 13,9 NA 
64387795 T/A p.E362V Het 1 0 Novel 28,3 NA 
64390345 C/A c.915G>T:p.E305D Het 2 1 rs370812331 20,9 1,6e-5 
64390450 A/C c.810T>G:p.N270K Het 1 0 Novel 25,1 NA 
64393933 A/C c.3847+2T>G Hom 1 0 Novel 24,4 NA 
64415814 G/C c.3284-4C>G Het 1 0 rs555038789 10,3 4,4e-4 
64416245 C/CA c.3124_3124delinsTG Het 1 0 Novel NA NA 
64416356 T/C p.S1005G Het 7 4 rs148473653 20,2 1,8e-3 
64418793 G/C p.P911R Het 2 0 Novel 25,9 NA 
64418979 C/T p.G849D Het 3 0 Novel 29,3 NA 
64428522 C/T p.G599S Het 2 0 rs561880923 33,0 9,0e-5 
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Genome 
Position 
Ref/Alt Variant Zygosity 
No. of 
PD 
patients 
Unaffected 
(Non-PD) 
dbSNP CADD GnomAD 
64434997 C/T p.R477H Het 5 0 rs140588352 24,4 8,0e-4 
64480499 CG/C c.672_673G Het 1 0 Novel NA NA 
64480574 C/T c.598G>A:p.A200T Het 4 0 rs797045803 19,7 7,2e-4 
64480610 G/C c.562C>G:p.P188A Het 3 8 Novel 0,758 NA 
64480970 AG/GC c.201_202GC Het 1 0 Novel NA NA 
64480978 AGC/A c.192_194T Het 1 0 Novel NA 0,0e+0 
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3.9. Structural Analysis of NRXN2α Protein with and Without Mutation 
In the protein structural analysis, we used in-silico modelling to predict the effect of the 
NRXN2α G849D variant on protein structure. The amino acid change occurs in the 
laminin G-like domain four. The variant residue Aspartic acid is much larger than the 
wild-type residue glycine. Also, the glycine residue is a non-polar, side chain free amino 
acid while the variant introduces a negatively charged amino acid with a carboxyl group 
side chain (CH2COOH) (Figure 3.4). The introduction of Aspartic acid could lead to 
unwanted interactions with the neighbouring residues and could possibly affect the 
function and activity of the protein.  
 
Figure 3.4 NRXN2α G849D amino acid residues. The amino acid structures of A. 
Glycine (G) and B. Aspartic acid (D).  
To model NRXN2α, the relevant template was identified on Swiss-Model 
(https://swissmodel.expasy.org/) using the Uniprot ID number Q9P2S2 (Transcript 
ENST00000265459.10) for the longest human NRXN2α protein. The homologous template 
PDBID 3qcw (Neurexin 1 alpha, from Bos Taurus) was chosen for structure prediction 
because it shared 71,60 % sequence identity and over 52% structural similarity with the 
target protein. The full crystal structure of the NRXN2α protein is still to be solved so the 
NRXN1α template was chosen instead.  
The GMQE score of the model was 0,62 (closer to one indicates greater reliability) and the 
QMEAN score was -0,86 (the closer to zero the more accurate the model) which suggests 
that the predicted model was reliable and accurate (Figure 3.5). The replacement residue 
did not appear to affect the secondary structure of the protein (α-helix), however the amino 
acids do greatly differ in size . 
A.  B.  
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Figure 3.5 Superimposition of the predicted NRXN2α G849D model onto the 
homologous template structure the wild-type residue, Glycine (G), is shown in green 
and the mutant residue, Aspartic acid (D), is shown in light blue.  
3.10. Generation of cDNA from Foetal Brain RNA Library  
Full-length NRXN2α cDNA is not commercially available. The approach in this study was 
therefore to generate full-length NRXN2α cDNA using reverse transcription of the 
Human Foetal Brain RNA library. The variant form of the protein would then be 
generated by site directed mutagenesis to facilitate functional studies, in which the 
variant impact versus the wild-type could be assessed in a neuronal cell line. 
3.10.1. cDNA Quality Assessment by Spectrophotometry and 
Gel Electrophoresis 
To generate a full-length gene product of NRXN2α, cDNA was synthesised using the 
QuantiNova™ Reverse Transcription kit (Qiagen, Hilden, Germany) from a commercially 
available Human Foetal Brain RNA library. The kit contains a RT Primer Mix that 
consists of a unique blend of oligo-dT (specificity for poly(A) tails) and random primers 
(can potentially anneal to any complementary RNA in the sample). This ensures that RT 
reaction will yield both full-length cDNA from RNA with poly(A) tail and fragmented 
cDNA templates from the library (including those generated from degraded RNA).  
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The concentration and purity of the cDNA generated, was measured by a NanoDrop 
spectrophotometer. An internal RNA control supplied with the RT kit was also included 
in the analysis to verify that the experiment worked. The measurements were taken using 
the ‘DNA mode’ and a no template control that was included in the RT was used as a 
blank. The concentration of the cDNA and the positive control was 2939,7 ng/ul and the 
RT internal control was 2971,1 ng/ul (Table 3.9). This suggests that the RT reaction 
worked well. The cDNA had a 260/280 ratio value of 1,85. This is the ratio of absorbance 
at 260nm and 280nm which is conventionally used to assess the purity of the nucleic acids, 
and it is generally accepted that a 260/280 ratio that is greater than 1,80 indicates 
adequate purity and integrity of DNA. The 260/230 ratio is a second measure of DNA 
purity, with the value of pure nucleic acids being within the range of 1,8-2,2.  
Table 3.9 cDNA concentration and purity results obtained from NanoDrop 
Sample 
Nucleic acid 
concentration 
Unit 260/230 260/280 
cDNA 
Library 
2939,7 ng/ul 1,78 1,85 
RT internal 
control 
2971,1 ng/ul 1,77 1,84 
 
The NanoDrop can give an indication of the purity of nucleic acids however it cannot 
distinguish between cDNA and gDNA contamination. Therefore, agarose gel 
electrophoresis was performed to distinguish between gDNA and cDNA on the basis of 
fragment size (Figure 3.6). The cDNA sample was loaded at two different amounts and 
a gDNA sample was included as a reference. Since cDNA was synthesised using RT 
random primers and oligo-dT primers, it is expected that there will be cDNA fragments 
of varying lengths, which will appear as a smear. When gDNA is not subjected to any sort 
of PCR amplification or shearing it remains very large in size, due to size exclusion it 
would not be able to move into the gel. This would result in a single solid band in the well 
where it was loaded. 
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Figure 3.6 Agarose gel electrophoresis to distinguish between genomic DNA and 
complementary DNA. cDNA generated from a Human Foetal Brain RNA library was 
run at two different concentrations on a 1% agarose gel. In lane 1 contains 800 ng of cDNA, 
lane 2 contains 400 ng cDNA at and lane 3 contains 90 ng of gDNA. M is a 100 bp DNA 
ladder (O'RangeRuler™ DNA Ladder, Thermo Scientific). 
Figure 3.6 shows that there was no gDNA contamination in the cDNA. Both the cDNA 
lanes appear to be smears, but lane 2 was faint. The smear shows the different sized 
fragments that were synthesised from the RNA library. 
3.10.2. cDNA Quality Assessment by Polymerase Chain 
Reaction 
3.10.2.1. Amplification of Exon 1 To Exon 2 of HBB from cDNA 
To further verify the purity of the generated cDNA from possible gDNA contamination, a 
section of the Human Beta-globin (HBB) gene was amplified. The HBB primer pair had 
been previously designed to span a small intron (130 bp) between exon 1 and exon 2. The 
presence of this small intron in gDNA will generate a product of 377 base pairs (bp), while 
the cDNA, which lacks the intron, will generate a product of 247 bp (Figure 2.3). As 
expected, the cDNA template yielded a PCR product of between 200 to 300 bp in size and 
the gDNA produced a PCR product of between 300 to 400 bp (Figure 3.7). 
3000 bp 
M              1             2                3 
100 bp 
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Figure 3.7 Visualisation of HBB products on a 1% agarose gel. In lane 1 is the gDNA 
product between 300-400bp, in lane 2 is the cDNA product between 200-300bp and in lane 
3 is the no template control (NTC). A 100 bp ladder was used (O'RangeRuler™ DNA 
Ladder, Thermo Scientific). 
The HBB amplification yielded products of the expected size indicating that there was no 
gDNA contamination in the synthesised cDNA. Sanger sequencing of the PCR products 
was conducted to confirm that the fragments obtained corresponded to the correct 
fragments. The sequencing confirmed that the observed products were indeed from HBB, 
and the sequence aligned to the reference at the correct size (Figure 3.9). The successful 
amplification from the cDNA also demonstrates that the RT experiment did successfully 
generate cDNA, as Taq polymerase are not able to amplify from RNA.  
These quality assessments are important because gDNA contamination might result in 
false-positive results in downstream analysis or increase the chances of non-specific 
binding of the primers in subsequent experiments. Since the HBB primers span only one 
intron, it was decided to use another primer set that spans multiple exons in order to 
further evaluate the quality of the cDNA. 
3.10.2.2. Amplification of Exon 2 To Exon 5 of PARK2 from cDNA 
To assess if there was RNA degradation in the Human Foetal Brain Library, the 
amplification of a longer product that spans multiple exons was necessary. Primers for 
another gene, PARK2 had been previously designed to amplify a region spanning from 
exon 2 to exon 5. For cDNA, these primers would produce a PCR product of 419bp whereas 
for gDNA the introns would result in a product 389 151 bp product which would not 
amplify by PCR (Figure 2.4). Figures 3.8 shows that the 419bp PCR product was 
successfully amplified from the cDNA. Sanger sequencing confirmed that the sequence 
corresponded to the correct region in PARK2 gene (Figure 3.10). Whereas the gDNA 
template did not produce a band as expected.  
800 bp 
 M            1            2            3 
100 bp 
400 bp 
300 bp 
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Figure 3.8 Visualisation of PARK2 PCR amplification products on a 1% agarose 
gel. In lane 1 and 2 are the PCR products from the synthesised cDNA, in lane 3 and 4 are 
the gDNA products and the NTC is in lane 5. M is a 100bp ladder (O'RangeRuler™ DNA 
Ladder, Thermo Scientific). 
These experiments verified that the synthesised cDNA was not contaminated with gDNA, 
that the RT of the Foetal Brain Library did synthesise cDNA fragments and these 
fragments spanned multiple exons. Taken together, this means that in theory, the cDNA 
is of sufficient quantity and quality to generate full-length NRXN2α cDNA. 
400 bp 
800 bp 
 M         1             2           3         4        5 
100 bp 
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Figure 3.9 Partial sequence chromatograph and alignment of the HBB cDNA fragments with an HBB cDNA reference. The cDNA 
amplicon is aligning accurately to the reference and was the expected size of 251 bp. 
Figure 3.10 Alignment of PARK2 cDNA fragment. The PARK2 cDNA amplicon correctly aligned to the cDNA reference sequence which 
confirms that the correct product was amplified from the cDNA, it was also the expected size of 400bp.
Gene 
Sequence origin 
Sequencing Result 
HBB 
Reference sequence 
cDNA PCR product 
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3.11. Polymerase Chain Reaction of NRXN2α from cDNA 
3.11.1. Amplification of Full-Length NRXN2α Inserts for 
Cloning 
The reason behind generating this full-length NRXN2α insert was to clone the insert into 
a pDsRed-Monomer-C1 vector for transfection into SH-SY5Y cells for further study of the 
gene in a neuronal cell model. 
Primers pairs (Section 2.10 in Methods), for the full-length NRXN2α gene were used to 
amplify full-length NRXN2α from the generated cDNA. The expected full-length NRXN2α 
fragment size is 5139 bp. In order to optimise the PCR conditions, annealing was 
performed at a range of temperatures from 50 to 62°C, at increments of 1°C (Figure 3.11). 
The gel electrophoresis showed that the majority of the 12 PCR reactions produced 
multiple bands and none of these bands corresponded to the expected size. 
 
Figure 3.11 Visualisation of PCR products generated using full-length NRXN2α 
primers on a 1% agarose gel. In lane 1 is the lowest annealing temperature of 50 0C, and 
in lane 12 is the highest temperature of 62 0C. In the lanes between lanes 1 and 12, the 
annealing temperature increases in increments of 10C. The NTC is in lane 13. M is a 
500bp DNA ladder (O'RangeRuler™ DNA Ladder, Thermo Scientific) and the expected 
PCR product size is 5139 bp.  
The multiple products observed are likely as a result of non-specific primer binding. 
Further PCR optimisation was performed by adding dimethyl sulfoxide (DMSO) at a 5% 
concentration and the MgCl2 concentration was also increased to 2,5 μM (Figure 3.12). 
DMSO was added to the PCR because of the high GC content in NRXN2α, the rationale 
being that DMSO would forms hydrogen bond with template cDNA, and as a result 
destabilise the double helix structure. This should in theory allow for easier primer 
binding and full-length amplification. The increase of MgCl2 concentration by a 0,5 μM 
increment was done to ensure verify that Taq polymerase had sufficient cofactor to 
2000 bp 
6000 bp 
1000 bp 
M     1     2      3      4     5      6     7      8      9    10    11    12   13    
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catalyse its activity and increase specificity. The resulting PCR products were larger than 
previously observed, between 2500 and 3000bp at annealing temperatures of 52 0C and 
530C. However, a product of the correct size was not observed.  
 
Figure 3.12 NRXN2α optimised PCR products on a 1% agarose gel. In lane 1 is the 
lowest annealing temperature of 52 0C, in lane 2 is 53 0C, in lane 4 is 54 0C, in lane 5 is 
550C and in lane 6 is the highest temperature of 560C. M is a 500bp DNA ladder 
(O'RangeRuler™ DNA Ladder, Thermo Scientific) and the expected PCR product size is 
5139 bp. The NTC is in lane 7.  
In an attempt to generate the correct PCR product, a different polymerase was chosen for 
amplification. Instead of GoTaq DNA Polymerase, Phusion® High-Fidelity DNA 
Polymerase was used. Phusion DNA Polymerase is ideal for amplifying difficult and large 
amplicons because it has a DNA-binding protein domain which enables attachment to the 
template for very long amplifications. It also has proofreading ability, therefore it is likely 
to produce a product that is more accurate.  
The gradient PCR was performed from 52 0C to 600C with increments of 10C (Figure 
3.13). A single sized product was observed at all annealing temperatures with Phusion, 
showing greater specificity than that of the GoTaq reactions. The products amplified were 
much smaller (~2 kb) than the expected size, indicating that the desired product of ~5 kb 
was still not amplified. 
2500 bp 
1000 bp 
M      1       2      3      4        5      6       7    
6000 bp 
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Figure 3.13 The amplification of NRXN2α using Phusion® High-Fidelity DNA 
Polymerase Taq, on a 1% agarose gel. The range of annealing temperatures is between 
52 C to 60C, increasing by 1C per lane. The PCR reaction are shown in lanes 1 to 9. A 
NTC was added to lane 10, which is not seen above. M is the1kb ladder . 
3.11.2. Assessment of Polymerase Chain Reaction Using 
Large Products 
To prove that the failure to amplify full-length NRXN2α from the cDNA was not due to 
experimental error or a problem with the PCR reagents, PCR amplification was performed 
using GoTaq DNA Polymerase on another similar-sized product. 
The p2Nsm3125LS plasmid and PCR primers (Section 2.3, Methods) which are known 
to amplify a product of 4039 bp, were used. The reaction was done in triplicate and the 
expected PCR product was successfully amplified as shown in Figure 3.14. This showed 
that the failure to amplify the full-length NRXN2α gene was not as a result of technical 
or experimental problems, nor was it the size limitations of the polymerase or the 
reagents.  
 
Figure 3.14 The amplification of the p2Nsm3125LS plasmid product shown on a 
1% agarose gel. In lane 1 to lane 3 is the plasmid amplicon, in size it is just beneath the 
5000 bp marker. M denotes the lane of the 1kb ladder used. The NTC is in lane 4 
6000 bp 
250 bp 
 M          1        2        3         4         5        6         7        8        9       
11    12   13    
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3.11.3. Polymerase Chain Reaction of NRXN2α Using Internal 
Primers to Generate Full-length CDNA 
As an alternative to amplifying full-length NRXN2α cDNA (expected fragment size 
5139bp) from the cDNA library generated, two new primer pairs were designed to amplify 
the NRXN2α gene in two overlapping fragments (one of 2593bp and the second of 2633 
bp). These primers are described in Table 2.2 in the Materials and Methods section. An 
internal NdeI site would facilitate subsequent ‘stitching’ of the two fragments to generate 
the full-length gene. Restriction enzyme sites for downstream ligation and cloning were 
added at the 5’ and 3’ ends of the gene. The rationale for these primers was that we 
thought that it may be easier to PCR the two smaller fragments instead of the 5kb 
fragment if the RNA in the library was partially degraded. 
The initial attempts to amplify the two fragments using a standard protocol and PCR 
conditions were unsuccessful as seen by the lack of products in the lanes of the agarose 
gel electrophoresis in Figure 3.15 A and B.  
 
Figure 3.15 PCR amplification of shorter NRXN2α primers on a 1 % agarose gel. 
A. NRXN2α EcoR1 5’ Forward and NRXN2α Internal 2 Reverse, the expected PCR 
product size is 2594 bp. In lane 1 to lane 3 are the three cDNA amplification products 
done in triplicate. The NTC is in lane 4. B. NRXN2α Internal 1 Forward and NRXN2α 
SAL1 3’ Reverse, the expected PCR product size is 2633bp. In lane 1 to lane 3 are the 
three cDNA amplification products done in triplicate, the NTC is in lane 4 and M is a 100 
bp DNA ladder (Solis BioDyne). 
Subsequently, we attempted to optimise the PCR by changing various factors. These 
included changing from Taq DNA Polymerase to High-Fidelity DNA Polymerase, the use 
of different annealing temperatures, modifying the concentration of the MgCl2 from 1,5 
µM to 2,5 µM and increasing the extension according to product size. However, the 
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bp 
100 
bp 
M        1        2         3      4 
1000 
bp 
3000 
bp 
 M    1        2          3        4 
100 
bp 
1000 
bp 
B. 
bp 
A. 
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optimisation attempts on the shorter NRXN2α primers to amplify the NRXN2α gene in 
two separate fragments were unsuccessful.  
3.11.4. cDNA Synthesis Using a NRXN2α Specific Reverse 
Transcription Gene Primers 
Lastly, in an effort to increase the reverse transcription efficiency and target specificity 
of the NRXN2α gene during cDNA synthesis from the Human Foetal Brain RNA library, 
we decided to use NRXN2α-specific primers during the initial cDNA synthesis step. A 
combination of four primers were designed that would bind to the 3´untranslated region 
(UTR) of the NRXN2α RNA, and these would be used instead of the random hexamers 
that were supplied with the QuantiNova™ Reverse Transcription kit, for cDNA synthesis. 
Due to cDNA being synthesised from multiple target specific primers, it is expected that 
if the resulting product was loaded on a gel there would be cDNA fragments around the 
size of the target gene (5139 bp). The gel electrophoresis (Figure 3.16) of the ‘gene specific’ 
cDNA shows a faint smear. The cDNA in lane 1 was previously synthesised from the RNA 
library using the hexamer primers that came with the kit and it was loaded as a positive 
control for reverse transcription. 
 
Figure 3.16 NRXN2α gene specific primers cDNA synthesis. Agarose gel 
electrophoresis of cDNA generated from a Human Foetal Brain RNA library. In lane1 is 
the previously generated cDNA using the hexamer primers included in the reverse 
transcription kit. In lane 2 is cDNA synthesised using NRXN2α specific primers. M is a 
100 bp DNA ladder (Solis BioDyne). 
Next, we attempted to amplify from this gene specific cDNA the NRXN2α gene using the 
primer sets that produce two overlapping fragments of ~2,5 kb. Standard PCR protocol 
and conditions were used in a gradient PCR to use multiple annealing temperatures on 
the primer sets. Though the gene specific cDNA was generated, the PCR of the two 
overlapping fragments of ~2,5 kb using normal Taq polymerase was unsuccessful. The 
PCR was repeated using the QIAGEN LongRange PCR Kit on the gene specific cDNA, but 
no amplification occurred.  
3000 bp 
100 bp 
M              1               2  
1000 bp 
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In summary, despite the design of several primer pairs, changing PCR reagents and 
multiple rounds of PCR optimisation attempts with both the hexamer generated cDNA as 
well as the ‘gene specific’ cDNA, full-length or two overlapping fragments of NRXN2α 
were never successfully produced from the Foetal brain library.  
3.11.5. Intron Spanning Primers to Generate Smaller 
Fragments of NRXN2α cDNA 
Since amplification of both full-length NRXN2α (~5kb) and the two overlapping fragments 
of NRXN2α from the gene specific cDNA were unsuccessful, we then considered whether 
the problem was the NRXN2α expression in the Human Foetal Brain RNA library. This 
could be as a result of degradation of the mRNA library caused by repeated freeze thaw 
cycles over time, or low levels of expression in the tissue from which the library was 
prepared. 
To examine this, we designed PCR primers to span small regions of NRXN2α cDNA. If a 
PCR product is produced it would mean that the synthesised cDNA library contained 
NRXN2α gene DNA fragments spanning multiple exons. The first primer set designed 
spanned from exon 2 to exon 7 and would produce a product of 475bp. The second primer 
set spanned from exon 19 to exon 22 and would produce a PCR product of 515bp.  
After optimisation, both the exon spanning primers successfully amplified the expected 
PCR product from the cDNA. The product generated from the exon 2 to exon 7 primer set 
produced a band close to 500 bp in size on the gel (Figure 3.17 A). The product was 
subsequently Sanger sequenced and produced the correct sequence which was 450 bp 
(Figure 3.18) with a sequence identity score of 92% to the NRXN2α cDNA reference. The 
exon 19 to exon 22 primer set, produced a band that was slightly above 500 bp in size 
(Figure 3.17 B). This product was also Sanger sequenced and produced a sequencing 
product that was 527 bp (Figure 3.19) and had a sequence similarity score of 88% 
compared to NRXN2α cDNA reference. The observed variation between the sequenced 
products and the gene reference might explain why the amplification of full-length 
NRXN2α did not work, primer binding sequences found using the reference might be not 
be locatable in the cDNA.  
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Figure 3.17 Gel electrophoresis of PCR products using the primers to generate 
smaller fragments of NRXN2α. The PCR products are visualised on a 1% agarose gel. 
A. NRXN2α Exon 2 to 7 product and the expected size is 475 bp. B. The gel of NRXN2α 
Exon 19 to 22 product and the expected size is 505 bp. In both gel image A and gel image 
B lane 1 to lane 3 are the gene specific cDNA amplifications products done in triplicate, 
the NTC is in lane 4 and M is a 100 bp DNA ladder (Solis BioDyne). 
The successful amplification of the fragments proves that there are NRXN2α fragments 
in the generated cDNA from the Human Foetal Brain RNA library. Sanger sequencing 
validated the products. This could mean that the gene cDNA might be fragmented, 
allowing only the amplification of smaller fragments. This might explain why the full-
length primers are unable to bind to the ends of the gene. 
 
3000 bp 
M      1       2         3     4 
500 bp 
3000 bp 
M       1        2       3       4 
500 bp 
A.  B.  
Stellenbosch University  https://scholar.sun.ac.za
85 
 
Sequence origin Bp Alignment 
Reference sequence 
cDNA PCR product 
1 – 75 
 
Reference sequence 
cDNA PCR product 
75 – 150 
 
Reference sequence 
cDNA PCR product 
150 – 225 
 
Reference sequence 
cDNA PCR product 
225 – 300 
 
Reference sequence 
cDNA PCR product 
300 – 375 
 
Reference sequence 
cDNA PCR product 
375 – 450 
 
Reference sequence 
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Figure 3.18 Sequence chromatograph and alignment Exon 2 to exon 7 cDNA product. The reference used for the alignment 
contains a 710 bp exon spanning from the end of exon 1 to the beginning of exon 8 region. The sequencing confirmed that the amplified 
product was the correct sequence and size.  
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Figure 3.19 Sequence chromatograph and alignment of Exon 19 to exon 22 cDNA product. The reference used for the alignment 
contains a 660 bp exon spanning from the end of exon 18 to the beginning of exon 23 region. The sequencing confirmed that the amplified 
product was the correct sequence and size.
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3.12. NRXN2α Protein Analysis 
3.12.1. Determining the NRXN2α Protein Concentration in 
Neuroblastoma Cells  
It was initially the intention to study the functional effect of NRXN2α G849D in 
comparison to the wild-type in an appropriate neuronal cellular model. Due to the inability 
to generate the full-length cloning insert of NRXN2α for the functional effect studies, we 
instead evaluated the Neuroblastoma (SH-SY5Y) cell line as a suitable in vitro model for 
future NRXN2α expression studies. To evaluate the suitability of this model, we 
determined the expression of endogenous NRXN2α protein in these cells and tested the 
reproducibility of the NRXN2α antibody in Western blotting experiments. 
3.12.1.1. Cell Proliferation  
Undifferentiated SH-SY5Y cells were cultured in medium containing all the essential 
components for the mitogenic effect (proliferation and cell growth). The cells grow as 
clusters of cells with multiple, short, fine cell processes (Figure 3.20). We simultaneously 
cultured four passage-12 SH-SY5Y cell flasks with a surface area of 75 cm2, for 5 days 
before lysing on the sixth day of proliferation. The majority of the cells were adherent and 
there was no significant morphological differentiation of SH-SY5Y cells over the culturing 
time. The images below are representative pictures of the growth rate taken from only one 
of the four flasks.  
 
Days in culture Cell image 
Day 1 (post thaw) 
 
Low Density 
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Day 3 
70 % confluent 
 
Day 5  
90% confluent 
 
High Density 
 
Figure 3.20 SH-SY5Y cell line proliferation. The cells which were incubated in growth 
media show an adherent growth pattern. The cells were examined in a Leica DMI 6000B 
inverted microscope and photographed at 20 and 100 x magnification. Data are 
representative pictures from one of four sample flasks. 
3.12.2. Western Blot Analysis of Endogenous NRXN2α 
Expression 
Firstly, aliquots of the protein lysates were used to determine the protein concentration 
by comparison to known standard concentrations of BSA ranging from 0-1000ng/ml. This 
was done using the colorimetric Bradford assay (Figure 3.21). The assay determines 
protein concentrations using the sample absorbance read at 595nm. The BSA standard 
curve was generated and the value of the slope of this standard curve, calculated from the 
line of best fit. This was used to calculate the concentration of the SH-SY5Y protein 
lysates. Four protein lysate samples were made from each of the four flasks and kept 
separate throughout the experiment. The protein concentrations were measured in 
triplicate and this provided an estimate of protein concentration in µg/µl which was used 
to calculate the volume required to load 100µg of sample into individual lanes of the SDS 
gel for the Western blotting experiments.  
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Figure 3.21 Protein assay standard curve. A standard curve (in blue) generated from 
BSA standards of 0 ng/µl, 100 ng/µl, 200 ng/µl, 300 ng/µl, 400 ng/µl, 500 ng/µl, 600 ng/µl, 
700 ng/µl, 800 ng/µl, 900 ng/µl and 1000µg. The absorption of each standard was measured 
at 595nm. A line of best (in green) was added and the value for the slope of this line was 
used to calculated from the concentration of protein samples. 
Western blots were performed on the four protein lysates. The protein concentrations of 
the lysates were measured in triplicate and this provided an estimate of protein 
concentration in µg/µl which was used to calculate the volume required to load 100µg of 
sample into individual lanes of the SDS gel for the Western blotting experiments. The 
optimal dilution of each of the antibodies was then experimentally determined by varying 
the dilution factor based on the recommended dilution. The Anti- NRXN2α antibody was 
diluted 1/400 (recommended), 1/500 and 1/1000 (Table 2.7, Methods). The Anti-GAPDH 
antibody was diluted 1/1000 (recommended) and 1/3000. The optimal dilutions for the 
Anti- NRXN2α antibody was found to be 1:500 (Figure 3.22), at 1/1000 no protein was 
visible. For the Anti-GAPDH antibody the optimised dilution was 1/3000. Using the 
optimised antibody dilutions, the experiment was repeated in triplicate (n=3). Anti- 
NRXN2α antibody at all dilutions showed bands at about 270 kDa, this did not correspond 
to the expected size of the endogenous protein (185 kDa). No non-specific binding or 
background was visible on the blots. A 37 kDa band for GAPDH was seen as expected.  
The size difference between the observed band 270 kDa and the expected band size 180 
kDa could be a result of incomplete unfolding which would influence electrophoretic 
mobility, preventing the protein from moving in the gel. Another possibility is that 
NRXN2α is a transmembrane protein, which are known to tend to oligomerize and 
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aggregate when heated. Heating samples to 95°C is a vital in the standard denaturing 
process before loading onto the SDS gel. Another reason we might be seeing the larger 
NRXN2α molecule could be because it is bound to another protein such as Neuroligins 
which are typically about 100 kDa in size. Protein identification using LC-MS-MS could 
be used to confirm that this band corresponds to NRXN2α and if it is bound to another 
protein it can also assist in its identification. 
 
Figure 3.22 Western blot showing endogenous NRXN2α expression in 
proliferating in SH-SY5Y cells. A is a representative blot showing the expression of 
endogenous NRXN2α protein in SH-SY5Y cells protein lysates. The 270 kDa band 
represents the NRXN2α protein detected by a 1:500 anti-NRXN2α antibody. Cytosolic 
marker, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used as a loading 
control, seen at approximately 37 kDa. Single representative blot is shown (n=3). B is a 
quantitative assessment showing the relative amount of endogenous NRXN2α protein in 
the protein lysates. NRXN2α was expression was measured as a ratio to GAPDH 
expression. Error bars indicate standard deviation of three experiments. Quantitative 
measurements of bands were performed using densitometry (Fiji software). 
A quantitative assessment of the blots was performed to measure and normalise the 
relative amount of endogenous NRXN2α expression to the loading control. For the blots 
with the 1:500 anti-NRXN2α antibody dilution, NRXN2α was stably expressed across all 
four flasks (Figure 3.22). The aim of these Western blotting experiments was to evaluate 
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the SH-SY5Y cell line as a suitable in vitro model for the functional study of NRXN2α 
expression. The experiments suggest that undifferentiated, SH-SY5Y cells that had not 
been transfected do express endogenous NRXN2α, however this needs to be verified using 
other methods.  
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Chapter Four 
4. Discussion 
There have been numerous studies that have established a genetic aetiology for PD in 
non-African populations but to date, studies on SSA patients have shown that the 
established pathogenic mutations in PD genes are a minor contributor ( Okubadejo et al., 
2008; Keyser et al., 2009; Bardien et al., 2009; Haylett et al., 2012; Yonova-Doing et al., 
2012). The present study, which was an effort to investigate a multiplex family with PD 
in order to identify a pathogenic mutation in a new PD gene or a novel mutation in a 
known PD gene, aims to contribute to this knowledge gap. For the realisation of the study 
objectives, the methodology employed included WES, Sanger sequencing, bioinformatic 
tools, HRM analysis, cell culture and Western blotting. 
4.1.  WES Results and the Prioritisation Process 
Here, we report the WES analysis conducted on a SA Afrikaner family exhibiting an AD 
form of PD with multiple affected individuals. Based on the absence of any of the known 
PD mutations in this family, as determined by WES conducted on three of the affected 
individuals (11.844,12.726 and 92.32), it was concluded that a novel mutation was 
responsible for the disease.  
 
As anticipated, the number of variants per individual yielded by WES exceeded 22 000, 
requiring the application of a stringent filtration criteria. WES analysis is a useful tool in 
the diagnostic screening of known disease-causing genes (Yang et al., 2013), however, it 
requires either large families (with multiple affected and unaffected individuals), for 
which genotype–phenotype co-segregation data can be obtained, or ,large case-control 
cohorts, in order to confirm any positive findings (Vilariño-Güell et al., 2011). 
The WES quality control was conducted by sequence alignment, variant calling, and 
annotation. Quality, quality measures (coverage, read depth) and population frequency 
filters were used to remove any variants that were commonly found in the population or 
variants of low sequencing quality, as they would likely be artefacts. Next, all the 
synonymous co-segregating variants were excluded from the list of candidates as the 
relevant variant was expected to modify the encoded protein.  
Considering the AD pattern of inheritance, the next criteria applied was that the variants 
must be heterozygous and must be shared between all the affected individuals, this 
reduced the number of variants significantly from nine to five.  
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Four of the five validated variants are novel (RFT1 p.A463G, NRXN2 p.G849D, TEP1 
p.Y412C and CCNF p.C363S) and one variant in CFAP65 p.T1023A had been previously 
reported (https://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgirs=rs748008106). In an effort to 
further prioritise the candidate list, the five variants were assessed for co-segregation 
amongst the four unaffected family members, and the two newly diagnosed family 
members (92.33 and 11.902). Considering the dominant inheritance pattern of disease, 
any variant that was present in the unaffected family members could be excluded as this 
would be strong evidence that the given variant is not disease-causing (Farlow et al., 
2016a; Ng et al., 2010; Verstraeten et al., 2015). The CCNF p.C363S variant was found in 
three unaffected individuals, this excludes it as the potential causal candidate and 
indicates that it might be a rare polymorphism. 
Four candidates co-segregating only in the affected individuals were therefore identified 
namely, RFT1 p.A463G, NRXN2α p.G849D, TEP1 p.Y412C and CFAP65 p.T1023A. Of 
the two newly diagnosed PD patients only one individual (92.33; mother of affected 
individual 92,32) shared all five validated variants with the three individuals on whom 
WES was performed. The other recently diagnosed PD patient (11.902) had only one 
variant in common with the other four affected individuals, which was the previously 
reported CFAP65 p.T1023A variant. It should be noted that four of the affected 
individuals all exhibited typical to mild PD, while individual 11.902 presented with a very 
late AAO with prominent symptoms being tremor and REM sleep behaviour disorder. This 
individual might be a phenocopy of disease as she is both genetically and phenotypically 
distinct from the other four. 
The disease presentation of a phenocopy is usually similar to the disease of other 
individuals of the same family. However, the genotyping of that phenocopy would 
elucidate the absence of the mutation(s) responsible that are found in the ‘true affected’ 
individuals who are mutation carriers (Nichols et al., 2005; Klein et al., 2011). Phenocopies 
in PD are well-documented, in a study of multiplex PD families by Nichols et al., (2005) 
with LRRK2 p.G2019S affected mutation carriers , it was found that approximately 25% 
of the affected siblings to the mutation carriers were homozygous for the wild-type allele, 
making them phenocopies of PD. In a familial PD study by Klein et al., (2011) conducted 
on 23 multiplex PD families, 27 PD patients (14,4%) were found to be phenocopies (Klein 
et al., 2011). As a result, individual 11.902 was considered to be a phenocopy, which is 
defined as an environmentally induced disease phenotype or that is genotypically different 
from the actual cause of disease. 
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To distinguish between what could be population specific polymorphisms and disease-
causing variants, we screened the four variants by HRM in 192 ethnically-matched 
neurologically normal controls and found that all four variants were absent in the 384 
screened alleles. Further screening of the four variants in publicly available databases 
ExAC and the 1000 Genomes Project, showed that the three novel variants (in RFT1, 
NRXN2α and TEP1) were absent in multiple populations (Table3.6). The previously 
reported CFAP65 variant, was however found in the ExAC database at a MAF frequency 
of 17 out of 2 100 000 individuals (give allele frequency) in the ExAC Aggregated 
Population (https://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs748008106. Although 
this variant was found in an online database which may include some diseased 
individuals, its MAF was rather low and additional information was required before it 
could be ruled out as the potential causal variant. 
To add further information about the potential causal role of variants before prioritising, 
various tools were applied. First, functional prediction tools (SIFT, PolyPhen-2, 
MutationTaster and CADD) were used to predict the likelihood of functional impact on 
the protein, and GERP which denotes the level of evolutionary constraint acting at a 
specific site in the genome was used. Subsequently, tissue expression data and pathway 
analysis were determined using publicly available databases to ascertain where the gene 
was highly expressed and in which pathways. None of the four variants were found to be 
either co-expressed, co-regulated or interact with any of the known PD genes. 
The factors, which initiated and later strengthened the suspicion of the causative nature 
of the NRXN2α p.G849D variant were the function and expression data of the protein, the 
predicted deleterious effect of the amino acid changes to the protein’s function, the 
segregation of the missense variant in only affected individuals, the conservation of the 
area where the variant is located and the low frequency of the novel variant in both online 
databased and ethnically-matched controls. Based on meeting the filtration criteria and 
being the most relevant to PD pathology, NRXN2α was selected as the top candidate for 
further study.  
The co-segregating variants shared between the three affected individuals were narrowed 
down to a list of candidates in a step-wise manner, using a comprehensive filtration 
approach. In recent years this method of filtration has been successfully applied in 
multiple studies investigating PD gene discovery. Most of the studies considered the 
following criteria for filtration and prioritisation (1) where the variant occurs (exonic, 
intronic or splice region), (2) the allele frequency of less than 1% in the control populations 
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of annotated frequency databases, (3) were predicted to be damaging by multiple in-silico 
functional and structural prediction programs, (4) be located in a highly conserved region, 
(5) were in a relevant Gene Ontology (GO) category, (6) were expressed in the brain, (7) 
segregated in at least 2 PD cases of the same family, and (8) were absent in the unaffected 
members of the families. The PD gene candidates that have been identified using this 
filtration approach include Parkin (p.Q34R and (p.V380L) (Myhre et al., 2008), CHCHD2 
(p.T61I) (Funayama et al., 2015), TMEM230 (p.184ProGext*5, p.R141L) (Deng et al., 
2016; Yan et al., 2017; Yang et al., 2017), TNK2 (pA977V) variant and the TNR (pT166A) 
(Farlow et al., 2016). 
In 2015 the American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) published standards and guidelines in order 
to establish consistency in variant classification among clinical genetic testing 
laboratories (Richards et al., 2015). These guidelines describe a framework for classifying 
variants as “pathogenic”, “likely pathogenic”, “uncertain significance”, “likely benign” or 
“benign” according to a series of criteria with levels of evidence defined as very strong, 
strong, moderate or supporting (Richards et al., 2015). The criteria for classification 
according to these standards is 
1. The information available on population frequency databases like ExAC and 
dbSNP 
2. The predictions made by multiple computational prediction tools 
3. Previously published functional studies showing the impact of modifying the 
protein 
4. The variant segregation data attained from genotyping the family 
5. Allelic Data, how the variant is inherited (heterozygous, homozygous, dominant 
or recessive) 
6. The clinical information that is available on the patients (Optional category as it’s 
not always available in the laboratory setting) 
According to the evidence classification of the ACMG guidelines the NRXN2α. p.G849D 
mutation is considered pathogenic with strong evidence. It gained a pathogenic moderate 
2 rating for frequency in population databases. The rating for computational prediction 
tools evidence was pathogenic strong 1. The rating gained from the information on the 
gene in previously published functional studies was pathogenic moderate 1. The 
segregation evidence got a pathogenic strong 1 with supporting evidence. Allelic data 
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criteria (heterozygous, with dominant inheritance) got a pathogenic moderate 2 rating. 
Lastly because we had clinical data of the family available that informed the diagnosis 
and described the disease in each individual, we gained a pathogenic with supporting 
evidence 4 rating.  
The filtration strategy that has been used in this study is in line with the ACMG 
guidelines going beyond what is suggested in the guidelines by obtaining additional 
information such as the protein expression data in the relevant tissue, structurally 
modelling the affected protein, screening the local control population and additionally 
screening other patients affected by the disease. 
4.2. Neurexin Protein Family 
Neurexins (NRXNs) constitute a family of highly polymorphic transmembrane proteins, 
reported to be highly expressed in the brain (Schreiner et al., 2014, 2015). They were 
initially identified at the synapse as calcium-dependent a-latrotoxin receptors (Ushkaryov 
et al., 1992; Ushkaryov and Südhof, 1993). NRXN1 [OMIM #600565] and NRXN3 [OMIM 
#600567] from this family of genes are amongst the largest genes in the mammalian 
genome, exceeding 1,6 Mb, and each gene encodes a longer α and a shorter β transcript. 
Due to multiple promoters and alternative splicing, thousands of isoforms are generated 
from the three neurexin genes (NRXN1, 2 and 3) (Missler and Südhof, 1998). Though these 
NRXN isoforms are co-expressed, each has a different mRNA and resulting protein. 
Furthermore, they are differentially distributed in neuronal cell types according to their 
specific function (Ullrich et al., 1995; Schreiner et al., 2014, 2015). 
Structurally αNeurexins are composed of six large extracellular laminin/neurexin/sex-
hormone binding globulin (LNS) domains, with three interspersed epidermal growth 
factor (EGF)-like regions as seen in Figure 4.1. Intracellularly, all neurexins contain a 
transmembrane region, a carboxy terminus and a short intracellular tail. The shorter β 
neurexins only have the sixth LNS domain on the extracellular side, and no EGF-like 
regions (Missler and Südhof, 1998; Rudenko et al., 1999, 2001).  
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Figure 4.1 Schematic structure of the two major isoforms (alpha and beta) of the 
NRXN2 proteins. SP, signal peptide; LNS 1–6, laminin neurexin sex hormone binding 
domains; EGF, epidermal growth factor-like domains; TM, transmembrane region; PDZ, 
domain binding site. The Black arrow indicates the location of the missense variant 
p.G849D found in the affected patients of this study. Image generated using Biorender. 
Studies have shown that neurexins are embedded in the presynaptic membrane and 
interact with multiple key postsynaptic surface proteins (Figure 4.2) namely Neuroligins 
(NLGNs) (Craig and Kang, 2007; Mukherjee et al., 2008), Leucine-rich repeat 
transmembrane neuronal proteins (LRRTMs) (de Wit et al., 2009; Ko et al., 2009; Siddiqui 
et al., 2010), Cbln (1 precursor protein) and GluRδ (δ-type glutamate receptor) (Uemura 
et al., 2010). Thus, neurexins are emerging as a very important family of synaptic 
regulation proteins. Figure 4.2 shows the schematic representation of the long NRXN2α 
and the shorter NRXN2β binding to NLGN in the synaptic cleft through the sixth LNS 
domain on the extracellular side of the neuronal membrane. The prioritised gene, 
NRXN2α [OMIM #600566], is known to be involved in calcium channel regulation, 
transmembrane signalling receptor activity, neuronal cell adhesion, synaptic organization 
and neuroligin family protein binding (Craig and Kang, 2007).  
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Figure 4.2 Schematic representation of NRXN2 and NLGN complex formation at 
the synaptic cleft. NLGN is shown in green. NRXNα and NRXNβ are shown in blue. 
The NRXNs bind to NLGN using the sixth LNS domain extracellular domain. Used with 
permission from Elsevier. 
4.3. Involvement of Neurexins in Human Disorders and Animal Studies 
Of the three neurexins, only NRXN1 inactivation has been well studied and it has been 
associated with multiple neurodevelopmental disorders including schizophrenia, Tourette 
syndrome, epilepsy and Autism Spectrum Disorders (Schaaf et al., 2012; Møller et al., 
2013; Yangngam et al., 2014; Dachtler et al., 2014; Chen et al., 2017; Dachtler et al., 2015).  
It is only recently that NRXN2 inactivation has come into focus in a study investigating 
synaptic impairment in mice (Dachtler et al., 2014). The inactivation of both NRXN1 and 
NRXN2 caused the dysregulation of neurotransmitter release, however the synaptic 
trafficking was not completely lost (Dachtler et al., 2014). Although these results do not 
directly explain the direct contribution of neurexins to Autism pathology, the study 
concluded that the observed deficiencies in presynaptic vesicular release confirmed the 
pathological significance of the neurexins in neurological disorders (Dachtler et al., 2014).  
In animal studies, genetic mutations of each neurexin uncovered diverse phenotypes that 
affect multiple aspects of synaptic function. In mice, constitutive single knockout (KO) of 
NRXN1α or NRXN2α with the expression of β -neurexins severely impaired the survival 
of the mice. Subsequently, the KO of all of the α -neurexins was invariably lethal (Missler 
et al., 2003). The α -neurexins KO mice had a decrease in inhibitory but not in excitatory 
synapse activity and displayed a dramatic impairment synaptic transmission, this was 
hypothesised to be as a result of a loss in presynaptic Ca2+ influx (Missler et al., 2003). 
Similarly, triple β -neurexin KO mice also exhibited a synaptic phenotype, however it was 
milder due to the compensatory mechanisms of the α -neurexins (Anderson et al., 
2015;Fuccillo et al., 2015)). 
In another animal study by Tabuchi and Südhof, (2002) a mutation was created in the 
mouse NRXN2α cDNA, at the end of the fourth LNS domain. This did not affect NRXN2β, 
but about half of the NRXN2α protein was lost. The region lost included the binding sites 
for NLGNs and LRRTMs which are located in LNS 6. Furthermore, the NRXN2α mutant 
exhibited a loss of synaptic activity in the neuron co-culture assay. In the presence of the 
wild-type NRXN2α clustering of glutamatergic components LRRTM2, PSD-95, NLGN2 
and gephyrin at dendrite contact sites was observed. The mutant however failed to cluster 
these postsynaptic components (Tabuchi and Südhof, 2002).  
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In summary, the genetic alternations that have been performed on NRXN2α showed a 
complete loss of function in binding to Ca2+, LRRM2 or NLGN2 in cell-based assays, as 
well as a complete loss of synaptic activity in animal models. It is therefore plausible that 
the NRXN2α gene may be involved in a neurological disease like PD. 
4.4. Possible Effect of the Missense Variant in NRXN2α 
All of the functional prediction tools had predicted that the missense variant in NRXN2α 
is likely to have a damaging effect on the protein’s function. The variant results in the 
exchange of a smaller non-polar amino acid for a larger negatively charged amino acid 
with a carboxyl group side chain (CH2COOH), in a prominent loop of the LNS 4 domain. 
This will potentially result in the disruption of the protein structure as the negatively 
charged amino acid may interact with the neighbouring residues which may stabilize what 
should be a flexible conformation of the LNS domain, meant for optimal extracellular 
binding. As previously discussed, the missense variant is located in a highly conserved 
area of the protein. This high degree of conservation potentially implies that this region 
of the protein may have important functions. Based on the prediction of high conservation, 
if this region is affected by the variant, it could lead to the instability of the protein.  
The extracellular region of the NRXN2α protein mediates synaptic protein interactions, 
cell adhesion, cell recognition and synaptic regulation. As a result it can speculated that 
the disruption of NRXN2α might affect the protein binding properties, synaptic 
transmission efficacy, the NRXN2α receptor function, presynaptic vesicular transport, 
alter the synaptic plasticity (loss of synaptic integrity), and in the worst-case scenario 
maybe even result in loss of synaptic regulation leading to the accumulation of metabolic 
products in the synapse as is commonly seen in PD (Fahn, 2010; Schapira and Jenner, 
2011; Picconi et al., 2012). 
Protein complexes at the postsynaptic site have been implicated in several PD animal 
models as a key factor in PD (Belluzzi et al., 2012; de la Fuente‐Fernández et al., 2004; 
Roach, 2007). However, recent research has shown that the proteins linked to PD such as 
SNCA and LRRK2 play a critical role at the presynaptic site (Li et al., 2010; Esposito et 
al., 2012). These studies have demonstrated that PD progression is affected by the 
dopamine release into the synaptic cleft which relies on functional presynaptic vesicular 
transport; synaptic vesicle trafficking, and the maintained regulation of presynaptic 
plasticity. All of these presynaptic features proposed to contribute to parkinsonism in 
animal models are closely associated with the function of NRXN2α. 
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As stated before, the MAF of the variant in the local control population and in populations 
in online databases was 0 % for the NRXN2α. p.G849D mutation, meaning that it is not 
present in the general population. This result further supports the causative nature of the 
variant, because disease-causing mutations are not expected to be common in the general 
population due to negative selection acting against them (Wong et al., 2003). The variant 
was absent in our cohort of 671 PD patients of multiple ethnicities. Also, we screened 
Annex, a web-based database that contains over 3000 exomes of patients with neurological 
diseases (Table 3.6, Results), predominantly PD, from one of our collaborators (Prof. Matt 
Farrer, Canada). None of these patients had the p.G849D variant however, 23 other likely 
pathogenic variants in the NRXN2 gene were shared amongst 50 patients diagnosed with 
PD. This includes 12 indels shared by 22 of the PD patients. 
Furthermore, in order to determine the expression of endogenous NRXN2α, Western 
blotting was done using the protein lysates from an un-transfected SH-SY5Y human 
Neuroblastoma cell line and a commercially available polyclonal NRXN2α antibody. The 
Western blots exhibited no non-specific binding or background and only a single band was 
observed. The size of the band (270 kDa) however, did not correspond to the expected size 
of the endogenous protein (185 kDa in lysates from a mouse Neuroblastoma cell line N2A). 
A search of the Celera mouse and human genome database 
(https://www.ocf.berkeley.edu/~edy/genome/celera.html) revealed that the mouse and 
human homologs of the gene exhibit exon and intron structures relatively similar in size. 
The NRXN2α Mus musculus homolog was 103,6 kb and the Homo sapiens homolog was 
106,4 kb (Tabuchi and Südhof, 2002). Therefore, the difference between the observed and 
expected sizes of the protein are not a result of species-specific gene structure.  
Membrane proteins like NRXN2α which are associated with lipid bilayers, have been 
shown to be difficult to denature in aqueous WB solutions because of high hydrophobicity 
and poor solubility often forming bulky quaternary protein structures (Kubicek et al., 
2014). This could explain the highly specific single protein band observed as unresolved 
quaternary NRXN2α proteins. The use of stronger detergents has been suggested to 
increase the purification and solubilisation (Mancia and Love, 2010). Another reason we 
might be seeing the larger NRXN2α molecule could be because it is bound to another 
protein such as NLNGs which are typically about 100 kDa in size. 
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4.5. Study Limitations 
Our study had a number of limitations. Though useful, the functional prediction tools are 
based on assumptions, and all tools have various short-comings. The developers of these 
tools emphasise that the terms ‘damaging’ or ‘deleterious’ should never be logically 
equated with causal of disease phenotype.  
The variant filtering strategy used follows what has previously been suggested in the 
literature. This influenced the type of variants filtered out at each stage and led to some 
variants making it to higher or lower ranking which may be incorrect. The filtration and 
interpretation of the data was also limited by the current knowledge about the genes and 
the information on them that is available in online databases. This incomplete knowledge 
about the function and disease associations of certain genes that may also lead to 
candidate variants being erroneously discarded. 
Another limitation of our study is in the limited sequencing scope of WES. One 
disadvantage of this approach is its inability to accurately detect structural variants such 
as inversions and translocations, as well as other types of variants such as non-coding 
variants, deletions, copy number variations and repeat expansions (Botstein and Risch, 
2003) (Krumm et al., 2012). Some non-coding variants may be important for controlling 
gene transcriptional regulation or splicing (Fromer et al., 2012). The target coverage along 
the length of exons in WES is usually uneven which causes errors in downstream analysis 
such as false-positive calls in variant calling analysis. Factors that may affect coverage in 
WES include the size of the exon, the presence or absence of repeat elements, GC content 
and segmental duplications (Belkadi et al., 2015; Kozarewa et al., 2009). 
A technical limitation of this study is that we were unable to generate full-length NRXN2α 
cDNA for functional studies. cDNA of this gene is not currently commercially available. 
We had initially planned to generate this NRXN2α cDNA to clone the wild-type and 
mutant inserts into pDsRed-Monomer-C1 vectors. This was to be transfected into the SH-
SY5Y Neuroblastoma cell line for further study of the wild-type and mutant form of the 
gene in a neuronal cell model. Unfortunately, we were unable to overcome the many 
technical challenges of generating full-length NRXN2α cDNA and consequently, only 
investigated the endogenous NRXN2α protein expression levels of the cell line using a 
commercially available antibody. This does lay a foundation for using this cell line to 
further study the NRXN2α protein.  
For further functional study of the variant, tissue samples like skin and brain biopsy were 
not available due to these procedures being invasive and brain biopsies are only performed 
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post-mortem. Lastly, because the analysis process is not an automated one, there is the 
chance for human error in the experiments, and interpretation of the data. 
4.6. Future Work 
Future work should include the verification of the protein detected by the anti- NRXN2α 
antibody, this could be done by protein identification using mass spectrometry tools such 
as MALDI-TOF Mass Spectrometry and Q-TOF Mass Spectrometry. The endogenous 
protein levels of NRXN2α could be assessed in other human cell types using the same 
primary antibody, to determine if the large sized bands observed in the SH-SY5Y cells are 
cell specific. To attain full-length NRXN2α, gene synthesis services could be utilised to 
create the wild-type construct of the gene. Alternatively, in vitro CRISPR/Cas9 could also 
be used to produce the desired NRXN2α variant to create the mutant endogenous cell 
model for further functional investigation. 
 Ultimately, the functional assessment of the NRXN2α variant is necessary to establish 
its biological significance. Proteomic studies should be pursued to determine the potential 
effect of the variant on the structure, physiological role and function of the protein. In 
addition, the other three candidate genes RFT1, TEP1 and CFAP65 should also be 
functionally investigated for their possible contribution to the disease pathogenesis. As 
sequencing technology is rapidly developing with frequent improvements to the 
technology and its bioinformatics solutions, the previously acquired WES data should be 
re-analysed for new insights. In future, individual 11.902 who was considered to be a 
phenocopy could be considered a true PD patient and the data re-evaluated to determine 
if the initial analysis was fair and no genetic variants were mistakenly discarded. 
Additionally, ongoing follow up should be maintained with the family to recruit any newly 
affected individuals. 
4.7. Conclusion 
In PD research, genetic studies conducted on multiplex families have led to the 
identification of genes that have elucidated some of the pathways involved in disease 
pathogenesis. This includes LRRK2, Parkin, PINK1 DJ-1 and SNCA (Nuytemans et al., 
2010). With the advancement of sequencing technologies, it is anticipated that additional 
PD causative genes will be identified. The present study provides several lines of evidence 
implicating a mutation in NRXN2α as a likely novel genetic variant that could contribute 
to PD pathology. To our knowledge, this is the first report of an association between 
NRXN2α and PD. As a candidate NRXN2α is well-suited for future efforts directed at in-
depth functional dissection. Elucidating the pathologic potential of variants and their 
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relative contribution to the phenotype may provide critical insight into disease 
mechanisms and potentially lead to development of improved therapeutic modalities for 
this debilitating disorder. 
Stellenbosch University  https://scholar.sun.ac.za
- 104 - 
 
Reference List 
Abdel-Salam, O.M.E., 2019. Use of Herbal Products/Alternative Medicines in 
Neurodegenerative Diseases (Alzheimer’s Disease and Parkinson’s Disease), in: Singh, S., 
Joshi, N. (Eds.), Pathology, Prevention and Therapeutics of Neurodegenerative Disease. 
Springer Singapore, Singapore, pp. 279–301. https://doi.org/10.1007/978-981-13-0944-
1_24 
Abou-Sleiman, P.M., Muqit, M.M.K., McDonald, N.Q., Yang, Y.X., Gandhi, S., Healy, D.G., 
Harvey, K., Harvey, R.J., Deas, E., Bhatia, K., Quinn, N., Lees, A., Latchman, D.S., Wood, 
N.W., 2006. A heterozygous effect for PINK1 mutations in Parkinson’s disease? Ann. 
Neurol. 60, 414–419. https://doi.org/10.1002/ana.20960 
Adzhubei, I., Jordan, D.M., Sunyaev, S.R., 2013. Predicting Functional Effect of Human 
Missense Mutations Using PolyPhen-2. Curr Protoc Hum Genet 0 7, Unit7.20. 
https://doi.org/10.1002/0471142905.hg0720s76 
Ahlskog, J.E., 2009. Parkin and PINK1 parkinsonism may represent nigral mitochondrial 
cytopathies distinct from Lewy body Parkinson’s disease. Parkinsonism Relat Disord 15, 
721–727. https://doi.org/10.1016/j.parkreldis.2009.09.010 
Akinyemi, R.O., 2012. Epidemiology of Parkinsonism and Parkinson’s disease in Sub-
Saharan Africa: Nigerian profile. J Neurosci Rural Pract 3, 233–234. 
https://doi.org/10.4103/0976-3147.102586 
Alfred Goldscheider, 1898. Physiologie des Muskelsinnes. Leipzig 432. 
Altschul, S.F., Madden, T.L., Schäffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J., 
1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search 
programs. Nucleic Acids Res 25, 3389–3402. 
Andrews, S., 2016. FASTQC [http://www. bioinformatics. babraham. ac. 
uk/projects/fastqc/]. Accessed. 
Antonini, A., Bauer, L., Dohin, E., Oertel, W.H., Rascol, O., Reichmann, H., Schmid, M., 
Singh, P., Tolosa, E., Chaudhuri, K.R., 2015. Effects of rotigotine transdermal patch in 
patients with Parkinson’s disease presenting with non-motor symptoms – results of a 
double-blind, randomized, placebo-controlled trial. Eur J Neurol 22, 1400–1407. 
https://doi.org/10.1111/ene.12757 
Appel-Cresswell, S., Rajput, A.H., Sossi, V., Thompson, C., Silva, V., McKenzie, J., Dinelle, 
K., McCormick, S.E., Vilariño-Güell, C., Stoessl, A.J., Dickson, D.W., Robinson, C.A., 
Stellenbosch University  https://scholar.sun.ac.za
- 105 - 
 
Farrer, M.J., Rajput, A., 2014. Clinical, positron emission tomography, and pathological 
studies of DNAJC13 p.N855S Parkinsonism. Mov. Disord. 29, 1684–1687. 
https://doi.org/10.1002/mds.26019 
Asakawa, S., Tsunematsu, K., Takayanagi, A., Sasaki, T., Shimizu, A., Shintani, A., 
Kawasaki, K., Mungall, A.J., Beck, S., Minoshima, S., Shimizu, N., 2001. The Genomic 
Structure and Promoter Region of the Human Parkin Gene. Biochemical and Biophysical 
Research Communications 286, 863–868. https://doi.org/10.1006/bbrc.2001.5490 
Bamshad, M.J., Ng, S.B., Bigham, A.W., Tabor, H.K., Emond, M.J., Nickerson, D.A., 
Shendure, J., 2011. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. 
Rev. Genet. 12, 745–755. https://doi.org/10.1038/nrg3031 
Bao, R., Huang, L., Andrade, J., Tan, W., Kibbe, W.A., Jiang, H., Feng, G., 2014. Review 
of Current Methods, Applications, and Data Management for the Bioinformatics Analysis 
of Whole Exome Sequencing. Cancer Inform 13, 67–82. 
https://doi.org/10.4137/CIN.S13779 
Bardien, S., Keyser, R., Lombard, D., Du Plessis, M., Human, H., Carr, J., 2010. Novel 
non-sense GCH1 mutation in a South African family diagnosed with dopa-responsive 
dystonia. European Journal of Neurology 17, 510–512. https://doi.org/10.1111/j.1468-
1331.2009.02725.x 
Bardien, S., Keyser, R., Yako, Y., Lombard, D., Carr, J., 2009. Molecular analysis of the 
parkin gene in South African patients diagnosed with Parkinson’s disease. Parkinsonism 
& Related Disorders 15, 116–121. https://doi.org/10.1016/j.parkreldis.2008.04.005 
Bardien, Soraya, Marsberg, A., Keyser, R., Lombard, D., Lesage, S., Brice, A., Carr, J., 
2010. LRRK2 G2019S mutation: frequency and haplotype data in South African 
Parkinson’s disease patients. J Neural Transm 117, 847–853. 
https://doi.org/10.1007/s00702-010-0423-6 
Barkhuizen, M., Anderson, D.G., van der Westhuizen, F.H., Grobler, A.F., 2017. A 
molecular analysis of the GBA gene in Caucasian South Africans with Parkinson’s 
disease. Mol Genet Genomic Med 5, 147–156. https://doi.org/10.1002/mgg3.267 
Baudhuin, L.M., Lagerstedt, S.A., Klee, E.W., Fadra, N., Oglesbee, D., Ferber, M.J., 2015. 
Confirming Variants in Next-Generation Sequencing Panel Testing by Sanger 
Sequencing. The Journal of Molecular Diagnostics 17, 456–461. 
https://doi.org/10.1016/j.jmoldx.2015.03.004 
Stellenbosch University  https://scholar.sun.ac.za
- 106 - 
 
Baumann, R.J., Jameson, H.D., McKean, H.E., Haack, D.G., Weisberg, L.M., 1980. 
Cigarette smoking and Parkinson disease. Neurology 30, 839. 
https://doi.org/10.1212/WNL.30.8.839 
Behnke, S., Berg, D., Naumann, M., Becker, G., 2005. Differentiation of Parkinson’s 
disease and atypical parkinsonian syndromes by transcranial ultrasound. Journal of 
Neurology, Neurosurgery & Psychiatry 76, 423–425. 
https://doi.org/10.1136/jnnp.2004.049221 
Belin, A.C., Westerlund, M., 2008. Parkinson’s disease: A genetic perspective. FEBS 
Journal 275, 1377–1383. https://doi.org/10.1111/j.1742-4658.2008.06301.x 
Belkadi, A., Bolze, A., Itan, Y., Cobat, A., Vincent, Q.B., Antipenko, A., Shang, L., Boisson, 
B., Casanova, J.-L., Abel, L., 2015. Whole-genome sequencing is more powerful than 
whole-exome sequencing for detecting exome variants. Proc. Natl. Acad. Sci. U.S.A. 112, 
5473–5478. https://doi.org/10.1073/pnas.1418631112 
Belluzzi, E., Greggio, E., Piccoli, G., 2012. Presynaptic dysfunction in Parkinson’s disease: 
a focus on LRRK2. Biochem. Soc. Trans. 40, 1111–1116. 
https://doi.org/10.1042/BST20120124 
Benabid, A.L., Chabardes, S., Mitrofanis, J., Pollak, P., 2009. Deep brain stimulation of 
the subthalamic nucleus for the treatment of Parkinson’s disease. The Lancet Neurology 
8, 67–81. https://doi.org/10.1016/S1474-4422(08)70291-6 
Benamer, H.T.S., de Silva, R., Siddiqui, K.A., Grosset, D.G., 2008. Parkinson’s disease in 
Arabs: A systematic review. Mov. Disord. 23, 1205–1210. 
https://doi.org/10.1002/mds.22041 
Blanckenberg, J., Bardien, S., Glanzmann, B., Okubadejo, N.U., Carr, J.A., 2013. The 
prevalence and genetics of Parkinson’s disease in sub-Saharan Africans. Journal of the 
Neurological Sciences 335, 22–25. https://doi.org/10.1016/j.jns.2013.09.010 
Blanckenberg, J., Ntsapi, C., Carr, J.A., Bardien, S., 2014. EIF4G1 R1205H and VPS35 
D620N mutations are rare in Parkinson’s disease from South Africa. Neurobiology of 
Aging 35, 445.e1-445.e3. https://doi.org/10.1016/j.neurobiolaging.2013.08.023 
Bonifati, V., Rizzu, P., van Baren, M.J., Schaap, O., Breedveld, G.J., Krieger, E., Dekker, 
M.C.J., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J.W., Vanacore, N., van Swieten, 
J.C., Brice, A., Meco, G., van Duijn, C.M., Oostra, B.A., Heutink, P., 2003. Mutations in 
Stellenbosch University  https://scholar.sun.ac.za
- 107 - 
 
the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 
256–259. https://doi.org/10.1126/science.1077209 
Bonifati, V., Rohé, C.F., Breedveld, G.J., Fabrizio, E., De Mari, M., Tassorelli, C., Tavella, 
A., Marconi, R., Nicholl, D.J., Chien, H.F., Fincati, E., Abbruzzese, G., Marini, P., De 
Gaetano, A., Horstink, M.W., Maat-Kievit, J.A., Sampaio, C., Antonini, A., Stocchi, F., 
Montagna, P., Toni, V., Guidi, M., Dalla Libera, A., Tinazzi, M., De Pandis, F., Fabbrini, 
G., Goldwurm, S., de Klein, A., Barbosa, E., Lopiano, L., Martignoni, E., Lamberti, P., 
Vanacore, N., Meco, G., Oostra, B.A., Italian Parkinson Genetics Network, 2005. Early-
onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and 
phenotypes. Neurology 65, 87–95. https://doi.org/10.1212/01.wnl.0000167546.39375.82 
Booker, D., 2012. Parkinson Disease and Rehabilitation Administration and Services. 
Southern Illinois University Carbondale. 
Bordoli, L., Schwede, T., 2012. Automated Protein Structure Modeling with SWISS-
MODEL Workspace and the Protein Model Portal. Methods Mol Biol 857, 107–136. 
https://doi.org/10.1007/978-1-61779-588-6_5 
Botstein, D., Risch, N., 2003. Discovering genotypes underlying human phenotypes: past 
successes for mendelian disease, future approaches for complex disease. Nat. Genet. 33 
Suppl, 228–237. https://doi.org/10.1038/ng1090 
Bower, J.H., Maraganore, D.M., McDonnell, S.K., Rocca, W.A., 1999. Incidence and 
distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52, 
1214–1220. 
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., Rüb, U., 
2002. Staging of the intracerebral inclusion body pathology associated with idiopathic 
Parkinson’s disease (preclinical and clinical stages). J. Neurol. 249 Suppl 3, III/1-5. 
Braak, H., Sastre, M., Bohl, J.R.E., Vos, R.A.I. de, Tredici, K.D., 2007. Parkinson’s disease: 
lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and 
postganglionic neurons. Acta Neuropathol 113, 421–429. https://doi.org/10.1007/s00401-
007-0193-x 
Braak, H., Tredici, K.D., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., Braak, E., 2003. 
Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging 
24, 197–211. https://doi.org/10.1016/S0197-4580(02)00065-9 
Stellenbosch University  https://scholar.sun.ac.za
- 108 - 
 
Brink, P.A., Crotti, L., Corfield, V., Goosen, A., Durrheim, G., Hedley, P., Heradien, M., 
Geldenhuys, G., Vanoli, E., Bacchini, S., Spazzolini, C., Lundquist, A.L., Roden, D.M., 
George, A.L., Schwartz, P.J., 2005. Phenotypic Variability and Unusual Clinical Severity 
of Congenital Long-QT Syndrome in a Founder Population. Circulation 112, 2602–2610. 
https://doi.org/10.1161/CIRCULATIONAHA.105.572453 
Burke, R.E., Dauer, W.T., Vonsattel, J.P.G., 2008. A Critical Evaluation of The Braak 
Staging Scheme for Parkinson’s Disease. Ann Neurol 64, 485–491. 
https://doi.org/10.1002/ana.21541 
Cacabelos, R., 2017a. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. 
International Journal of Molecular Sciences 18, 551. https://doi.org/10.3390/ijms18030551 
Cacabelos, R., 2017b. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int 
J Mol Sci 18. https://doi.org/10.3390/ijms18030551 
Calne, D.B., Langston, J.W., 1983. Aetiology of Parkinson’s disease. Lancet 2, 1457–1459. 
Campbell, M.C., Tishkoff, S.A., 2008. African Genetic Diversity: Implications for Human 
Demographic History, Modern Human Origins, and Complex Disease Mapping. Annual 
Review of Genomics and Human Genetics 9, 403–433. 
https://doi.org/10.1146/annurev.genom.9.081307.164258 
Campenhausen, S. von, Bornschein, B., Wick, R., Bötzel, K., Sampaio, C., Poewe, W., 
Oertel, W., Siebert, U., Berger, K., Dodel, R., 2005. Prevalence and incidence of 
Parkinson’s disease in Europe. European Neuropsychopharmacology 15, 473–490. 
https://doi.org/10.1016/j.euroneuro.2005.04.007 
Carr, J., Guella, I., Szu-Tu, C., Boolay, S., Glanzmann, B., Farrer, M.J., Bardien, S., 2016. 
Double homozygous mutations (R275W and M432V) in the ParkinGene associated with 
late-onset Parkinson’s disease: Homozygous Mutations in Parkin Gene. Movement 
Disorders 31, 423–425. https://doi.org/10.1002/mds.26524 
Challis, D., Yu, J., Evani, U.S., Jackson, A.R., Paithankar, S., Coarfa, C., Milosavljevic, 
A., Gibbs, R.A., Yu, F., 2012. An integrative variant analysis suite for whole exome next-
generation sequencing data. BMC Bioinformatics 13, 8. https://doi.org/10.1186/1471-2105-
13-8 
Chartier-Harlin, M.-C., Dachsel, J.C., Vilariño-Güell, C., Lincoln, S.J., Leprêtre, F., 
Hulihan, M.M., Kachergus, J., Milnerwood, A.J., Tapia, L., Song, M.-S., Le Rhun, E., 
Mutez, E., Larvor, L., Duflot, A., Vanbesien-Mailliot, C., Kreisler, A., Ross, O.A., Nishioka, 
Stellenbosch University  https://scholar.sun.ac.za
- 109 - 
 
K., Soto-Ortolaza, A.I., Cobb, S.A., Melrose, H.L., Behrouz, B., Keeling, B.H., Bacon, J.A., 
Hentati, E., Williams, L., Yanagiya, A., Sonenberg, N., Lockhart, P.J., Zubair, A.C., Uitti, 
R.J., Aasly, J.O., Krygowska-Wajs, A., Opala, G., Wszolek, Z.K., Frigerio, R., Maraganore, 
D.M., Gosal, D., Lynch, T., Hutchinson, M., Bentivoglio, A.R., Valente, E.M., Nichols, 
W.C., Pankratz, N., Foroud, T., Gibson, R.A., Hentati, F., Dickson, D.W., Destée, A., 
Farrer, M.J., 2011. Translation Initiator EIF4G1 Mutations in Familial Parkinson 
Disease. Am J Hum Genet 89, 398–406. https://doi.org/10.1016/j.ajhg.2011.08.009 
Chen, L.Y., Jiang, M., Zhang, B., Gokce, O., Südhof, T.C., 2017. Conditional Deletion of 
All Neurexins Defines Diversity of Essential Synaptic Organizer Functions for Neurexins. 
Neuron 94, 611-625.e4. https://doi.org/10.1016/j.neuron.2017.04.011 
Cheng, H.-C., Ulane, C.M., Burke, R.E., 2010. Clinical Progression in Parkinson’s Disease 
and the Neurobiology of Axons. Ann Neurol 67, 715–725. 
https://doi.org/10.1002/ana.21995 
Cherukuri, P.F., Maduro, V., Fuentes-Fajardo, K.V., Lam, K., Adams, D.R., Tifft, C.J., 
Mullikin, J.C., Gahl, W.A., Boerkoel, C.F., 2015. Replicate exome-sequencing in a 
multiple-generation family: improved interpretation of next-generation sequencing data. 
BMC Genomics 16. https://doi.org/10.1186/s12864-015-2107-y 
Choi, Y., Chan, A.P., 2015. PROVEAN web server: a tool to predict the functional effect of 
amino acid substitutions and indels. Bioinformatics 31, 2745–2747. 
https://doi.org/10.1093/bioinformatics/btv195 
Cilia, R., Sironi, F., Akpalu, A., Cham, M., Sarfo, F.S., Brambilla, T., Bonetti, A., Amboni, 
M., Goldwurm, S., Pezzoli, G., 2011. Screening LRRK2 gene mutations in patients with 
Parkinson’s disease in Ghana. J Neurol 259, 569–570. https://doi.org/10.1007/s00415-011-
6210-y 
Clarke, C.E., Patel, S., Ives, N., Rick, C.E., Woolley, R., Wheatley, K., Walker, M.F., Zhu, 
S., Kandiyali, R., Yao, G., Sackley, C.M., Group, on behalf of the P.R.C., 2016. UK 
Parkinson’s Disease Society Brain Bank Diagnostic Criteria. NIHR Journals Library. 
Colosimo, C., Morgante, L., Antonini, A., Barone, P., Avarello, T.P., Bottacchi, E., Cannas, 
A., Ceravolo, M.G., Ceravolo, R., Cicarelli, G., Gaglio, R.M., Giglia, L., Iemolo, F., 
Manfredi, M., Meco, G., Nicoletti, A., Pederzoli, M., Petrone, A., Pisani, A., Pontieri, F.E., 
Quatrale, R., Ramat, S., Scala, R., Volpe, G., Zappulla, S., Bentivoglio, A.R., Stocchi, F., 
Trianni, G., Dotto, P.D., Simoni, L., Marconi, R., Group, and P.S., 2010. Non-motor 
Stellenbosch University  https://scholar.sun.ac.za
- 110 - 
 
symptoms in atypical and secondary parkinsonism: the PRIAMO study. J Neurol 257, 5. 
https://doi.org/10.1007/s00415-009-5255-7 
Cosnett, J.E., 1973. Neurological disease in Natal. Tropical Neurology 270. 
Craig, A.M., Kang, Y., 2007. Neurexin-neuroligin signaling in synapse development. Curr. 
Opin. Neurobiol. 17, 43–52. https://doi.org/10.1016/j.conb.2007.01.011 
Cubo, E., Doumbe, J., Martinez-Martin, P., Rodriguez-Blazquez, C., Kuate, C., Mariscal, 
N., Lopez, I., Noubissi, G., Mapoure, Y.N., Jon, J.L., Mbahe, S., Tchaleu, B., Catalan, M.-
J., 2014. Comparison of the clinical profile of Parkinson’s disease between Spanish and 
Cameroonian Cohorts. Journal of the Neurological Sciences 336, 122–126. 
https://doi.org/10.1016/j.jns.2013.10.021 
Dachtler, J., Glasper, J., Cohen, R.N., Ivorra, J.L., Swiffen, D.J., Jackson, A.J., Harte, 
M.K., Rodgers, R.J., Clapcote, S.J., 2014. Deletion of α-neurexin II results in autism-
related behaviors in mice. Transl Psychiatry 4, e484. https://doi.org/10.1038/tp.2014.123 
Dachtler, J., Ivorra, J.L., Rowland, T.E., Lever, C., Rodgers, R.J., Clapcote, S.J., 2015. 
Heterozygous Deletion of α-Neurexin I or α-Neurexin II Results in Behaviors Relevant to 
Autism and Schizophrenia. Behav Neurosci 129, 765–776. 
https://doi.org/10.1037/bne0000108 
Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A., Batzoglou, S., 2010. 
Identifying a High Fraction of the Human Genome to be under Selective Constraint Using 
GERP++. PLOS Computational Biology 6, e1001025. 
https://doi.org/10.1371/journal.pcbi.1001025 
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D.B., Stoessl, A.J., 2004. 
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic 
model. Brain 127, 888–899. https://doi.org/10.1093/brain/awh102 
de Lau, L.M., Breteler, M.M., 2006. Epidemiology of Parkinson’s disease. The Lancet 
Neurology 5, 525–535. 
de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., 
Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., Hofman, A., 2000. 
Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based 
cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S21-23. 
de Wit, J., Sylwestrak, E., O’Sullivan, M.L., Otto, S., Tiglio, K., Savas, J.N., Yates, J.R., 
Comoletti, D., Taylor, P., Ghosh, A., 2009. LRRTM2 Interacts with Neurexin1 and 
Stellenbosch University  https://scholar.sun.ac.za
- 111 - 
 
Regulates Excitatory Synapse Formation. Neuron 64, 799–806. 
https://doi.org/10.1016/j.neuron.2009.12.019 
Deng, H.-X., Shi, Y., Yang, Y., Ahmeti, K.B., Miller, N., Huang, C., Cheng, L., Zhai, H., 
Deng, S., Nuytemans, K., Corbett, N.J., Kim, M.J., Deng, H., Tang, B., Yang, Z., Xu, Y., 
Chan, P., Huang, B., Gao, X.-P., Song, Z., Liu, Z., Fecto, F., Siddique, N., Foroud, T., 
Jankovic, J., Ghetti, B., Nicholson, D.A., Krainc, D., Melen, O., Vance, J.M., Pericak-
Vance, M.A., Ma, Y.-C., Rajput, A.H., Siddique, T., 2016. Identification of TMEM230 
mutations in familial Parkinson’s disease. Nat. Genet. 48, 733–739. 
https://doi.org/10.1038/ng.3589 
Department of Economic and Social Affairs, 2016. Policy - United Nations Population 
Division [WWW Document]. United Nations Org. URL 
http://www.un.org/en/development/desa/population/theme/policy/index.shtml (accessed 
5.3.16). 
Di Fonzo, A., Dekker, M.C.J., Montagna, P., Baruzzi, A., Yonova, E.H., Correia Guedes, 
L., Szczerbinska, A., Zhao, T., Dubbel-Hulsman, L.O.M., Wouters, C.H., de Graaff, E., 
Oyen, W.J.G., Simons, E.J., Breedveld, G.J., Oostra, B.A., Horstink, M.W., Bonifati, V., 
2009. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal 
syndrome. Neurology 72, 240–245. https://doi.org/10.1212/01.wnl.0000338144.10967.2b 
Di Monte, D.A., Lavasani, M., Manning-Bog, A.B., 2002a. Environmental factors in 
Parkinson’s disease. Neurotoxicology 23, 487–502. 
Di Monte, D.A., Lavasani, M., Manning-Bog, A.B., 2002b. Environmental Factors in 
Parkinson’s Disease. NeuroToxicology 23, 487–502. https://doi.org/10.1016/S0161-
813X(02)00099-2 
Dick, F.D., De Palma, G., Ahmadi, A., Scott, N.W., Prescott, G.J., Bennett, J., Semple, S., 
Dick, S., Counsell, C., Mozzoni, P., Haites, N., Wettinger, S.B., Mutti, A., Otelea, M., 
Seaton, A., Söderkvist, P., Felice, A., 2007. Environmental risk factors for Parkinson’s 
disease and parkinsonism: the Geoparkinson study. Occup Environ Med 64, 666–672. 
https://doi.org/10.1136/oem.2006.027003 
Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, 
K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A., Tanner, C.M., 2007. Projected 
number of people with Parkinson disease in the most populous nations, 2005 through 
2030. Neurology 68, 384–386. https://doi.org/10.1212/01.wnl.0000247740.47667.03 
Stellenbosch University  https://scholar.sun.ac.za
- 112 - 
 
Dotchin, C., Msuya, O., Kissima, J., Massawe, J., Mhina, A., Moshy, A., Aris, E., Jusabani, 
A., Whiting, D., Masuki, G., Walker, R., 2008. The prevalence of Parkinson’s disease in 
rural Tanzania. Mov. Disord. 23, 1567–1672. https://doi.org/10.1002/mds.21898 
Driver, J.A., Logroscino, G., Gaziano, J.M., Kurth, T., 2009. Incidence and remaining 
lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438. 
https://doi.org/10.1212/01.wnl.0000341769.50075.bb 
Drouet, V., Lesage, S., 2014. Synaptojanin 1 Mutation in Parkinson’s Disease Brings 
Further Insight into the Neuropathological Mechanisms. Biomed Res Int 2014. 
https://doi.org/10.1155/2014/289728 
Esposito, G., Ana Clara, F., Verstreken, P., 2012. Synaptic vesicle trafficking and 
Parkinson’s disease. Dev Neurobiol 72, 134–144. https://doi.org/10.1002/dneu.20916 
Fahn, S., 2010. Parkinson’s disease: 10 years of progress, 1997–2007. Mov. Disord. 25, S2–
S14. https://doi.org/10.1002/mds.22796 
Farlow, J.L., Robak, L.A., Hetrick, K., Bowling, K., Boerwinkle, E., Coban-Akdemir, Z.H., 
Gambin, T., Gibbs, R.A., Gu, S., Jain, P., Jankovic, J., Jhangiani, S., Kaw, K., Lai, D., Lin, 
H., Ling, H., Liu, Y., Lupski, J.R., Muzny, D., Porter, P., Pugh, E., White, J., Doheny, K., 
Myers, R.M., Shulman, J.M., Foroud, T., 2016a. Whole-Exome Sequencing in Familial 
Parkinson Disease. JAMA Neurol 73, 68–75. 
https://doi.org/10.1001/jamaneurol.2015.3266 
Farlow, J.L., Robak, L.A., Hetrick, K., Bowling, K., Boerwinkle, E., Coban-Akdemir, Z.H., 
Gambin, T., Gibbs, R.A., Gu, S., Jain, P., Jankovic, J., Jhangiani, S., Kaw, K., Lai, D., Lin, 
H., Ling, H., Liu, Y., Lupski, J.R., Muzny, D., Porter, P., Pugh, E., White, J., Doheny, K., 
Myers, R.M., Shulman, J.M., Foroud, T., 2016b. Whole-Exome Sequencing in Familial 
Parkinson Disease. JAMA Neurol 73, 68–75. 
https://doi.org/10.1001/jamaneurol.2015.3266 
Femi, O., Ibrahim, A., Aliyu, S., 2012. Clinical profile of parkinsonian disorders in the 
tropics: Experience at Kano, northwestern Nigeria. Journal of Neurosciences in Rural 
Practice 3, 237. https://doi.org/10.4103/0976-3147.102589 
Flanagan, S.E., Patch, A.-M., Ellard, S., 2010. Using SIFT and PolyPhen to Predict Loss-
of-Function and Gain-of-Function Mutations. Genetic Testing and Molecular Biomarkers 
14, 533–537. https://doi.org/10.1089/gtmb.2010.0036 
Stellenbosch University  https://scholar.sun.ac.za
- 113 - 
 
Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., Marks, W.J.J., 
Rothlind, J., Sagher, O., Moy, C., Pahwa, R., Burchiel, K., Hogarth, P., Lai, E.C., Duda, 
J.E., Holloway, K., Samii, A., Horn, S., Bronstein, J.M., Stoner, G., Starr, P.A., Simpson, 
R., Baltuch, G., De Salles, A., Huang, G.D., Reda, D.J., 2010. Pallidal versus Subthalamic 
Deep-Brain Stimulation for Parkinson’s Disease [WWW Document]. 
http://dx.doi.org/10.1056/NEJMoa0907083. https://doi.org/10.1056/NEJMoa0907083 
Forno, L.S., 1996. Neuropathology of Parkinson’s Disease. J Neuropathol Exp Neurol 55, 
259–272. https://doi.org/10.1097/00005072-199603000-00001 
Frigerio, R., Fujishiro, H., Ahn, T.-B., Josephs, K.A., Maraganore, D.M., DelleDonne, A., 
Parisi, J.E., Klos, K.J., Boeve, B.F., Dickson, D.W., Ahlskog, E.J., 2011. Incidental Lewy 
Body Disease: Do some cases represent a preclinical stage of Dementia with Lewy Bodies? 
Neurobiol Aging 32, 857–863. https://doi.org/10.1016/j.neurobiolaging.2009.05.019 
Fromer, M., Moran, J.L., Chambert, K., Banks, E., Bergen, S.E., Ruderfer, D.M., 
Handsaker, R.E., McCarroll, S.A., O’Donovan, M.C., Owen, M.J., Kirov, G., Sullivan, P.F., 
Hultman, C.M., Sklar, P., Purcell, S.M., 2012. Discovery and statistical genotyping of 
copy-number variation from whole-exome sequencing depth. Am. J. Hum. Genet. 91, 597–
607. https://doi.org/10.1016/j.ajhg.2012.08.005 
Fuccillo, M.V., Földy, C., Gökce, Ö., Rothwell, P.E., Sun, G.L., Malenka, R.C., Südhof, T.C., 
2015. Single-Cell mRNA Profiling Reveals Cell-Type-Specific Expression of Neurexin 
Isoforms. Neuron 87, 326–340. https://doi.org/10.1016/j.neuron.2015.06.028 
Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., Ogaki, K., 
Ando, M., Yoshino, H., Tomiyama, H., Nishioka, K., Hasegawa, K., Saiki, H., Satake, W., 
Mogushi, K., Sasaki, R., Kokubo, Y., Kuzuhara, S., Toda, T., Mizuno, Y., Uchiyama, Y., 
Ohno, K., Hattori, N., 2015a. CHCHD2 mutations in autosomal dominant late-onset 
Parkinson’s disease: a genome-wide linkage and sequencing study. The Lancet Neurology 
14, 274–282. https://doi.org/10.1016/S1474-4422(14)70266-2 
Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., Ogaki, K., 
Ando, M., Yoshino, H., Tomiyama, H., Nishioka, K., Hasegawa, K., Saiki, H., Satake, W., 
Mogushi, K., Sasaki, R., Kokubo, Y., Kuzuhara, S., Toda, T., Mizuno, Y., Uchiyama, Y., 
Ohno, K., Hattori, N., 2015b. CHCHD2 mutations in autosomal dominant late-onset 
Parkinson’s disease: a genome-wide linkage and sequencing study. The Lancet Neurology 
14, 274–282. https://doi.org/10.1016/S1474-4422(14)70266-2 
Stellenbosch University  https://scholar.sun.ac.za
- 114 - 
 
Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., Ogaki, K., 
Ando, M., Yoshino, H., Tomiyama, H., Nishioka, K., Hasegawa, K., Saiki, H., Satake, W., 
Mogushi, K., Sasaki, R., Kokubo, Y., Kuzuhara, S., Toda, T., Mizuno, Y., Uchiyama, Y., 
Ohno, K., Hattori, N., 2015c. CHCHD2 mutations in autosomal dominant late-onset 
Parkinson’s disease: a genome-wide linkage and sequencing study. The Lancet Neurology 
14, 274–282. https://doi.org/10.1016/S1474-4422(14)70266-2 
Futai, K., Hayashi, Y., 2008. Transsynaptic Regulation of Presynaptic Release Machinery 
in Central Synapses by Cell Adhesion Molecules, in: Molecular Mechanisms of 
Neurotransmitter Release, Contemporary Neuroscience. Humana Press, Totowa, NJ, pp. 
315–326. https://doi.org/10.1007/978-1-59745-481-0_15 
Gagliardi, M., Iannello, G., Colica, C., Annesi, G., Quattrone, A., 2017. Analysis of 
CHCHD2 gene in familial Parkinson’s disease from Calabria. Neurobiol. Aging 50, 169.e5-
169.e6. https://doi.org/10.1016/j.neurobiolaging.2016.10.022 
Geldenhuys, G., Glanzmann, B., Lombard, D., Boolay, S., Carr, J., Bardien, S., 2014. 
Identification of a common founder couple for 40 South African Afrikaner families with 
Parkinson’s disease. SAMJ: South African Medical Journal 104, 413–419. 
Ghosh, R., Oak, N., Plon, S.E., 2017. Evaluation of in silico algorithms for use with 
ACMG/AMP clinical variant interpretation guidelines. Genome Biology 18, 225. 
https://doi.org/10.1186/s13059-017-1353-5 
Gibb, W.R., Lees, A.J., 1988. The relevance of the Lewy body to the pathogenesis of 
idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51, 745–752. 
Gilks, W.P., Abou-Sleiman, P.M., Gandhi, S., Jain, S., Singleton, A., Lees, A.J., Shaw, K., 
Bhatia, K.P., Bonifati, V., Quinn, N.P., Lynch, J., Healy, D.G., Holton, J.L., Revesz, T., 
Wood, N.W., 2005. A common LRRK2 mutation in idiopathic Parkinson’s disease. Lancet 
365, 415–416. https://doi.org/10.1016/S0140-6736(05)17830-1 
Giri, A., Mok, K.Y., Jansen, I., Sharma, M., Tesson, C., Mangone, G., Lesage, S., Bras, 
J.M., Shulman, J.M., Sheerin, U.-M., International Parkinson’s Disease Consortium 
(IPDGC), Díez-Fairen, M., Pastor, P., Martí, M.J., Ezquerra, M., Tolosa, E., Correia-
Guedes, L., Ferreira, J., Amin, N., van Duijn, C.M., van Rooij, J., Uitterlinden, A.G., 
Kraaij, R., Nalls, M., Simón-Sánchez, J., 2017. Lack of evidence for a role of genetic 
variation in TMEM230 in the risk for Parkinson’s disease in the Caucasian population. 
Neurobiol. Aging 50, 167.e11-167.e13. 
https://doi.org/10.1016/j.neurobiolaging.2016.10.004 
Stellenbosch University  https://scholar.sun.ac.za
- 115 - 
 
Glanzmann, B., 2013. An investigation into the molecular aetiology of Parkinson’s disease 
in South African patients. Stellenbosch University, Stellenbosch. 
Glanzmann, B., Lombard, D., Carr, J., Bardien, S., 2013. Screening of two indel 
polymorphisms in the 5′UTR of the DJ-1 gene in South African Parkinson’s disease 
patients. J Neural Transm 121, 135–138. https://doi.org/10.1007/s00702-013-1094-x 
Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E.M., Brockman, W., Fennell, 
T., Giannoukos, G., Fisher, S., Russ, C., Gabriel, S., Jaffe, D.B., Lander, E.S., Nusbaum, 
C., 2009. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively 
Parallel Targeted Sequencing. Nat Biotechnol 27, 182–189. 
https://doi.org/10.1038/nbt.1523 
Golbe, L.I., Lazzarini, A.M., Spychala, J.R., Johnson, W.G., Stenroos, E.S., Mark, M.H., 
Sage, J.I., 2001. The tau A0 allele in Parkinson’s disease. Movement Disorders 16, 442–
447. https://doi.org/10.1002/mds.1087 
Gordon, A., Hannon, G.J., 2010. Fastx-toolkit. FASTQ/A short-reads preprocessing tools 
(unpublished) http://hannonlab. cshl. edu/fastx_toolkit 5. 
Gorell, J.M., Rybicki, B.A., Johnson, C.C., Peterson, E.L., 1999. Smoking and Parkinson’s 
disease. Neurology 52, 115. https://doi.org/10.1212/WNL.52.1.115 
Grandinetti, A., Morens, D.M., Reed, D., MacEachern, D., 1994. Prospective Study of 
Cigarette Smoking and the Risk of Developing Idiopathic Parkinson’s Disease. Am J 
Epidemiol 139, 1129–1138. https://doi.org/10.1093/oxfordjournals.aje.a116960 
Greeff, J.M., 2007. Deconstructing Jaco: genetic heritage of an Afrikaner. Ann. Hum. 
Genet. 71, 674–688. https://doi.org/10.1111/j.1469-1809.2007.00363.x 
Groiss, S.J., Wojtecki, L., Südmeyer, M., Schnitzler, A., 2009. Deep Brain Stimulation in 
Parkinson’s         Disease. Ther Adv Neurol Disord 2, 20–28. 
https://doi.org/10.1177/1756285609339382 
Group, T.P.S., 2006. Randomized placebo-controlled study of the nicotinic agonist SIB-
1508Y in Parkinson disease. Neurology 66, 408–410. 
https://doi.org/10.1212/01.wnl.0000196466.99381.5c 
Guex, N., Peitsch, M.C., 1997. SWISS-MODEL and the Swiss-PdbViewer: an environment 
for comparative protein modeling. Electrophoresis 18, 2714–2723. 
https://doi.org/10.1002/elps.1150181505 
Stellenbosch University  https://scholar.sun.ac.za
- 116 - 
 
Haaxma, C.A., Bloem, B.R., Borm, G.F., Oyen, W.J.G., Leenders, K.L., Eshuis, S., Booij, 
J., Dluzen, D.E., Horstink, M.W.I.M., 2007. Gender differences in Parkinson’s disease. J 
Neurol Neurosurg Psychiatry 78, 819–824. https://doi.org/10.1136/jnnp.2006.103788 
Haeuptle, M.A., Pujol, F.M., Neupert, C., Winchester, B., Kastaniotis, A.J., Aebi, M., 
Hennet, T., 2008. Human RFT1 Deficiency Leads to a Disorder of N-Linked Glycosylation. 
The American Journal of Human Genetics 82, 600–606. 
https://doi.org/10.1016/j.ajhg.2007.12.021 
Haimanot, R.T.-, Abebe, M., Gebre-Mariam, A., Forsgren, L., Heijbel, J., Holmgren, G., 
Ekstedt, J., 1990. Community-Based Study of Neurological Disorders in Rural Central 
Ethiopia. NED 9, 263–277. https://doi.org/10.1159/000110783 
HALL, T., 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis 
program for Windows 95/98/NT, in: Nucleic Acids Symp. Ser. pp. 95–98. 
Halliday, G., Lees, A., Stern, M., 2011. Milestones in Parkinson’s disease--clinical and 
pathologic features. Mov. Disord. 26, 1015–1021. https://doi.org/10.1002/mds.23669 
Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Bass, M.B., Arruda, I., 
Robinson, M.O., 1997. A mammalian telomerase-associated protein. Science 275, 973–977. 
Hauser, R.A., Pahwa, R., McClain, T.A., Lyons, K.E., 2016. Parkinson Disease: Practice 
Essentials, Background, Anatomy. 
Hayden, M.R., Hopkins, H.C., Macrea, M., Beighton, P.H., 1980. The origin of 
Huntington’s chorea in the Afrikaner population of South Africa. S Afr Med J 58, 197–
200. 
Haylett, W.L., Keyser, R.J., du Plessis, M.C., van der Merwe, C., Blanckenberg, J., 
Lombard, D., Carr, J., Bardien, S., 2012. Mutations in the parkin gene are a minor cause 
of Parkinson’s disease in the South African population. Parkinsonism & Related Disorders 
18, 89–92. https://doi.org/10.1016/j.parkreldis.2011.09.022 
Heese, J.A., 1971. Die herkoms van die Afrikaner, 1657-1867. 
Helenius, J., Ng, D.T.W., Marolda, C.L., Walter, P., Valvano, M.A., Aebi, M., 2002. 
Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 
protein. Nature 415, 447–450. https://doi.org/10.1038/415447a 
Hellenbrand, W., Seidler, A., Robra, B.P., Vieregge, P., Oertel, W.H., Joerg, J., Nischan, 
P., Schneider, E., Ulm, G., 1997. Smoking and Parkinson’s disease: a case-control study 
in Germany. Int J Epidemiol 26, 328–339. https://doi.org/10.1093/ije/26.2.328 
Stellenbosch University  https://scholar.sun.ac.za
- 117 - 
 
Hertzman, C., Wiens, M., Bowering, D., Snow, B., Calne, D., 1990. Parkinson’s disease: A 
case-control study of occupational and environmental risk factors. American Journal of 
Industrial Medicine 17, 349–355. https://doi.org/10.1002/ajim.4700170307 
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., Pringsheim, T., 2016. The Incidence of 
Parkinson’s Disease: A Systematic Review and Meta-Analysis. NED 46, 292–300. 
https://doi.org/10.1159/000445751 
Hughes, A.J., Daniel, S.E., Kilford, L., Lees, A.J., 1992. Accuracy of clinical diagnosis of 
idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol 
Neurosurg Psychiatry 55, 181–184. https://doi.org/10.1136/jnnp.55.3.181 
Iacono, D., Geraci-Erck, M., Rabin, M.L., Adler, C.H., Serrano, G., Beach, T.G., Kurlan, 
R., 2015. Parkinson disease and incidental Lewy body disease. Neurology 85, 1670–1679. 
https://doi.org/10.1212/WNL.0000000000002102 
International Human Genome Sequencing Consortium, 2001. Initial sequencing and 
analysis of the human genome. Nature 409, 860–921. https://doi.org/10.1038/35057062 
Jankovic, J., 2008. Parkinson’s disease: clinical features and diagnosis. J Neurol 
Neurosurg Psychiatry 79, 368–376. https://doi.org/10.1136/jnnp.2007.131045 
Jansen, I.E., Bras, J.M., Lesage, S., Schulte, C., Gibbs, J.R., Nalls, M.A., Brice, A., Wood, 
N.W., Morris, H., Hardy, J.A., Singleton, A.B., Gasser, T., Heutink, P., Sharma, M., 
IPDGC, 2015. CHCHD2 and Parkinson’s disease. Lancet Neurol 14, 678–679. 
https://doi.org/10.1016/S1474-4422(15)00094-0 
Kanehisa, M., Goto, S., 2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic 
Acids Res 28, 27–30. https://doi.org/10.1093/nar/28.1.27 
Kapur, S.S., Stebbins, G.T., Goetz, C.G., 2012. Vibration Therapy for Parkinson’s Disease: 
Charcot’s Studies Revisited. Journal of Parkinson’s Disease 2, 23–27. 
https://doi.org/10.3233/JPD-2012-12079 
Karayiorgou, M., Torrington, M., Abecasis, G.R., Pretorius, H., Robertson, B., Kaliski, S., 
Lay, S., Sobin, C., Möller, N., Lundy, S.L., Blundell, M.L., Gogos, J.A., Roos, J.L., 2004. 
Phenotypic characterization and genealogical tracing in an Afrikaner schizophrenia 
database. Am. J. Med. Genet. 124B, 20–28. https://doi.org/10.1002/ajmg.b.20090 
Karczewski, K.J., Weisburd, B., Thomas, B., Solomonson, M., Ruderfer, D.M., Kavanagh, 
D., Hamamsy, T., Lek, M., Samocha, K.E., Cummings, B.B., Birnbaum, D., Daly, M.J., 
Stellenbosch University  https://scholar.sun.ac.za
- 118 - 
 
MacArthur, D.G., 2017. The ExAC browser: displaying reference data information from 
over 60 000 exomes. Nucleic Acids Res 45, D840–D845. https://doi.org/10.1093/nar/gkw971 
Keyser, R.J., Lesage, S., Brice, A., Carr, J., Bardien, S., 2010a. Assessing the prevalence 
of PINK1 genetic variants in South African patients diagnosed with early- and late-onset 
Parkinson’s disease. Biochemical and Biophysical Research Communications 398, 125–
129. https://doi.org/10.1016/j.bbrc.2010.06.049 
Keyser, R.J., Lesage, S., Brice, A., Carr, J., Bardien, S., 2010b. Assessing the prevalence 
of PINK1 genetic variants in South African patients diagnosed with early- and late-onset 
Parkinson’s disease. Biochemical and Biophysical Research Communications 398, 125–
129. https://doi.org/10.1016/j.bbrc.2010.06.049 
Keyser, R.J., Lombard, D., Veikondis, R., Carr, J., Bardien, S., 2009a. Analysis of exon 
dosage using MLPA in South African Parkinson’s disease patients. Neurogenetics 11, 
305–312. https://doi.org/10.1007/s10048-009-0229-6 
Keyser, R.J., Van Der Merwe, L., Venter, M., Kinnear, C., Warnich, L., Carr, J., Bardien, 
S., 2009b. Identification of a novel functional deletion variant in the 5’-UTR of the DJ-1 
gene. https://doi.org/10.1186/1471-2350-10-105 
Khodadadi, H., Azcona, L.J., Aghamollaii, V., Omrani, M.D., Garshasbi, M., Taghavi, S., 
Tafakhori, A., Shahidi, G.A., Jamshidi, J., Darvish, H., Paisán-Ruiz, C., 2017. PTRHD1 
(C2orf79) mutations lead to autosomal recessive intellectual disability and parkinsonism. 
Mov Disord 32, 287–291. https://doi.org/10.1002/mds.26824 
Kircher, M., Witten, D.M., Jain, P., O’Roak, B.J., Cooper, G.M., Shendure, J., 2014. A 
general framework for estimating the relative pathogenicity of human genetic variants. 
Nat. Genet. 46, 310–315. https://doi.org/10.1038/ng.2892 
Kisoli, A., Gray, W.K., Dotchin, C.L., Orega, G., Dewhurst, F., Paddick, S.-M., Longdon, 
A., Chaote, P., Dewhurst, M., Walker, R.W., 2015. Levels of functional disability in elderly 
people in Tanzania with dementia, stroke and Parkinson’s disease. Acta 
Neuropsychiatrica 27, 206–212. https://doi.org/10.1017/neu.2015.9 
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., 
Yokochi, M., Mizuno, Y., Shimizu, N., 1998. Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism. Nature 392, 605–608. https://doi.org/10.1038/33416 
Stellenbosch University  https://scholar.sun.ac.za
- 119 - 
 
Klein, C., Chuang, R., Marras, C., Lang, A.E., 2011. The curious case of phenocopies in 
families with genetic Parkinson’s disease. Mov. Disord. 26, 1793–1802. 
https://doi.org/10.1002/mds.23853 
Klein, C., Westenberger, A., 2012. Genetics of Parkinson’s Disease. Cold Spring Harb 
Perspect Med 2. https://doi.org/10.1101/cshperspect.a008888 
Knoll, D.P., de Vries, W.N., De Wet, W.J., 1988. Genealogie van’n familie met osteogenesis 
imperfecta: Die stamregister van Pieter Willem Adriaan Piek. Familia 25, 46–64. 
Ko, J., Fuccillo, M.V., Malenka, R.C., Südhof, T.C., 2009. LRRTM2 Functions as a 
Neurexin Ligand in Promoting Excitatory Synapse Formation. Neuron 64, 791–798. 
https://doi.org/10.1016/j.neuron.2009.12.012 
Kohanski, M.A., Dwyer, D.J., Collins, J.J., 2010. How antibiotics kill bacteria: from 
targets to networks. Nat Rev Microbiol 8, 423–435. https://doi.org/10.1038/nrmicro2333 
Koressaar, T., Remm, M., 2007. Enhancements and modifications of primer design 
program Primer3. Bioinformatics 23, 1289–1291. 
https://doi.org/10.1093/bioinformatics/btm091 
Koschmidder, E., Weissbach, A., Brüggemann, N., Kasten, M., Klein, C., Lohmann, K., 
2016. A nonsense mutation in <em>CHCHD2</em> in a patient with Parkinson disease. 
Neurology 86, 577. https://doi.org/10.1212/WNL.0000000000002361 
Kowal, S.L., Dall, T.M., Chakrabarti, R., Storm, M.V., Jain, A., 2013. The current and 
projected economic burden of Parkinson’s disease in the United States. Mov. Disord. 28, 
311–318. https://doi.org/10.1002/mds.25292 
Kozarewa, I., Ning, Z., Quail, M.A., Sanders, M.J., Berriman, M., Turner, D.J., 2009. 
Amplification-free Illumina sequencing-library preparation facilitates improved mapping 
and assembly of (G+C)-biased genomes. Nat. Methods 6, 291–295. 
https://doi.org/10.1038/nmeth.1311 
Krebs, C.E., Karkheiran, S., Powell, J.C., Cao, M., Makarov, V., Darvish, H., Di Paolo, G., 
Walker, R.H., Shahidi, G.A., Buxbaum, J.D., De Camilli, P., Yue, Z., Paisán-Ruiz, C., 2013. 
The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive 
Parkinsonism with generalized seizures. Hum. Mutat. 34, 1200–1207. 
https://doi.org/10.1002/humu.22372 
Krumm, N., Sudmant, P.H., Ko, A., O’Roak, B.J., Malig, M., Coe, B.P., NHLBI Exome 
Sequencing Project, Quinlan, A.R., Nickerson, D.A., Eichler, E.E., 2012. Copy number 
Stellenbosch University  https://scholar.sun.ac.za
- 120 - 
 
variation detection and genotyping from exome sequence data. Genome Res. 22, 1525–
1532. https://doi.org/10.1101/gr.138115.112 
Kubicek, J., Block, H., Maertens, B., Spriestersbach, A., Labahn, J., 2014. Expression and 
purification of membrane proteins. Meth. Enzymol. 541, 117–140. 
https://doi.org/10.1016/B978-0-12-420119-4.00010-0 
Kumar, P., Henikoff, S., Ng, P.C., 2009. Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nat Protoc 4, 1073–1081. 
https://doi.org/10.1038/nprot.2009.86 
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., 
Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., 
Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., Meldrim, J., 
Mesirov, J.P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., 
Sheridan, A., Sougnez, C., Stange-Thomann, Y., Stojanovic, N., Subramanian, A., Wyman, 
D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, 
N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, 
L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., 
McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J.C., Mungall, A., Plumb, R., 
Ross, M., Shownkeen, R., Sims, S., Waterston, R.H., Wilson, R.K., Hillier, L.W., 
McPherson, J.D., Marra, M.A., Mardis, E.R., Fulton, L.A., Chinwalla, A.T., Pepin, K.H., 
Gish, W.R., Chissoe, S.L., Wendl, M.C., Delehaunty, K.D., Miner, T.L., Delehaunty, A., 
Kramer, J.B., Cook, L.L., Fulton, R.S., Johnson, D.L., Minx, P.J., Clifton, S.W., Hawkins, 
T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, 
J.F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., Gibbs, R.A., Muzny, D.M., 
Scherer, S.E., Bouck, J.B., Sodergren, E.J., Worley, K.C., Rives, C.M., Gorrell, J.H., 
Metzker, M.L., Naylor, S.L., Kucherlapati, R.S., Nelson, D.L., Weinstock, G.M., Sakaki, 
Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., 
Totoki, Y., Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, 
P., Bruls, T., Pelletier, E., Robert, C., Wincker, P., Smith, D.R., Doucette-Stamm, L., 
Rubenfield, M., Weinstock, K., Lee, H.M., Dubois, J., Rosenthal, A., Platzer, M., 
Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, 
L., Rowen, L., Madan, A., Qin, S., Davis, R.W., Federspiel, N.A., Abola, A.P., Proctor, M.J., 
Myers, R.M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D.R., Olson, M.V., Kaul, R., 
Raymond, C., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G.A., Athanasiou, M., 
Schultz, R., Roe, B.A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R., 
Stellenbosch University  https://scholar.sun.ac.za
- 121 - 
 
McCombie, W.R., de la Bastide, M., Dedhia, N., Blöcker, H., Hornischer, K., Nordsiek, G., 
Agarwala, R., Aravind, L., Bailey, J.A., Bateman, A., Batzoglou, S., Birney, E., Bork, P., 
Brown, D.G., Burge, C.B., Cerutti, L., Chen, H.C., Church, D., Clamp, M., Copley, R.R., 
Doerks, T., Eddy, S.R., Eichler, E.E., Furey, T.S., Galagan, J., Gilbert, J.G., Harmon, C., 
Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L.S., 
Jones, T.A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W.J., Kitts, P., Koonin, E.V., Korf, 
I., Kulp, D., Lancet, D., Lowe, T.M., McLysaght, A., Mikkelsen, T., Moran, J.V., Mulder, 
N., Pollara, V.J., Ponting, C.P., Schuler, G., Schultz, J., Slater, G., Smit, A.F., Stupka, E., 
Szustakowki, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., 
Williams, A., Wolf, Y.I., Wolfe, K.H., Yang, S.P., Yeh, R.F., Collins, F., Guyer, M.S., 
Peterson, J., Felsenfeld, A., Wetterstrand, K.A., Patrinos, A., Morgan, M.J., de Jong, P., 
Catanese, J.J., Osoegawa, K., Shizuya, H., Choi, S., Chen, Y.J., Szustakowki, J., 
International Human Genome Sequencing Consortium, 2001. Initial sequencing and 
analysis of the human genome. Nature 409, 860–921. https://doi.org/10.1038/35057062 
Langmead, B., Salzberg, S.L., 2012. Fast gapped-read alignment with Bowtie 2. Nat 
Methods 9, 357–359. https://doi.org/10.1038/nmeth.1923 
Langston, J.W., 2006. The parkinson’s complex: Parkinsonism is just the tip of the iceberg. 
Ann Neurol. 59, 591–596. https://doi.org/10.1002/ana.20834 
Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I., 1983. Chronic Parkinsonism in 
humans due to a product of meperidine-analog synthesis. Science 219, 979–980. 
Lesage, S., Brice, A., 2009. Parkinson’s disease: from monogenic forms to genetic 
susceptibility factors. Hum. Mol. Genet. 18, R48-59. https://doi.org/10.1093/hmg/ddp012 
Lesage, S., Dürr, A., Tazir, M., Lohmann, E., Leutenegger, A.-L., Janin, S., Pollak, P., 
Brice, A., 2006. LRRK2 G2019S as a Cause of Parkinson’s Disease in North African Arabs. 
The New England Journal of Medicine 354, 422–3. 
LeWitt, P.A., Hauser, R.A., Grosset, D.G., Stocchi, F., Saint-Hilaire, M.-H., Ellenbogen, 
A., Leinonen, M., Hampson, N.B., DeFeo-Fraulini, T., Freed, M.I., Kieburtz, K.D., 2016. 
A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s 
disease. Mov Disord. n/a-n/a. https://doi.org/10.1002/mds.26611 
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, 
G., Durbin, R., 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 
25, 2078–2079. https://doi.org/10.1093/bioinformatics/btp352 
Stellenbosch University  https://scholar.sun.ac.za
- 122 - 
 
Li, X., Kierczak, M., Shen, X., Ahsan, M., Carlborg, Ö., Marklund, S., 2013. PASE: a novel 
method for functional prediction of amino acid substitutions based on physicochemical 
properties. Front Genet 4. https://doi.org/10.3389/fgene.2013.00021 
Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., 
Rice, M.E., Yue, Z., 2010. Enhanced Striatal Dopamine Transmission and Motor 
Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson’s 
Disease Mutation G2019S. J. Neurosci. 30, 1788–1797. 
https://doi.org/10.1523/JNEUROSCI.5604-09.2010 
Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., Benabid, 
A.-L., 1998. Electrical Stimulation of the Subthalamic Nucleus in Advanced Parkinson’s 
Disease. New England Journal of Medicine 339, 1105–1111. 
https://doi.org/10.1056/NEJM199810153391603 
Liou, H.H., Tsai, M.C., Chen, C.J., Jeng, J.S., Chang, Y.C., Chen, S.Y., Chen, R.C., 1997. 
Environmental risk factors and Parkinson’s disease: a case-control study in Taiwan. 
Neurology 48, 1583–1588. 
Liu, X., Han, S., Wang, Z., Gelernter, J., Yang, B.-Z., 2013. Variant Callers for Next-
Generation Sequencing Data: A Comparison Study. PLoS One 8. 
https://doi.org/10.1371/journal.pone.0075619 
Lombard A, Gelfand M, 1978. Parkinson’s disease in the African. The Central African 
journal of medicine 24, 5–8. 
Mahne, A.C., Carr, J.A., Bardien, S., Schutte, C.-M., 2016. Clinical findings and genetic 
screening for copy number variation mutations in a cohort of South African patients with 
Parkinson’s disease. South African Medical Journal 106, 623+. 
Mancia, F., Love, J., 2010. High-throughput expression and purification of membrane 
proteins. J. Struct. Biol. 172, 85–93. https://doi.org/10.1016/j.jsb.2010.03.021 
Mandemakers, W., Quadri, M., Stamelou, M., Bonifati, V., 2017. TMEM230: How does it 
fit in the etiology and pathogenesis of Parkinson’s disease? Movement Disorders 32, 1159–
1162. https://doi.org/10.1002/mds.27061 
Mardis, E.R., 2008. Next-generation DNA sequencing methods. Annu Rev Genomics Hum 
Genet 9, 387–402. https://doi.org/10.1146/annurev.genom.9.081307.164359 
Mather, C.A., Mooney, S.D., Salipante, S.J., Scroggins, S., Wu, D., Pritchard, C.C., Shirts, 
B.H., 2016. CADD score has limited clinical validity for the identification of pathogenic 
Stellenbosch University  https://scholar.sun.ac.za
- 123 - 
 
variants in non-coding regions in a hereditary cancer panel. Genet Med 18, 1269–1275. 
https://doi.org/10.1038/gim.2016.44 
Maxam, A.M., Gilbert, W., 1977. A new method for sequencing DNA. Proc. Natl. Acad. Sci. 
U.S.A. 74, 560–564. 
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., 
Garimella, K., Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., 2010. The Genome 
Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing 
data. Genome Res. 20, 1297–1303. https://doi.org/10.1101/gr.107524.110 
Meireles, J., Massano, J., 2012. Cognitive Impairment and Dementia in Parkinson’s 
Disease: Clinical Features, Diagnosis, and Management. Front Neurol 3. 
https://doi.org/10.3389/fneur.2012.00088 
Meng, H., Yamashita, C., Shiba-Fukushima, K., Inoshita, T., Funayama, M., Sato, S., 
Hatta, T., Natsume, T., Umitsu, M., Takagi, J., Imai, Y., Hattori, N., 2017a. Loss of 
Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure 
and destabilizes cytochrome c. Nature Communications 8, 15500. 
https://doi.org/10.1038/ncomms15500 
Meng, H., Yamashita, C., Shiba-Fukushima, K., Inoshita, T., Funayama, M., Sato, S., 
Hatta, T., Natsume, T., Umitsu, M., Takagi, J., Imai, Y., Hattori, N., 2017b. Loss of 
Parkinson’s disease-associated protein CHCHD2 affects mitochondrial crista structure 
and destabilizes cytochrome c. Nature Communications 8, 15500. 
https://doi.org/10.1038/ncomms15500 
Metzker, M.L., 2010a. Sequencing technologies — the next generation. Nature Reviews 
Genetics 11, 31–46. https://doi.org/10.1038/nrg2626 
Metzker, M.L., 2010b. Sequencing technologies - the next generation. Nat. Rev. Genet. 11, 
31–46. https://doi.org/10.1038/nrg2626 
Meynert, A.M., Ansari, M., FitzPatrick, D.R., Taylor, M.S., 2014. Variant detection 
sensitivity and biases in whole genome and exome sequencing. BMC Bioinformatics 15, 
247. https://doi.org/10.1186/1471-2105-15-247 
Mi, H., Thomas, P., 2009. PANTHER Pathway: An Ontology-Based Pathway Database 
Coupled with Data Analysis Tools, in: Protein Networks and Pathway Analysis, Methods 
in Molecular Biology. Humana Press, pp. 123–140. https://doi.org/10.1007/978-1-60761-
175-2_7 
Stellenbosch University  https://scholar.sun.ac.za
- 124 - 
 
Missler, M., Südhof, T.C., 1998. Neurexins: three genes and 1001 products. Trends Genet. 
14, 20–26. https://doi.org/10.1016/S0168-9525(97)01324-3 
Missler, M., Zhang, W., Rohlmann, A., Kattenstroth, G., Hammer, R.E., Gottmann, K., 
Südhof, T.C., 2003. Alpha-neurexins couple Ca2+ channels to synaptic vesicle exocytosis. 
Nature 423, 939–948. https://doi.org/10.1038/nature01755 
Møller, R.S., Weber, Y.G., Klitten, L.L., Trucks, H., Muhle, H., Kunz, W.S., Mefford, H.C., 
Franke, A., Kautza, M., Wolf, P., Dennig, D., Schreiber, S., Rückert, I.-M., Wichmann, H.-
E., Ernst, J.P., Schurmann, C., Grabe, H.J., Tommerup, N., Stephani, U., Lerche, H., 
Hjalgrim, H., Helbig, I., Sander, T., EPICURE Consortium, 2013. Exon-disrupting 
deletions of NRXN1 in idiopathic generalized epilepsy. Epilepsia 54, 256–264. 
https://doi.org/10.1111/epi.12078 
Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M., 2005. Molecular pathophysiology of 
Parkinson’s disease. Annu. Rev. Neurosci. 28, 57–87. 
https://doi.org/10.1146/annurev.neuro.28.061604.135718 
Moreland, J.L., Gramada, A., Buzko, O.V., Zhang, Q., Bourne, P.E., 2005. The Molecular 
Biology Toolkit (MBT): a modular platform for developing molecular visualization 
applications. BMC Bioinformatics 6, 21. https://doi.org/10.1186/1471-2105-6-21 
Mukherjee, K., Sharma, M., Urlaub, H., Bourenkov, G.P., Jahn, R., Südhof, T.C., Wahl, 
M.C., 2008. CASK Functions as a Mg2+-Independent Neurexin Kinase. Cell 133, 328–339. 
https://doi.org/10.1016/j.cell.2008.02.036 
Müller, W.E., Pedigo, N.W., 1994. Brain aging: a risk factor of neurodegenerative 
disorders and a target for therapeutic intervention. Life Sci. 55, 1975–1976. 
Munoz, D.G., Fujioka, S., 2018. Caffeine and Parkinson disease: A possible diagnostic and 
pathogenic breakthrough. Neurology 90, 205–206. 
https://doi.org/10.1212/WNL.0000000000004898 
Myhre, R., Steinkjer, S., Stormyr, A., Nilsen, G.L., Zayyad, H.A., Horany, K., Nusier, M.K., 
Klungland, H., 2008. Significance of the parkin and PINK1 gene in Jordanian families 
with incidences of young-onset and juvenile parkinsonism. BMC Neurol 8, 47. 
https://doi.org/10.1186/1471-2377-8-47 
Ng M. C. Y., Lam V. K. L., Tam C. H. T., Chan A. W. H., So W.‐Y., Ma R. C. W., Zee B. C. 
Y., Waye M. M. Y., Mak W. W., Hu C., Wang C. R., Tong P. C. Y., Jia W. P., Chan J. C. N., 
null null, 2010. Association of the POU class 2 homeobox 1 gene (POU2F1) with 
Stellenbosch University  https://scholar.sun.ac.za
- 125 - 
 
susceptibility to Type 2 diabetes in Chinese populations. Diabetic Medicine 27, 1443–
1449. https://doi.org/10.1111/j.1464-5491.2010.03124.x 
Ng, P.C., Henikoff, S., 2003. SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res. 31, 3812–3814. 
Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D., 
Shannon, P.T., Jabs, E.W., Nickerson, D.A., Shendure, J., Bamshad, M.J., 2010. Exome 
sequencing identifies the cause of a mendelian disorder. Nat. Genet. 42, 30–35. 
https://doi.org/10.1038/ng.499 
Nichols, W.C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C.A., 
Michaels, V.E., Reed, T., Rudolph, A., Shults, C.W., Singleton, A., Foroud, T., Parkinson 
Study Group-PROGENI investigators, 2005. Genetic screening for a single common 
LRRK2 mutation in familial Parkinson’s disease. Lancet 365, 410–412. 
https://doi.org/10.1016/S0140-6736(05)17828-3 
Nisheeth Bandaru, Chen Guo, Yanxi Chen, Tyrone Lee, Peijue Zhang, 2015. In silico 
prediction of clinical pathogenicty by CADD scoring of exome variants found in genome of 
a Male belonging to the Chinese Dai Minority. Biology Computes. 
Nuytemans, K., Theuns, J., Cruts, M., Van Broeckhoven, C., 2010. Genetic etiology of 
Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and 
LRRK2 genes: a mutation update. Hum. Mutat. 31, 763–780. 
https://doi.org/10.1002/humu.21277 
Obeso, J.A., Olanow, C.W., Nutt, J.G., 2000. Levodopa motor complications in Parkinson’s 
disease. Trends in Neurosciences 23, S2–S7. https://doi.org/10.1016/S1471-
1931(00)00031-8 
Okubadejo, N., Britton, A., Crews, C., Akinyemi, R., Hardy, J., Singleton, A., Bras, J., 
2008. Analysis of Nigerians with Apparently Sporadic Parkinson Disease for Mutations 
in LRRK2 , PRKN and ATXN3. PLOS ONE 3, e3421. 
https://doi.org/10.1371/journal.pone.0003421 
Okubadejo, N.U., 2008a. An analysis of genetic studies of Parkinson’s disease in Africa. 
Parkinsonism & Related Disorders 14, 177–182. 
https://doi.org/10.1016/j.parkreldis.2007.08.006 
Stellenbosch University  https://scholar.sun.ac.za
- 126 - 
 
Okubadejo, N.U., 2008b. An analysis of genetic studies of Parkinson’s disease in Africa. 
Parkinsonism & Related Disorders 14, 177–182. 
https://doi.org/10.1016/j.parkreldis.2007.08.006 
Osuntokun, B.., Adeuja, A.O.., Schoenberg, B.., Bademosi, O., Nottidge, V.., Olumide, A.., 
Lge, O., Yaria, F., Bolis, C.., 1987. Neurological disorders in Nigerian Africans: a 
community-based study. Acta Neurologica Scandinavica 75, 13–21. 
https://doi.org/10.1111/j.1600-0404.1987.tb07883.x 
Ovallath, S., Deepa, P., 2013. The history of parkinsonism: Descriptions in ancient Indian 
medical literature. Mov Disord. 28, 566–568. https://doi.org/10.1002/mds.25420 
Paisán-Ruíz, C., Jain, S., Evans, E.W., Gilks, W.P., Simón, J., van der Brug, M., López de 
Munain, A., Aparicio, S., Gil, A.M., Khan, N., Johnson, J., Martinez, J.R., Nicholl, D., 
Carrera, I.M., Pena, A.S., de Silva, R., Lees, A., Martí-Massó, J.F., Pérez-Tur, J., Wood, 
N.W., Singleton, A.B., 2004. Cloning of the gene containing mutations that cause PARK8-
linked Parkinson’s disease. Neuron 44, 595–600. 
https://doi.org/10.1016/j.neuron.2004.10.023 
Parkinson, J., 1817. An Essay on the Shaking Palsy. Sheerwood, Neely and Jones, 
Paternoster Row , London. 
Patel, Z.H., Kottyan, L.C., Lazaro, S., Williams, M.S., Ledbetter, D.H., Tromp, 
H.B.,Gerard, Rupert, A., Kohram, M., Wagner, M., Husami, A., Qian, Y., Valencia, C.A., 
Zhang, K., Hostetter, M.K., Harley, J.B., Kaufman, K.M., 2014. The struggle to find 
reliable results in exome sequencing data: filtering out Mendelian errors. Front Genet 5. 
https://doi.org/10.3389/fgene.2014.00016 
Perier, C., Bové, J., Vila, M., 2011. Mitochondria and Programmed Cell Death in 
Parkinson’s Disease: Apoptosis and Beyond. Antioxidants & Redox Signaling 16, 883–895. 
https://doi.org/10.1089/ars.2011.4074 
Picconi, B., Piccoli, G., Calabresi, P., 2012. Synaptic dysfunction in Parkinson’s disease. 
Adv. Exp. Med. Biol. 970, 553–572. https://doi.org/10.1007/978-3-7091-0932-8_24 
Pillai, S., Gopalan, V., Lam, A.K.-Y., 2017. Review of sequencing platforms and their 
applications in phaeochromocytoma and paragangliomas. Critical Reviews in Oncology / 
Hematology 116, 58–67. https://doi.org/10.1016/j.critrevonc.2017.05.005 
Stellenbosch University  https://scholar.sun.ac.za
- 127 - 
 
Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R., Siepel, A., 2010. Detection of nonneutral 
substitution rates on mammalian phylogenies. Genome Res 20, 110–121. 
https://doi.org/10.1101/gr.097857.109 
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., 
Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., 
Athanassiadou, A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., 
Di Iorio, G., Golbe, L.I., Nussbaum, R.L., 1997. Mutation in the alpha-synuclein gene 
identified in families with Parkinson’s disease. Science 276, 2045–2047. 
Pontén F., Schwenk J. M., Asplund A., Edqvist P.‐H. D., 2011. The Human Protein Atlas 
as a proteomic resource for biomarker discovery. Journal of Internal Medicine 270, 428–
446. https://doi.org/10.1111/j.1365-2796.2011.02427.x 
Postuma, R.B., Lang, A.E., Munhoz, R.P., Charland, K., Pelletier, A., Moscovich, M., Filla, 
L., Zanatta, D., Rios Romenets, S., Altman, R., Chuang, R., Shah, B., 2012. Caffeine for 
treatment of Parkinson disease: a randomized controlled trial. Neurology 79, 651–658. 
https://doi.org/10.1212/WNL.0b013e318263570d 
Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D.L., 2014a. The prevalence of 
Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 29, 1583–1590. 
https://doi.org/10.1002/mds.25945 
Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D.L., 2014b. The prevalence of 
Parkinson&apos;s disease: A systematic review and meta‐analysis. Movement Disorders 
29, 1583–1590. https://doi.org/10.1002/mds.25945 
Pruitt, K.D., Brown, G.R., Hiatt, S.M., Thibaud-Nissen, F., Astashyn, A., Ermolaeva, O., 
Farrell, C.M., Hart, J., Landrum, M.J., McGarvey, K.M., Murphy, M.R., O’Leary, N.A., 
Pujar, S., Rajput, B., Rangwala, S.H., Riddick, L.D., Shkeda, A., Sun, H., Tamez, P., Tully, 
R.E., Wallin, C., Webb, D., Weber, J., Wu, W., DiCuccio, M., Kitts, P., Maglott, D.R., 
Murphy, T.D., Ostell, J.M., 2014. RefSeq: an update on mammalian reference sequences. 
Nucleic Acids Res. 42, D756-763. https://doi.org/10.1093/nar/gkt1114 
Quadri, M., Fang, M., Picillo, M., Olgiati, S., Breedveld, G.J., Graafland, J., Wu, B., Xu, 
F., Erro, R., Amboni, M., Pappatà, S., Quarantelli, M., Annesi, G., Quattrone, A., Chien, 
H.F., Barbosa, E.R., International Parkinsonism Genetics Network, Oostra, B.A., Barone, 
P., Wang, J., Bonifati, V., 2013. Mutation in the SYNJ1 gene associated with autosomal 
recessive, early-onset Parkinsonism. Hum. Mutat. 34, 1208–1215. 
https://doi.org/10.1002/humu.22373 
Stellenbosch University  https://scholar.sun.ac.za
- 128 - 
 
Quadri, M., Mandemakers, W., Grochowska, M.M., Masius, R., Geut, H., Fabrizio, E., 
Breedveld, G.J., Kuipers, D., Minneboo, M., Vergouw, L.J.M., Carreras Mascaro, A., 
Yonova-Doing, E., Simons, E., Zhao, T., Di Fonzo, A.B., Chang, H.-C., Parchi, P., Melis, 
M., Correia Guedes, L., Criscuolo, C., Thomas, A., Brouwer, R.W.W., Heijsman, D., 
Ingrassia, A.M.T., Calandra Buonaura, G., Rood, J.P., Capellari, S., Rozemuller, A.J., 
Sarchioto, M., Fen Chien, H., Vanacore, N., Olgiati, S., Wu-Chou, Y.-H., Yeh, T.-H., Boon, 
A.J.W., Hoogers, S.E., Ghazvini, M., IJpma, A.S., van IJcken, W.F.J., Onofrj, M., Barone, 
P., Nicholl, D.J., Puschmann, A., De Mari, M., Kievit, A.J., Barbosa, E., De Michele, G., 
Majoor-Krakauer, D., van Swieten, J.C., de Jong, F.J., Ferreira, J.J., Cossu, G., Lu, C.-S., 
Meco, G., Cortelli, P., van de Berg, W.D.J., Bonifati, V., 2018a. LRP10 genetic variants in 
familial Parkinson’s disease and dementia with Lewy bodies: a genome-wide linkage and 
sequencing study. The Lancet Neurology 17, 597–608. https://doi.org/10.1016/S1474-
4422(18)30179-0 
Quadri, M., Mandemakers, W., Grochowska, M.M., Masius, R., Geut, H., Fabrizio, E., 
Breedveld, G.J., Kuipers, D., Minneboo, M., Vergouw, L.J.M., Carreras Mascaro, A., 
Yonova-Doing, E., Simons, E., Zhao, T., Di Fonzo, A.B., Chang, H.-C., Parchi, P., Melis, 
M., Correia Guedes, L., Criscuolo, C., Thomas, A., Brouwer, R.W.W., Heijsman, D., 
Ingrassia, A.M.T., Calandra Buonaura, G., Rood, J.P., Capellari, S., Rozemuller, A.J., 
Sarchioto, M., Fen Chien, H., Vanacore, N., Olgiati, S., Wu-Chou, Y.-H., Yeh, T.-H., Boon, 
A.J.W., Hoogers, S.E., Ghazvini, M., IJpma, A.S., van IJcken, W.F.J., Onofrj, M., Barone, 
P., Nicholl, D.J., Puschmann, A., De Mari, M., Kievit, A.J., Barbosa, E., De Michele, G., 
Majoor-Krakauer, D., van Swieten, J.C., de Jong, F.J., Ferreira, J.J., Cossu, G., Lu, C.-S., 
Meco, G., Cortelli, P., van de Berg, W.D.J., Bonifati, V., International Parkinsonism 
Genetics Network, 2018b. LRP10 genetic variants in familial Parkinson’s disease and 
dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurol 
17, 597–608. https://doi.org/10.1016/S1474-4422(18)30179-0 
Quik, M., Kulak, J.M., 2002. Nicotine and Nicotinic Receptors; Relevance to Parkinson’s 
Disease. NeuroToxicology 23, 581–594. https://doi.org/10.1016/S0161-813X(02)00036-0 
Quinlan, K.G.R., Seto, J.T., Turner, N., Vandebrouck, A., Floetenmeyer, M., Macarthur, 
D.G., Raftery, J.M., Lek, M., Yang, N., Parton, R.G., Cooney, G.J., North, K.N., 2010. α-
Actinin-3 deficiency results in reduced glycogen phosphorylase activity and altered 
calcium handling in skeletal muscle. Hum Mol Genet 19, 1335–1346. 
https://doi.org/10.1093/hmg/ddq010 
Stellenbosch University  https://scholar.sun.ac.za
- 129 - 
 
Rabbani, B., Tekin, M., Mahdieh, N., 2014. The promise of whole-exome sequencing in 
medical genetics. J. Hum. Genet. 59, 5–15. https://doi.org/10.1038/jhg.2013.114 
Ragland, M., Hutter, C., Zabetian, C., Edwards, K., 2009. Association Between the 
Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson’s 
Disease: A HuGE Review and Meta-Analysis. Am J Epidemiol 170, 1344–1357. 
https://doi.org/10.1093/aje/kwp288 
Ramsay, M., Tiemessen, C.T., Choudhury, A., Soodyall, H., 2011. Africa: the next frontier 
for human disease gene discovery? Hum. Mol. Genet. 20, R214–R220. 
https://doi.org/10.1093/hmg/ddr401 
Reeve, A., Simcox, E., Turnbull, D., 2014. Ageing and Parkinson’s disease: Why is 
advancing age the biggest risk factor? Ageing Research Reviews 14, 19–30. 
https://doi.org/10.1016/j.arr.2014.01.004 
Reissner, C., Klose, M., Fairless, R., Missler, M., 2008. Mutational analysis of the 
neurexin/neuroligin complex reveals essential and regulatory components. PNAS 105, 
15124–15129. https://doi.org/10.1073/pnas.0801639105 
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, 
M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H.L., 2015. Standards and Guidelines 
for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the 
American College of Medical Genetics and Genomics and the Association for Molecular 
Pathology. Genet Med 17, 405–424. https://doi.org/10.1038/gim.2015.30 
Ritchie, G.R.S., Dunham, I., Zeggini, E., Flicek, P., 2014. Functional annotation of 
noncoding sequence variants. Nat. Methods 11, 294–296. 
https://doi.org/10.1038/nmeth.2832 
Roach, E.S., 2007. Both Postsynaptic and Presynaptic Dysfunction Contribute to 
Parkinson Disease: Any Mechanism Will Not Do. Arch Neurol 64, 143–143. 
https://doi.org/10.1001/archneur.64.1.143 
Robert, C., Fuentes-Utrilla, P., Troup, K., Loecherbach, J., Turner, F., Talbot, R., 
Archibald, A.L., Mileham, A., Deeb, N., Hume, D.A., Watson, M., 2014. Design and 
development of exome capture sequencing for the domestic pig (Sus scrofa). BMC 
Genomics 15, 550. https://doi.org/10.1186/1471-2164-15-550 
Rogaeva, E., Johnson, J., Lang, A.E., Gulick, C., Gwinn-Hardy, K., Kawarai, T., Sato, C., 
Morgan, A., Werner, J., Nussbaum, R., Petit, A., Okun, M.S., McInerney, A., Mandel, R., 
Stellenbosch University  https://scholar.sun.ac.za
- 130 - 
 
Groen, J.L., Fernandez, H.H., Postuma, R., Foote, K.D., Salehi-Rad, S., Liang, Y., 
Reimsnider, S., Tandon, A., Hardy, J., St George-Hyslop, P., Singleton, A.B., 2004. 
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch. 
Neurol. 61, 1898–1904. https://doi.org/10.1001/archneur.61.12.1898 
Ross, G.W., Abbott, R.D., Petrovitch, H., Morens, D.M., Grandinetti, A., Tung, K.H., 
Tanner, C.M., Masaki, K.H., Blanchette, P.L., Curb, J.D., Popper, J.S., White, L.R., 2000. 
Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283, 
2674–2679. 
Rudenko, G., Hohenester, E., Muller, Y.A., 2001. LG/LNS domains: multiple functions – 
one business end? Trends in Biochemical Sciences 26, 363–368. 
https://doi.org/10.1016/S0968-0004(01)01832-1 
Rudenko, G., Nguyen, T., Chelliah, Y., Sudhof, T.C., Deisenhofer, J., 1999. The structure 
of the ligand-binding domain of neurexin Ib: regulation of LNS domain function by 
alternative splicing. Cell 99, 93–102. 
Samaranch, L., Lorenzo-Betancor, O., Arbelo, J.M., Ferrer, I., Lorenzo, E., Irigoyen, J., 
Pastor, M.A., Marrero, C., Isla, C., Herrera-Henriquez, J., Pastor, P., 2010. PINK1-linked 
parkinsonism is associated with Lewy body pathology. Brain 133, 1128–1142. 
https://doi.org/10.1093/brain/awq051 
Sanger, F., Nicklen, S., Coulson, A.R., 1977. DNA sequencing with chain-terminating 
inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74, 5463–5467. 
Saunders-Pullman, R., 2003. Estrogens and Parkinson disease: Neuroprotective, 
symptomatic, neither, or both? Endocrine 21, 81–87. 
https://doi.org/10.1385/ENDO:21:1:81 
Saux, O.L., Beck, K., Sachsinger, C., Treiber, C., Göring, H.H., Curry, K., Johnson, E.W., 
Bercovitch, L., Marais, A.-S., Terry, S.F., Viljoen, D.L., Boyd, C.D., 2002. Evidence for a 
founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa. 
Hum Genet 111, 331–338. https://doi.org/10.1007/s00439-002-0808-1 
Schaaf, C.P., Boone, P.M., Sampath, S., Williams, C., Bader, P.I., Mueller, J.M., 
Shchelochkov, O.A., Brown, C.W., Crawford, H.P., Phalen, J.A., Tartaglia, N.R., Evans, 
P., Campbell, W.M., Chun-Hui Tsai, A., Parsley, L., Grayson, S.W., Scheuerle, A., Luzzi, 
C.D., Thomas, S.K., Eng, P.A., Kang, S.-H.L., Patel, A., Stankiewicz, P., Cheung, S.W., 
2012. Phenotypic spectrum and genotype–phenotype correlations of NRXN1 exon 
deletions. Eur J Hum Genet 20, 1240–1247. https://doi.org/10.1038/ejhg.2012.95 
Stellenbosch University  https://scholar.sun.ac.za
- 131 - 
 
Schapira, A.H., Jenner, P., 2011. Etiology and pathogenesis of Parkinson’s disease. Mov. 
Disord. 26, 1049–1055. https://doi.org/10.1002/mds.23732 
Schoenberg, B.S., Osuntokun, B.O., Adeuja, A.O.G., Bademosi, O., Nottidge, V., Anderson, 
D.W., Haerer, A.F., 1988. Comparison of the prevalence of Parkinson’s disease in black 
populations in the rural United States and in rural Nigeria Door‐to‐door community 
studies. Neurology 38, 645–645. https://doi.org/10.1212/WNL.38.4.645 
Schreiner, D., Nguyen, T.-M., Russo, G., Heber, S., Patrignani, A., Ahrné, E., Scheiffele, 
P., 2014. Targeted Combinatorial Alternative Splicing Generates Brain Region-Specific 
Repertoires of Neurexins. Neuron 84, 386–398. 
https://doi.org/10.1016/j.neuron.2014.09.011 
Schreiner, D., Simicevic, J., Ahrné, E., Schmidt, A., Scheiffele, P., 2015. Quantitative 
isoform-profiling of highly diversified recognition molecules. eLife 4. 
https://doi.org/10.7554/eLife.07794 
Schrödinger L, 2015. The PyMOL Molecular Graphics System, Version 2.0 [WWW 
Document]. URL http://www.pymol.org/ (accessed 10.24.18). 
Schulte, E.C., Mollenhauer, B., Zimprich, A., Bereznai, B., Lichtner, P., Haubenberger, 
D., Pirker, W., Brücke, T., Molnar, M.J., Peters, A., Gieger, C., Trenkwalder, C., 
Winkelmann, J., 2012. Variants in eukaryotic translation initiation factor 4G1 in sporadic 
Parkinson’s disease. Neurogenetics 13, 281–285. https://doi.org/10.1007/s10048-012-0334-
9 
Schuster, S.C., 2008. Next-generation sequencing transforms today’s biology. Nat. 
Methods 5, 16–18. https://doi.org/10.1038/nmeth1156 
Schwarz, J.M., Cooper, D.N., Schuelke, M., Seelow, D., 2014. MutationTaster2: mutation 
prediction for the deep-sequencing age. Nat Meth 11, 361–362. 
https://doi.org/10.1038/nmeth.2890 
Schwarze, K., Buchanan, J., Taylor, J.C., Wordsworth, S., 2018. Are whole-exome and 
whole-genome sequencing approaches cost-effective? A systematic review of the literature. 
Genetics in Medicine. https://doi.org/10.1038/gim.2017.247 
Seidler, A., Hellenbrand, W., Robra, B.P., Vieregge, P., Nischan, P., Joerg, J., Oertel, W.H., 
Ulm, G., Schneider, E., 1996. Possible environmental, occupational, and other etiologic 
factors for Parkinson’s disease: a case-control study in Germany. Neurology 46, 1275–
1284. 
Stellenbosch University  https://scholar.sun.ac.za
- 132 - 
 
Semchuk, K.M., Love, E.J., Lee, R.G., 1993. Parkinson’s disease: a test of the 
multifactorial etiologic hypothesis. Neurology 43, 1173–1180. 
Semchuk, K.M., Love, E.J., Lee, R.G., 1992. Parkinson’s disease and exposure to 
agricultural work and pesticide chemicals. Neurology 42, 1328–1335. 
Semchuk, K.M., Love, E.J., Lee, R.G., 1991. Parkinson’s disease and exposure to rural 
environmental factors: a population based case-control study. Canadian journal of 
neurological sciences 18, 279–286. 
Sherer, T.B., Richardson, J.R., Testa, C.M., Seo, B.B., Panov, A.V., Yagi, T., Matsuno-
Yagi, A., Miller, G.W., Greenamyre, J.T., 2007. Mechanism of toxicity of pesticides acting 
at complex I: relevance to environmental etiologies of Parkinson’s disease. J. Neurochem. 
100, 1469–1479. https://doi.org/10.1111/j.1471-4159.2006.04333.x 
Sherry, S.T., Ward, M.-H., Kholodov, M., Baker, J., Phan, L., Smigielski, E.M., Sirotkin, 
K., 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29, 308–311. 
Shihab, H.A., Rogers, M.F., Gough, J., Mort, M., Cooper, D.N., Day, I.N.M., Gaunt, T.R., 
Campbell, C., 2015. An integrative approach to predicting the functional effects of non-
coding and coding sequence variation. Bioinformatics 31, 1536–1543. 
https://doi.org/10.1093/bioinformatics/btv009 
Siddiqui, T.J., Pancaroglu, R., Kang, Y., Rooyakkers, A., Craig, A.M., 2010. LRRTMs and 
Neuroligins Bind Neurexins with a Differential Code to Cooperate in Glutamate Synapse 
Development. J. Neurosci. 30, 7495–7506. https://doi.org/10.1523/JNEUROSCI.0470-
10.2010 
Sidransky, E., Lopez, G., 2012. The link between the GBA gene and parkinsonism. The 
Lancet Neurology 11, 986–998. https://doi.org/10.1016/S1474-4422(12)70190-4 
Siepel, A., 2005. PhastCons HOWTO [WWW Document]. URL 
http://compgen.cshl.edu/phast/phastCons-HOWTO.html (accessed 7.5.18). 
Siva, N., 2008. 1000 Genomes project [WWW Document]. Nature Biotechnology. 
https://doi.org/10.1038/nbt0308-256b 
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., Goedert, M., 1998. α-
Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and 
dementia with Lewy bodies. Proc Natl Acad Sci U S A 95, 6469–6473. 
Stefani, A., Lozano, A.M., Peppe, A., Stanzione, P., Galati, S., Tropepi, D., Pierantozzi, M., 
Brusa, L., Scarnati, E., Mazzone, P., 2007. Bilateral deep brain stimulation of the 
Stellenbosch University  https://scholar.sun.ac.za
- 133 - 
 
pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 130, 1596–
1607. https://doi.org/10.1093/brain/awl346 
Steinberg, F., Gallon, M., Winfield, M., Thomas, E., Bell, A.J., Heesom, K.J., Tavaré, J.M., 
Cullen, P.J., 2013. A global analysis of SNX27-retromer assembly and cargo specificity 
reveals a function in glucose and metal ion transport. Nat Cell Biol 15, 461–471. 
https://doi.org/10.1038/ncb2721 
Sudhaman, S., Prasad, K., Behari, M., Muthane, U.B., Juyal, R.C., Thelma, B.K., 2016. 
Discovery of a frameshift mutation in podocalyxin-like (PODXL) gene, coding for a neural 
adhesion molecule, as causal for autosomal-recessive juvenile Parkinsonism. J. Med. 
Genet. 53, 450–456. https://doi.org/10.1136/jmedgenet-2015-103459 
Sun, Q., Wang, Y., Zhang, Y., Liu, F., Cheng, X., Hou, N., Zhao, X., Yang, X., 2007. 
Expression profiling reveals dysregulation of cellular cytoskeletal genes in HBx–induced 
hepatocarcinogenesis. Cancer Biology & Therapy 6, 668–674. 
https://doi.org/10.4161/cbt.6.5.3955 
Sunkin, S.M., Ng, L., Lau, C., Dolbeare, T., Gilbert, T.L., Thompson, C.L., Hawrylycz, M., 
Dang, C., 2013. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the 
central nervous system. Nucleic Acids Res 41, D996–D1008. 
https://doi.org/10.1093/nar/gks1042 
Tabuchi, K., Südhof, T.C., 2002. Structure and evolution of neurexin genes: insight into 
the mechanism of alternative splicing. Genomics 79, 849–859. 
https://doi.org/10.1006/geno.2002.6780 
Tan, E.-K., Yew, K., Chua, E., Puvan, K., Shen, H., Lee, E., Puong, K.-Y., Zhao, Y., 
Pavanni, R., Wong, M.-C., Jamora, D., de Silva, D., Moe, K.-T., Woon, F.-P., Yuen, Y., Tan, 
L., 2006. PINK1 mutations in sporadic early-onset Parkinson’s disease. Mov. Disord. 21, 
789–793. https://doi.org/10.1002/mds.20810 
Tang, S., Wang, X., Li, W., Yang, X., Li, Z., Liu, W., Li, C., Zhu, Z., Wang, L., Wang, 
Jiaxiong, Zhang, L., Sun, X., Zhi, E., Wang, H., Li, H., Jin, L., Luo, Y., Wang, Jian, Yang, 
S., Zhang, F., 2017. Biallelic Mutations in CFAP43 and CFAP44 Cause Male Infertility 
with Multiple Morphological Abnormalities of the Sperm Flagella. The American Journal 
of Human Genetics 100, 854–864. https://doi.org/10.1016/j.ajhg.2017.04.012 
Tattini, L., D’Aurizio, R., Magi, A., 2015. Detection of Genomic Structural Variants from 
Next-Generation Sequencing Data. Front Bioeng Biotechnol 3. 
https://doi.org/10.3389/fbioe.2015.00092 
Stellenbosch University  https://scholar.sun.ac.za
- 134 - 
 
Thacker, E.L., O’Reilly, E.J., Weisskopf, M.G., Chen, H., Schwarzschild, M.A., 
McCullough, M.L., Calle, E.E., Thun, M.J., Ascherio, A., 2007. Temporal relationship 
between cigarette smoking and risk of Parkinson disease. Neurology 68, 764–768. 
https://doi.org/10.1212/01.wnl.0000256374.50227.4b 
Thal, D.R., Del Tredici, K., Braak, H., 2004. Neurodegeneration in normal brain aging and 
disease. Sci Aging Knowledge Environ 2004, pe26. 
https://doi.org/10.1126/sageke.2004.23.pe26 
The 1000 Genomes Project Consortium, 2015. A global reference for human genetic 
variation. Nature 526, 68–74. https://doi.org/10.1038/nature15393 
Tipping, A.J., Pearson, T., Morgan, N.V., Gibson, R.A., Kuyt, L.P., Havenga, C., 
Gluckman, E., Joenje, H., de Ravel, T., Jansen, S., Mathew, C.G., 2001. Molecular and 
genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner 
population of South Africa. Proceedings of the National Academy of Sciences 98, 5734–
5739. https://doi.org/10.1073/pnas.091402398 
Tolosa, E., Wenning, G., Poewe, W., 2006. The diagnosis of Parkinson’s disease. The 
Lancet Neurology 5, 75–86. https://doi.org/10.1016/S1474-4422(05)70285-4 
Topper, L.M., Campbell, M.S., Tugendreich, S., Daum, J.R., Burke, D.J., Hieter, P., 
Gorbsky, G.J., 2002. The dephosphorylated form of the anaphase-promoting complex 
protein Cdc27/Apc3 concentrates on kinetochores and chromosome arms in mitosis. Cell 
Cycle 1, 282–292. 
Trenkwalder, C., Arnulf, I., Postuma, R., 2017. Parkinsonism, in: Principles and Practice 
of Sleep Medicine. Elsevier, pp. 892-902.e5. https://doi.org/10.1016/B978-0-323-24288-
2.00092-1 
Trinh, J., Guella, I., McKenzie, M., Gustavsson, E.K., Szu-Tu, C., Petersen, M.S., Rajput, 
A., Rajput, A.H., McKeown, M., Jeon, B.S., Aasly, J.O., Bardien, S., Farrer, M.J., 2015. 
Novel LRRK2 mutations in Parkinsonism. Parkinsonism & Related Disorders 21, 1119–
1121. https://doi.org/10.1016/j.parkreldis.2015.07.011 
Uemura, T., Lee, S.-J., Yasumura, M., Takeuchi, T., Yoshida, T., Ra, M., Taguchi, R., 
Sakimura, K., Mishina, M., 2010. Trans-Synaptic Interaction of GluRδ2 and Neurexin 
through Cbln1 Mediates Synapse Formation in the Cerebellum. Cell 141, 1068–1079. 
https://doi.org/10.1016/j.cell.2010.04.035 
Stellenbosch University  https://scholar.sun.ac.za
- 135 - 
 
Ullrich, B., Ushkaryov, Y.A., Südhof, T.C., 1995. Cartography of neurexins: More than 
1000 isoforms generated by alternative splicing and expressed in distinct subsets of 
neurons. Neuron 14, 497–507. https://doi.org/10.1016/0896-6273(95)90306-2 
Ushkaryov, Y.A., Petrenko, A.G., Geppert, M., Sudhof, T.C., 1992. Neurexins: synaptic 
cell surface proteins related to the alpha-latrotoxin receptor and laminin. Science 257, 50–
56. https://doi.org/10.1126/science.1621094 
Ushkaryov, Y.A., Südhof, T.C., 1993. Neurexin III alpha: extensive alternative splicing 
generates membrane-bound and soluble forms. PNAS 90, 6410–6414. 
https://doi.org/10.1073/pnas.90.14.6410 
Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M.K., Harvey, K., Gispert, S., 
Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R., 
González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P., Latchman, D.S., 
Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W., 2004. Hereditary early-onset 
Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160. 
https://doi.org/10.1126/science.1096284 
van der Merwe, C., Carr, J., Glanzmann, B., Bardien, S., 2016. Exonic rearrangements in 
the known Parkinson’s disease-causing genes are a rare cause of the disease in South 
African patients. Neuroscience Letters 619, 168–171. 
https://doi.org/10.1016/j.neulet.2016.03.028 
Velkoff, V.A., Kowal, P.R., Census Bureau, U.S., 2007. Population Aging in Sub-Saharan 
Africa: Demographic Dimensions 2006. U.S. Government Printing Office,Washington, DC. 
https://doi.org/P95/07-1 
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., 
Yandell, M., Evans, C.A., Holt, R.A., Gocayne, J.D., Amanatides, P., Ballew, R.M., Huson, 
D.H., Wortman, J.R., Zhang, Q., Kodira, C.D., Zheng, X.H., Chen, L., Skupski, M., 
Subramanian, G., Thomas, P.D., Zhang, J., Gabor Miklos, G.L., Nelson, C., Broder, S., 
Clark, A.G., Nadeau, J., McKusick, V.A., Zinder, N., Levine, A.J., Roberts, R.J., Simon, 
M., Slayman, C., Hunkapiller, M., Bolanos, R., Delcher, A., Dew, I., Fasulo, D., Flanigan, 
M., Florea, L., Halpern, A., Hannenhalli, S., Kravitz, S., Levy, S., Mobarry, C., Reinert, 
K., Remington, K., Abu-Threideh, J., Beasley, E., Biddick, K., Bonazzi, V., Brandon, R., 
Cargill, M., Chandramouliswaran, I., Charlab, R., Chaturvedi, K., Deng, Z., Di Francesco, 
V., Dunn, P., Eilbeck, K., Evangelista, C., Gabrielian, A.E., Gan, W., Ge, W., Gong, F., Gu, 
Z., Guan, P., Heiman, T.J., Higgins, M.E., Ji, R.R., Ke, Z., Ketchum, K.A., Lai, Z., Lei, Y., 
Stellenbosch University  https://scholar.sun.ac.za
- 136 - 
 
Li, Z., Li, J., Liang, Y., Lin, X., Lu, F., Merkulov, G.V., Milshina, N., Moore, H.M., Naik, 
A.K., Narayan, V.A., Neelam, B., Nusskern, D., Rusch, D.B., Salzberg, S., Shao, W., Shue, 
B., Sun, J., Wang, Z., Wang, A., Wang, X., Wang, J., Wei, M., Wides, R., Xiao, C., Yan, C., 
Yao, A., Ye, J., Zhan, M., Zhang, W., Zhang, H., Zhao, Q., Zheng, L., Zhong, F., Zhong, W., 
Zhu, S., Zhao, S., Gilbert, D., Baumhueter, S., Spier, G., Carter, C., Cravchik, A., Woodage, 
T., Ali, F., An, H., Awe, A., Baldwin, D., Baden, H., Barnstead, M., Barrow, I., Beeson, K., 
Busam, D., Carver, A., Center, A., Cheng, M.L., Curry, L., Danaher, S., Davenport, L., 
Desilets, R., Dietz, S., Dodson, K., Doup, L., Ferriera, S., Garg, N., Gluecksmann, A., Hart, 
B., Haynes, J., Haynes, C., Heiner, C., Hladun, S., Hostin, D., Houck, J., Howland, T., 
Ibegwam, C., Johnson, J., Kalush, F., Kline, L., Koduru, S., Love, A., Mann, F., May, D., 
McCawley, S., McIntosh, T., McMullen, I., Moy, M., Moy, L., Murphy, B., Nelson, K., 
Pfannkoch, C., Pratts, E., Puri, V., Qureshi, H., Reardon, M., Rodriguez, R., Rogers, Y.H., 
Romblad, D., Ruhfel, B., Scott, R., Sitter, C., Smallwood, M., Stewart, E., Strong, R., Suh, 
E., Thomas, R., Tint, N.N., Tse, S., Vech, C., Wang, G., Wetter, J., Williams, S., Williams, 
M., Windsor, S., Winn-Deen, E., Wolfe, K., Zaveri, J., Zaveri, K., Abril, J.F., Guigó, R., 
Campbell, M.J., Sjolander, K.V., Karlak, B., Kejariwal, A., Mi, H., Lazareva, B., Hatton, 
T., Narechania, A., Diemer, K., Muruganujan, A., Guo, N., Sato, S., Bafna, V., Istrail, S., 
Lippert, R., Schwartz, R., Walenz, B., Yooseph, S., Allen, D., Basu, A., Baxendale, J., Blick, 
L., Caminha, M., Carnes-Stine, J., Caulk, P., Chiang, Y.H., Coyne, M., Dahlke, C., Mays, 
A., Dombroski, M., Donnelly, M., Ely, D., Esparham, S., Fosler, C., Gire, H., Glanowski, 
S., Glasser, K., Glodek, A., Gorokhov, M., Graham, K., Gropman, B., Harris, M., Heil, J., 
Henderson, S., Hoover, J., Jennings, D., Jordan, C., Jordan, J., Kasha, J., Kagan, L., Kraft, 
C., Levitsky, A., Lewis, M., Liu, X., Lopez, J., Ma, D., Majoros, W., McDaniel, J., Murphy, 
S., Newman, M., Nguyen, T., Nguyen, N., Nodell, M., Pan, S., Peck, J., Peterson, M., Rowe, 
W., Sanders, R., Scott, J., Simpson, M., Smith, T., Sprague, A., Stockwell, T., Turner, R., 
Venter, E., Wang, M., Wen, M., Wu, D., Wu, M., Xia, A., Zandieh, A., Zhu, X., 2001. The 
sequence of the human genome. Science 291, 1304–1351. 
https://doi.org/10.1126/science.1058040 
Verstraeten, A., Theuns, J., Van Broeckhoven, C., 2015. Progress in unraveling the genetic 
etiology of Parkinson disease in a genomic era. Trends in Genetics 31, 140–149. 
https://doi.org/10.1016/j.tig.2015.01.004 
Vilariño-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., 
Soto-Ortolaza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A., Behrouz, B., Melrose, H.L., 
Hentati, E., Puschmann, A., Evans, D.M., Conibear, E., Wasserman, W.W., Aasly, J.O., 
Stellenbosch University  https://scholar.sun.ac.za
- 137 - 
 
Burkhard, P.R., Djaldetti, R., Ghika, J., Hentati, F., Krygowska-Wajs, A., Lynch, T., 
Melamed, E., Rajput, A., Rajput, A.H., Solida, A., Wu, R.-M., Uitti, R.J., Wszolek, Z.K., 
Vingerhoets, F., Farrer, M.J., 2011a. VPS35 Mutations in Parkinson Disease. Am J Hum 
Genet 89, 162–167. https://doi.org/10.1016/j.ajhg.2011.06.001 
Vilariño-Güell, C., Wider, C., Ross, O.A., Dachsel, J.C., Kachergus, J.M., Lincoln, S.J., 
Soto-Ortolaza, A.I., Cobb, S.A., Wilhoite, G.J., Bacon, J.A., Behrouz, B., Melrose, H.L., 
Hentati, E., Puschmann, A., Evans, D.M., Conibear, E., Wasserman, W.W., Aasly, J.O., 
Burkhard, P.R., Djaldetti, R., Ghika, J., Hentati, F., Krygowska-Wajs, A., Lynch, T., 
Melamed, E., Rajput, A., Rajput, A.H., Solida, A., Wu, R.-M., Uitti, R.J., Wszolek, Z.K., 
Vingerhoets, F., Farrer, M.J., 2011b. VPS35 Mutations in Parkinson Disease. Am J Hum 
Genet 89, 162–167. https://doi.org/10.1016/j.ajhg.2011.06.001 
Wang, L., Aasly, J.O., Annesi, G., Bardien, S., Bozi, M., Brice, A., Carr, J., Chung, S.J., 
Clarke, C., Crosiers, D., Deutschländer, A., Eckstein, G., Farrer, M.J., Goldwurm, S., 
Garraux, G., Hadjigeorgiou, G.M., Hicks, A.A., Hattori, N., Klein, C., Jeon, B., Kim, Y.J., 
Lesage, S., Lin, J.-J., Lynch, T., Lichtner, P., Lang, A.E., Mok, V., Jasinska-Myga, B., 
Mellick, G.D., Morrison, K.E., Opala, G., Pihlstrøm, L., Pramstaller, P.P., Park, S.S., 
Quattrone, A., Rogaeva, E., Ross, O.A., Stefanis, L., Stockton, J.D., Silburn, P.A., Theuns, 
J., Tan, E.K., Tomiyama, H., Toft, M., Van Broeckhoven, C., Uitti, R.J., Wirdefeldt, K., 
Wszolek, Z., Xiromerisiou, G., Yueh, K.-C., Zhao, Y., Gasser, T., Maraganore, D.M., 
Krüger, R., Sharma, M., 2015. Large-scale assessment of polyglutamine repeat expansions 
in Parkinson disease. Neurology 85, 1283–1292. 
https://doi.org/10.1212/WNL.0000000000002016 
Watanabe, Y., Himeda, T., Araki, T., 2005. Mechanisms of MPTP toxicity and their 
implications for therapy of Parkinson’s disease. Med. Sci. Monit. 11, RA17-23. 
Weaver, F.M., 2009. Bilateral Deep Brain Stimulation vs Best Medical Therapy for 
Patients With Advanced Parkinson DiseaseA Randomized Controlled Trial. JAMA 301, 
63. https://doi.org/10.1001/jama.2008.929 
Weinrich, S.L., Pruzan, R., Ma, L., Ouellette, M., Tesmer, V.M., Holt, S.E., Bodnar, A.G., 
Lichtsteiner, S., Kim, N.W., Trager, J.B., Taylor, R.D., Carlos, R., Andrews, W.H., Wright, 
W.E., Shay, J.W., Harley, C.B., Morin, G.B., 1997. Reconstitution of human telomerase 
with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. 
Genet. 17, 498–502. https://doi.org/10.1038/ng1297-498 
Stellenbosch University  https://scholar.sun.ac.za
- 138 - 
 
Williams, K.L., Topp, S., Yang, S., Smith, B., Fifita, J.A., Warraich, S.T., Zhang, K.Y., 
Farrawell, N., Vance, C., Hu, X., Chesi, A., Leblond, C.S., Lee, A., Rayner, S.L., 
Sundaramoorthy, V., Dobson-Stone, C., Molloy, M.P., Blitterswijk, M. van, Dickson, D.W., 
Petersen, R.C., Graff-Radford, N.R., Boeve, B.F., Murray, M.E., Pottier, C., Don, E., 
Winnick, C., McCann, E.P., Hogan, A., Daoud, H., Levert, A., Dion, P.A., Mitsui, J., 
Ishiura, H., Takahashi, Y., Goto, J., Kost, J., Gellera, C., Gkazi, A.S., Miller, J., Stockton, 
J., Brooks, W.S., Boundy, K., Polak, M., Muñoz-Blanco, J.L., Esteban-Pérez, J., Rábano, 
A., Hardiman, O., Morrison, K.E., Ticozzi, N., Silani, V., Belleroche, J. de, Glass, J.D., 
Kwok, J.B.J., Guillemin, G.J., Chung, R.S., Tsuji, S., Jr, R.H.B., García-Redondo, A., 
Rademakers, R., Landers, J.E., Gitler, A.D., Rouleau, G.A., Cole, N.J., Yerbury, J.J., 
Atkin, J.D., Shaw, C.E., Nicholson, G.A., Blair, I.P., 2016. CCNF mutations in 
amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications 7, 
11253. https://doi.org/10.1038/ncomms11253 
Winkler, A.S., Tütüncü, E., Trendafilova, A., Meindl, M., Kaaya, J., Schmutzhard, E., 
Kassubek, J., 2010. Parkinsonism in a population of northern Tanzania: a community-
based door-to-door study in combination with a prospective hospital-based evaluation. 
Journal of Neurology 257, 799–805. http://dx.doi.org/10.1007/s00415-009-5420-z 
Winklhofer, K.F., Haass, C., 2010. Mitochondrial dysfunction in Parkinson’s disease. 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Mitochondrial 
Dysfunction 1802, 29–44. https://doi.org/10.1016/j.bbadis.2009.08.013 
Wong, G.K.-S., Yang, Z., Passey, D.A., Kibukawa, M., Paddock, M., Liu, C.-R., Bolund, L., 
Yu, J., 2003. A Population Threshold for Functional Polymorphisms. Genome Res 13, 
1873–1879. https://doi.org/10.1101/gr.1324303 
Yan, W., Tang, B., Zhou, X., Lei, L., Li, K., Sun, Q., Xu, Q., Yan, X., Guo, J., Liu, Z., 2017. 
TMEM230 mutation analysis in Parkinson’s disease in a Chinese population. Neurobiol. 
Aging 49, 219.e1-219.e3. https://doi.org/10.1016/j.neurobiolaging.2016.10.007 
Yang, X., An, R., Xi, J., Zheng, J., Chen, Y., Huang, H., Tian, S., Zhao, Q., Ning, P., Xu, 
Y., 2017. Sequencing TMEM230 in Chinese patients with sporadic or familial Parkinson’s 
disease. Movement Disorders 32, 800–802. https://doi.org/10.1002/mds.26996 
Yang, Y., Muzny, D.M., Reid, J.G., Bainbridge, M.N., Willis, A., Ward, P.A., Braxton, A., 
Beuten, J., Xia, F., Niu, Z., Hardison, M., Person, R., Bekheirnia, M.R., Leduc, M.S., Kirby, 
A., Pham, P., Scull, J., Wang, M., Ding, Y., Plon, S.E., Lupski, J.R., Beaudet, A.L., Gibbs, 
R.A., Eng, C.M., 2013. Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian 
Stellenbosch University  https://scholar.sun.ac.za
- 139 - 
 
Disorders. New England Journal of Medicine 369, 1502–1511. 
https://doi.org/10.1056/NEJMoa1306555 
Yangngam, S., Plong-On, O., Sripo, T., Roongpraiwan, R., Hansakunachai, T., Wirojanan, 
J., Sombuntham, T., Ruangdaraganon, N., Limprasert, P., 2014. Mutation Screening of 
the Neurexin 1 Gene in Thai Patients with Intellectual Disability and Autism Spectrum 
Disorder. Genet Test Mol Biomarkers 18, 510–515. 
https://doi.org/10.1089/gtmb.2014.0003 
Yonova-Doing, E., Atadzhanov, M., Quadri, M., Kelly, P., Shawa, N., Musonda, S.T.S., 
Simons, E.J., Breedveld, G.J., Oostra, B.A., Bonifati, V., 2012. Analysis of LRRK2, SNCA, 
Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson’s disease. Parkinsonism & 
Related Disorders 18, 567–571. https://doi.org/10.1016/j.parkreldis.2012.02.018 
Zarranz, J.J., Alegre, J., Gómez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., 
Hoenicka, J., Rodriguez, O., Atarés, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Muñoz, 
D.G., de Yebenes, J.G., 2004. The new mutation, E46K, of alpha-synuclein causes 
Parkinson and Lewy body dementia. Ann. Neurol. 55, 164–173. 
https://doi.org/10.1002/ana.10795 
Zarranz, J.J., Fernández-Bedoya, A., Lambarri, I., Gómez-Esteban, J.C., Lezcano, E., 
Zamacona, J., Madoz, P., 2005. Abnormal sleep architecture is an early feature in the 
E46K familial synucleinopathy. Mov. Disord. 20, 1310–1315. 
https://doi.org/10.1002/mds.20581 
Zhang, Z.X., Román, G.C., 1993. Worldwide occurrence of Parkinson’s disease: an updated 
review. Neuroepidemiology 12, 195–208. https://doi.org/10.1159/000110318 
Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S.H., Offman, M.N., 
Haubenberger, D., Spielberger, S., Schulte, E.C., Lichtner, P., Rossle, S.C., Klopp, N., 
Wolf, E., Seppi, K., Pirker, W., Presslauer, S., Mollenhauer, B., Katzenschlager, R., Foki, 
T., Hotzy, C., Reinthaler, E., Harutyunyan, A., Kralovics, R., Peters, A., Zimprich, F., 
Brücke, T., Poewe, W., Auff, E., Trenkwalder, C., Rost, B., Ransmayr, G., Winkelmann, 
J., Meitinger, T., Strom, T.M., 2011. A Mutation in VPS35, Encoding a Subunit of the 
Retromer Complex, Causes Late-Onset Parkinson Disease. Am J Hum Genet 89, 168–175. 
https://doi.org/10.1016/j.ajhg.2011.06.008 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., 
Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, 
I.C., Vieregge, P., Asmus, F., Müller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, 
Stellenbosch University  https://scholar.sun.ac.za
- 140 - 
 
T.M., Wszolek, Z.K., Gasser, T., 2004. Mutations in LRRK2 cause autosomal-dominant 
parkinsonism with pleomorphic pathology. Neuron 44, 601–607. 
https://doi.org/10.1016/j.neuron.2004.11.005 
Zou, Y.-M., Liu, J., Tian, Z.-Y., Lu, D., Zhou, Y.-Y., 2015. Systematic review of the 
prevalence and incidence of Parkinson’s disease in the People’s Republic of China. 
Neuropsychiatr Dis Treat 11, 1467–1472. https://doi.org/10.2147/NDT.S85380 
Zrinzo, L., Foltynie, T., Limousin, P., Hariz, M.I., 2011. Reducing hemorrhagic 
complications in functional neurosurgery: a large case series and systematic literature 
review. Journal of Neurosurgery 116, 84–94. https://doi.org/10.3171/2011.8.JNS101407 
 
URL List 
Institute/Program Web address 
Background 
National Human 
Genome Research 
Institute 
https://www.genome.gov/27565109/the-cost-of-sequencing-
a-human-genome/ 
Pedigree Chart 
GenoPro Genealogy 
Software 
https://www.genopro.com/ 
WES Analysis 
Burrows-Wheeler 
Aligner 
bio-bwa.sourceforge.net/ 
ANNOVAR Software annovar.openbioinformatics.org/ 
Genome Analysis 
Toolkit 
https://software.broadinstitute.org/gatk/ 
SAMtools mpileup samtools.sourceforge.net/mpileup.shtml 
Sanger Sequencing 
Primer3 4.0.0  http://primer3.ut.ee 
Primer - Basic Local 
Alignment Search Tool 
https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
BioEdit 7.2.0 www.mbio.ncsu.edu/BioEdit/bioedit.html 
Ensembl Genome 
Browser database  
http://www.ensembl.org 
Bioinformatic In-silico Analysis 
ExAC database  http://exac.broadinstitute.org/ 
1000 Genomes Project http://browser.1000genomes.org/index.html 
Stellenbosch University  https://scholar.sun.ac.za
- 141 - 
 
dbSNP https://www.ncbi.nlm.nih.gov/snp 
SIFT http://sift.jcvi.org/ 
PolyPhen-2  http://genetics.bwh.harvard.edu/pph2/ 
MutationTaster http://www.mutationtaster.org/) 
CADD http://cadd.gs.washington.edu/ 
GERP++  http://mendel.stanford.edu/SidowLab/downloads/gerp/ 
KEGG Pathways 
Analyser  
http://www.genome.jp/kegg/pathway.html 
PANTHER Pathway 
Analyser  
http://www.pantherdb.org/pathway/ 
Allen Brain Atlas  www.brain-map.org/ 
Human Protein Atlas https://www.proteinatlas.org/ 
AnnEx https://annex.can.ubc.ca/ 
Protein modelling 
SWISS-MODEL 
Webserver  
https://swissmodel.expasy.org/ 
BLASTP https://blast.ncbi.nlm.nih.gov/BLAST.cgi?PAGE=Proteins 
PyMOL / https://pymol.org/ 
Swiss-PDB Viewer https://spdbv.vital-it.ch/ 
  
Western Blot Analysis 
ImageJ  http://imagej.nih.gov/ij/ 
  
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
- 142 - 
 
Appendices 
1. Appendix I 
1. Supplementary Tables 
Table 1 List of genes not conclusively implicated in PD 
Gene (locus) Typical symptoms Age of onset Reference 
ATP13A2 
(PARK9) 
Early-onset 
Dementia 
Spasticity supranuclear 
Gaze palsy 
Fast progression 
≤50 Ferreira et al. 2016 
ATP1A3 Early-onset 
Dystonia 
Poor response to Levodopa 
Fast progression 
NR McKeon et al. 2007 
CHCHD2 Autosomal Dominant 
Late-onset 
Hyperreflexia 
Good response to Levodopa 
Slow progression 
≥60 Funayama et al 2015 
 Jansen et al., 2015; 
Koschmidder et al., 
2016; 
Gagliardi et al., 2017 
 Meng et al., 2017 
 
 
 
DCTN1 Late-onset parkinsonism 
Poor response to Levodopa 
≥55 Aji et al. 2013 
Araki et al. 2014 
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Gene (locus) Typical symptoms Age of onset Reference 
DNAJC13 Early-onset parkinsonism 
Lewy bodies present 
Good response to Levodopa 
Slow progression  
≥40 Velarino-Guell et al. 
2014 
Appel-Cresswell et al., 
2014 
DNAJC6 
(PARK19) 
Juvenile-onset 
Poor response to Levodopa 
Pyramidal signs 
Dystonia 
Seizures 
Mental retardation 
Fast progression 
≤10 Edvardson et al. 2012 
Köroğlu et al. 2013 
Olgiati et al. 2016 
GBA Late-onset 
Typical 
Good response to Levodopa 
Cognitive and behavioural 
symptoms 
≥60 Sidransky et al. 2009 
(Sidransky and López, 
2012) 
PANK2 Early-onset 
Dystonia 
≥20 Zhou et al. 2001 
Schneider et al. 2012 
PLA2G6 
(PARK14) 
Early-onset 
Atypical 
Fast progression 
≥30 Paisan -Ruiz et al. 2009 
Schneider et al. 2012 
PODXL Juvenile-onset 
Good response to Levodopa 
Dyskinesia 
 Off-dystonia 
≤20 (Sudhaman et al., 2016) 
PTRHD1 Early-onset ≤30 Khodadadi et al., 2017 
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Gene (locus) Typical symptoms Age of onset Reference 
Good response to Levodopa 
Pyramidal signs 
Dystonia 
Mental retardation 
Muscular weakness 
RAB39B Early-onset PD 
Dopaminergic neuronal loss 
Lewy bodies 
Good response to Levodopa 
Mental retardation 
X-linked inheritance 
≤40 Wilson et al. 2014 
Lesage et al. 2015 
SPG11 Early-onset 
Spastic paraplegia  
≤50 Guidubaldi et al. 2011 
TMEM230 Early-onset 
Autosomal dominant 
Lewy bodies present 
Good response to Levodopa 
Slow progression 
≤50 HX Deng 2016 
DA Olszewska 2016 
Deng et al 2016 
Mandemakers et al., 
2017 
Giri et al., 2017 
Yan et al., 2017 
UCHL1 
(PARK5) 
Early-onset 
Autosomal dominant 
Slow progression 
≤50 Leroy et al. 1998 
Maraganore, et al.1999 
(Ragland et al., 2009) 
VPS13C Early-onset 
Dopamine neuronal loss 
Good response to Levodopa 
≤50  Lesage et al 2016 
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Gene (locus) Typical symptoms Age of onset Reference 
Rigidity 
Resting tremor 
Fast Progression 
NR: Not reported 
 
Table 2 A summary of all published mutation screening studies performed on SA PD 
patients 
Gene Patients Methods  Main findings Reference 
Autosomal Dominant Genes 
ATXN2 
(Ataxin 2) 
398 Polyglutamine repeat 
expansions 
(PCR, Capillary Gel 
Electrophoresis) 
No pathogenic 
mutations were found 
(Wang et al., 
2015) 
ATXN3 
(Ataxin 3) 
398 Polyglutamine repeat 
expansions 
(PCR, Capillary 
Electrophoresis) 
No pathogenic 
mutations were found 
(Wang et al., 
2015) 
CACNA1A 
(Calcium 
Voltage-Gated 
Channel 
Subunit Alpha1 
A) 
398 Polyglutamine repeat 
expansions 
(PCR, Capillary 
Electrophoresis) 
No pathogenic 
mutations were found 
(Wang et al., 
2015) 
EIF4G1 
(Eukaryotic 
Translation 
Initiation 
Factor 4G1) 
418 R1205H mutation 
(KASP genotyping 
assay) 
 
p.R1205H mutation 
was not present 
(Blanckenberg et 
al., 2014) 
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Gene Patients Methods  Main findings Reference 
GBA 
(Glucocerebrosi
dase Beta) 
105 Exons 8, 9, 10 and11 
were screened 
(PCR, Capillary 
Electrophoresis) 
Severe mutations, like 
p.L444P were absent 
(Barkhuizen et 
al., 2017) 
GCH1 
(GTP 
Cyclohydrolase 
1) 
88 Exons 1,2,3,5 and 6 
(Exon dosage 
analysis using 
MLPA) 
No pathogenic 
mutations were found 
(Keyser et al., 
2010) 
LRRK2 
(Leucine-Rich 
Repeat Kinase 
2) 
205 G2019S mutation 
(HRM analysis) 
Four probands 
harboured the 
mutation in a 
heterozygous state 
(Bardien et al., 
2010) 
 88 Exons 
1,2,10,15,27,41,49 
(Exon dosage 
analysis using 
MLPA) 
No pathogenic 
mutations were found 
(Keyser et al., 
2009a) 
 23 All 51 exons 
(sequencing) 
Four rare non-
synonymous variants 
unique to patients with 
PD in SA were 
observed 
p.I610T 
p.H1758P 
p.N2133S 
p. T2324S 
(Trinh et al., 
2015) 
 210 Exons 1, 2, 8, 10, 15, 
27,49 and G2019S. 
No pathogenic 
mutations were found 
(van der Merwe 
et al., 2016) 
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Gene Patients Methods  Main findings Reference 
(Exon dosage 
analysis using 
MLPA)) 
 16 G2019S. 
(MLPA and CNV) 
No pathogenic 
mutations were found 
(Mahne et al., 
2016) 
SNCA 
(Alpha-
Synuclein) 
88 All six exons and 
A30P (exon dosage 
analysis using 
MLPA) 
One patient had a 
whole-gene triplication 
(Keyser et al., 
2009) 
 210 All six exons and 
A30P 
(Exon dosage 
analysis using 
MLPA) 
No pathogenic 
mutations were found 
(van der Merwe 
et al., 2016) 
 16 Black 
patients 
All six exons and 
A30P 
 (Exon dosage 
analysis using 
MLPA) 
No pathogenic 
mutations were found 
(Mahne et al., 
2016) 
TBP 
(TATA box 
binding 
protein) 
398 Polyglutamine repeat 
expansions 
(PCR, Capillary 
Electrophoresis) 
No pathogenic 
mutations were found 
(Wang et al., 
2015) 
VPS35 
(Vascular 
Protein 
Sorting-
associated 
protein 35) 
418 D620N Mutation 
(KASP genotyping 
assay) 
 
p.D620N mutation was 
not present 
(Blanckenberg et 
al., 2014) 
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Gene Patients Methods  Main findings Reference 
Autosomal Recessive Genes 
ATP13A2 
(ATPase Type 
13A2) 
88 Exons 2 and 9 
(dosage analysis 
MLPA) 
No pathogenic 
mutations were found 
(Keyser et al., 
2009a) 
DJ-1 
 (Daisuke-
Junko-1/ 
PARK7) 
30 All seven exons and 
5'-UTR 
(dosage analysis 
MLPA) 
16 bp deletion variant 
(g.-6_+10del) was 
identified and shown to 
reduce transcriptional 
activity by 
approximately 50% in 
cell culture systems 
(Keyser et al., 
2009b) 
 150 5’UTR g.-6_+10del 
variant 
(ss831883147) 
(dosage analysis 
MLPA) 
Two patients had the 
deletion 
(Keyser et al., 
2009b) 
 402 5’UTR g.-6_+10del 
variant 
(ss831883147) 
(KASP genotyping 
assay) 
One patient carried the 
deletion allele in a 
heterozygous state; the 
allele frequency was 
estimated to be 0,1 % 
(1/804). None of the 
528 controls had this 
variant 
(Glanzmann et 
al., 2013) 
 402 5’UTR g.168_185del 
variant 
(ss831883149) 
(HRM) 
Present in <1% of both 
cases and controls 
(Glanzmann et 
al., 2013) 
PARK2 91 All 12 exons No pathogenic 
mutations were found 
(Bardien et al., 
2009) 
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Gene Patients Methods  Main findings Reference 
(Parkin) (SSCP and HRM) 
 229 All 12 exons 
(HRM and MLPA) 
Heterozygous, 
homozygous and four 
novel mutations in the 
Parkin gene were 
found. 
P113fsX163 deletion of 
exon 3 
G430D deletion of exon 
4 
Duplication of exons 
2e6 duplication of exon 
5 
Silent substitutions 
(p.P37P, p.C238C, 
p.L261L, p.A397A and 
p.R402R) 
Polymorphisms ( 
p.A82E and p.P437L) 
Variants found in 
matched controls at 
MAF ≥1% 
(p.Q34R, p.S167N, 
p.M192L, p.R334C, 
p.V380L, p.D394N). 
(Haylett et al., 
2012) 
 88 All 12 exons (dosage 
analysis MLPA) 
Heterozygous 
duplication of exon 2 
Heterozygous deletion 
of exon 9 
(Keyser et al., 
2009a) 
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Gene Patients Methods  Main findings Reference 
Heletion of exon 4 in 
another proband. 
Heterozygous p.G430D 
mutation  
 3  R275W, M432V 
(WES and MLPA) 
Identified both 
homozygous and 
heterozygous forms of 
p.R275W, p.M432V 
variants  
(Carr et al., 2016) 
 210 All 12 exons 
(MLPA and CNV) 
Exon 4 deletion 
p.M192L 
polymorphism found in 
13 individuals 
(van der Merwe 
et al., 2016) 
 16 All 12 exons 
(MLPA and CNV) 
One heterozygous 
deletion of exon 4  
(Mahne et al., 
2016) 
PINK1 
(PTEN-induced 
putative kinase 
1) 
154 All eight exons 
(HRM and 
sequencing) 
16 sequence variants 
found 
13 were 
polymorphisms (of 
which five were novel) 
One homozygous 
mutation p.Y258X One 
novel heterozygous 
variant p.P305A 
One heterozygous 
variant p.E476K) 
(Keyser et al., 
2010a) 
 88 All eight exons 
(dosage analysis 
MLPA) 
No pathogenic 
mutations were found 
(Keyser et al., 
2009a) 
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Gene Patients Methods  Main findings Reference 
 210 All eight exons 
(MLPA and CNV) 
No pathogenic 
mutations were found 
(van der Merwe 
et al., 2016) 
AD, Autosomal Dominant; AR, Autosomal Recessive; CNV, Copy Number Variation; 
HRM, High Resolution Melt; MLPA, Multiplex Ligation-dependent Probe Amplification; 
SSCP, Single Strand Conformation Polymorphism Analysis; KASP, Kompetitive Allele 
Specific Polymerase Chain Reaction; UTR, Untranslated Region; WES, Whole Exome 
Sequencing
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Table 3 HRM control screening results  
Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
67,86 Caucasian Female 46 Absent  Absent  Absent  Absent  Absent  
68,68 Caucasian Female 44 Absent  Absent  Absent  Absent  Absent  
68,71 Caucasian Male 68 Absent  Absent  Absent  Absent  Absent  
68,92 Caucasian Female 81 Absent  Absent  Absent  Absent  Absent  
68,93 Caucasian Female 68 Absent  Absent  Absent  Absent  Absent  
68,94 Caucasian Male 63 Absent  Absent  Absent  Absent  Absent  
68,95 Caucasian Male 70 Absent  Absent  Absent  Absent  Absent  
69,16 Caucasian Male 52 Absent  Absent  Absent  Absent  Absent  
69,17 Caucasian Female 53 Absent  Absent  Absent  Absent  Absent  
69,38 Caucasian Male 78 Absent  Absent  Absent  Absent  Absent  
69,39 Caucasian Male 51 Absent  Absent  Absent  Absent  Absent  
69,40 Caucasian Male 64 Absent  Absent  Absent  Absent  Absent  
69,41 Caucasian Female 58 Absent  Absent  Absent  Absent  Absent  
69,65 Caucasian Male 67 Absent  Absent  Absent  Absent  Absent  
69,66 Caucasian Female 58 Absent  Absent  Absent  Absent  Absent  
69,67 Caucasian Male 71 Absent  Absent  Absent  Absent  Absent  
69,81 Caucasian Female 46 Absent  Absent  Absent  Absent  Absent  
69,82 Caucasian Male 74 Absent  Absent  Absent  Absent  Absent  
69,84 Caucasian Male 57 Absent  Absent  Absent  Absent  Absent  
69,85 Caucasian Male 46 Absent  Absent  Absent  Absent  Absent  
69,86 Caucasian Male 60 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
70,28 Caucasian Female 62 Absent  Absent  Absent  Absent  Absent  
70,44 Caucasian Male 51 Absent  Absent  Absent  Absent  Absent  
70,45 Caucasian Male 72 Absent  Absent  Absent  Absent  Absent  
70,58 Caucasian Male 82 Absent  Absent  Absent  Absent  Absent  
70,63 Caucasian Female 39 Absent  Absent  Absent  Absent  Absent  
70,64 Caucasian Male 46 Absent  Absent  Absent  Absent  Absent  
70,65 Caucasian Female 47 Absent  Absent  Absent  Absent  Absent  
70,97 Caucasian Male 69 Absent  Absent  Absent  Absent  Absent  
70,99 Caucasian Male 60 Absent  Absent  Absent  Absent  Absent  
71,41 Caucasian Female 34 Absent  Absent  Absent  Absent  Absent  
71,42 Caucasian Female 35 Absent  Absent  Absent  Absent  Absent  
71,43 Caucasian Male 61 Absent  Absent  Absent  Absent  Absent  
71,59 Caucasian Female 56 Absent  Absent  Absent  Absent  Absent  
71,60 Caucasian Female 49 Absent  Absent  Absent  Absent  Absent  
71,79 Caucasian Male 64 Absent  Absent  Absent  Absent  Absent  
71,80 Caucasian Male 56 Absent  Absent  Absent  Absent  Absent  
71,82 Caucasian Female 64 Absent  Absent  Absent  Absent  Absent  
72,43 Caucasian Female 70 Absent  Absent  Absent  Absent  Absent  
72,45 Caucasian Male 62 Absent  Absent  Absent  Absent  Absent  
72,52 Caucasian Female 40 Absent  Absent  Absent  Absent  Absent  
72,53 Caucasian Male 37 Absent  Absent  Absent  Absent  Absent  
72,55 Caucasian Male 50 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
72,57 Caucasian Male 41 Absent  Absent  Absent  Absent  Absent  
72,58 Caucasian Male 38 Absent  Absent  Absent  Absent  Absent  
72,61 Caucasian Male 69 Absent  Absent  Absent  Absent  Absent  
72,98 Caucasian Male 75 Absent  Absent  Absent  Absent  Absent  
73,00 Caucasian Female 33 Absent  Absent  Absent  Absent  Absent  
73,05 Caucasian Male 61 Absent  Absent  Absent  Absent  Absent  
73,08 Caucasian Male 63 Absent  Absent  Absent  Absent  Absent  
73,13 Caucasian Female 50 Absent  Absent  Absent  Absent  Absent  
73,15 Caucasian Female 74 Absent  Absent  Absent  Absent  Absent  
73,16 Caucasian Female 57 Absent  Absent  Absent  Absent  Absent  
73,18 Caucasian Male 67 Absent  Absent  Absent  Absent  Absent  
73,33 Caucasian Male 70 Absent  Absent  Absent  Absent  Absent  
73,35 Caucasian Female 63 Absent  Absent  Absent  Absent  Absent  
73,36 Caucasian Female 53 Absent  Absent  Absent  Absent  Absent  
73,38 Caucasian Female 74 Absent  Absent  Absent  Absent  Absent  
73,42 Caucasian Female 48 Absent  Absent  Absent  Absent  Absent  
73,44 Caucasian Male 51 Absent  Absent  Absent  Absent  Absent  
73,45 Caucasian Female 69 Absent  Absent  Absent  Absent  Absent  
74,14 Caucasian Male 40 Absent  Absent  Absent  Absent  Absent  
74,16 Caucasian Male 58 Absent  Absent  Absent  Absent  Absent  
74,37 Caucasian Female 38 Absent  Absent  Absent  Absent  Absent  
75,68 Caucasian Female 41 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
75,69 Caucasian Male 50 Absent  Absent  Absent  Absent  Absent  
75,71 Caucasian Male 58 Absent  Absent  Absent  Absent  Absent  
75,74 Caucasian Male 64 Absent  Absent  Absent  Absent  Absent  
75,76 Caucasian Female 49 Absent  Absent  Absent  Absent  Absent  
75,78 Caucasian Male 79 Absent  Absent  Absent  Absent  Absent  
75,79 Caucasian Male 64 Absent  Absent  Absent  Absent  Absent  
75,82 Caucasian Male 76 Absent  Absent  Absent  Absent  Absent  
75,85 Caucasian Male 46 Absent  Absent  Absent  Absent  Absent  
76,22 Caucasian Male 41 Absent  Absent  Absent  Absent  Absent  
76,24 Caucasian Male 66 Absent  Absent  Absent  Absent  Absent  
76,25 Caucasian Male 70 Absent  Absent  Absent  Absent  Absent  
77,10 Caucasian Female 50 Absent  Absent  Absent  Absent  Absent  
78,33 Caucasian Male 63 Absent  Absent  Absent  Absent  Absent  
78,35 Caucasian Male 41 Absent  Absent  Absent  Absent  Absent  
78,42 Caucasian Female 29 Absent  Absent  Absent  Absent  Absent  
86,90 Caucasian Male 47 Absent  Absent  Absent  Absent  Absent  
86,97 Caucasian Male 54 Absent  Absent  Absent  Absent  Absent  
86,98 Caucasian Female 49 Absent  Absent  Absent  Absent  Absent  
87,01 Caucasian Female 43 Absent  Absent  Absent  Absent  Absent  
87,04 Caucasian Male 35 Absent  Absent  Absent  Absent  Absent  
87,06 Caucasian Male 59 Absent  Absent  Absent  Absent  Absent  
87,08 Caucasian Female 44 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
87,09 Caucasian Female 62 Absent  Absent  Absent  Absent  Absent  
87,12 Caucasian Male 61 Absent  Absent  Absent  Absent  Absent  
87,16 Caucasian Female 47 Absent  Absent  Absent  Absent  Absent  
87,17 Caucasian Male 59 Absent  Absent  Absent  Absent  Absent  
87,18 Caucasian Male 72 Absent  Absent  Absent  Absent  Absent  
87,20 Caucasian Female 71 Absent  Absent  Absent  Absent  Absent  
87,21 Caucasian Male 46 Absent  Absent  Absent  Absent  Absent  
87,22 Caucasian Male 48 Absent  Absent  Absent  Absent  Absent  
87,23 Caucasian Female 29 Absent  Absent  Absent  Absent  Absent  
50,87 Afrikaner Male 87 Absent  Absent  Absent  Absent  Absent  
51,68 Afrikaner Female 104 Absent  Absent  Absent  Absent  Absent  
52,25 Afrikaner Female 101 Absent  Absent  Absent  Absent  Absent  
52,37 Afrikaner Female 84 Absent  Absent  Absent  Absent  Absent  
52,96 Afrikaner Male 48 Absent  Absent  Absent  Absent  Absent  
52,97 Afrikaner Female 89 Absent  Absent  Absent  Absent  Absent  
52,98 Afrikaner Male 85 Absent  Absent  Absent  Absent  Absent  
52,99 Afrikaner Female 105 Absent  Absent  Absent  Absent  Absent  
53,00 Afrikaner Female 93 Absent  Absent  Absent  Absent  Absent  
53,01 Afrikaner Male 92 Absent  Absent  Absent  Absent  Absent  
53,02 Afrikaner Female 97 Absent  Absent  Absent  Absent  Absent  
53,03 Afrikaner Female 92 Absent  Absent  Absent  Absent  Absent  
53,04 Afrikaner Female 86 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
53,14 Afrikaner Female 93 Absent  Absent  Absent  Absent  Absent  
53,15 Afrikaner Female 87 Absent  Absent  Absent  Absent  Absent  
53,16 Afrikaner Female 91 Absent  Absent  Absent  Absent  Absent  
53,43 Afrikaner Male 58 Absent  Absent  Absent  Absent  Absent  
53,68 Afrikaner Female 92 Absent  Absent  Absent  Absent  Absent  
53,69 Afrikaner Female 89 Absent  Absent  Absent  Absent  Absent  
53,70 Afrikaner Female 92 Absent  Absent  Absent  Absent  Absent  
54,08 Afrikaner Male 64 Absent  Absent  Absent  Absent  Absent  
54,09 Afrikaner Male 92 Absent  Absent  Absent  Absent  Absent  
54,10 Afrikaner Female 97 Absent  Absent  Absent  Absent  Absent  
54,11 Afrikaner Female 86 Absent  Absent  Absent  Absent  Absent  
54,12 Afrikaner Female 90 Absent  Absent  Absent  Absent  Absent  
54,13 Afrikaner Female 89 Absent  Absent  Absent  Absent  Absent  
54,23 Afrikaner Female 86 Absent  Absent  Absent  Absent  Absent  
54,24 Afrikaner Female 91 Absent  Absent  Absent  Absent  Absent  
54,25 Afrikaner Female 87 Absent  Absent  Absent  Absent  Absent  
54,26 Afrikaner Female 100 Absent  Absent  Absent  Absent  Absent  
54,27 Afrikaner Female 104 Absent  Absent  Absent  Absent  Absent  
54,58 Afrikaner Female 94 Absent  Absent  Absent  Absent  Absent  
54,59 Afrikaner Female 95 Absent  Absent  Absent  Absent  Absent  
54,60 Afrikaner Female 92 Absent  Absent  Absent  Absent  Absent  
54,61 Afrikaner Male 88 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
54,64 Afrikaner Female 86 Absent  Absent  Absent  Absent  Absent  
54,65 Afrikaner Male 94 Absent  Absent  Absent  Absent  Absent  
54,66 Afrikaner Female 98 Absent  Absent  Absent  Absent  Absent  
54,67 Afrikaner Female 84 Absent  Absent  Absent  Absent  Absent  
54,68 Afrikaner Male 79 Absent  Absent  Absent  Absent  Absent  
54,69 Afrikaner Female 103 Absent  Absent  Absent  Absent  Absent  
54,70 Afrikaner Female 97 Absent  Absent  Absent  Absent  Absent  
54,71 Afrikaner Female 87 Absent  Absent  Absent  Absent  Absent  
54,72 Afrikaner Female 101 Absent  Absent  Absent  Absent  Absent  
54,80 Afrikaner Female 89 Absent  Absent  Absent  Absent  Absent  
54,81 Afrikaner Female 91 Absent  Absent  Absent  Absent  Absent  
54,82 Afrikaner Female 100 Absent  Absent  Absent  Absent  Absent  
54,83 Afrikaner Female 95 Absent  Absent  Absent  Absent  Absent  
54,84 Afrikaner Female 89 Absent  Absent  Absent  Absent  Absent  
54,85 Afrikaner Female 96 Absent  Absent  Absent  Absent  Absent  
54,87 Afrikaner Female 95 Absent  Absent  Absent  Absent  Absent  
67,89 Afrikaner Male 61 Absent  Absent  Absent  Absent  Absent  
68,69 Afrikaner Male 61 Absent  Absent  Absent  Absent  Absent  
68,70 Afrikaner Male 54 Absent  Absent  Absent  Absent  Absent  
69,18 Afrikaner Female 47 Absent  Absent  Absent  Absent  Absent  
69,19 Afrikaner Male 83 Absent  Absent  Absent  Absent  Absent  
69,20 Afrikaner Male 55 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
69,45 Afrikaner Male 38 Absent  Absent  Absent  Absent  Absent  
69,46 Afrikaner Male 35 Absent  Absent  Absent  Absent  Absent  
69,47 Afrikaner Female 73 Absent  Absent  Absent  Absent  Absent  
70,60 Afrikaner Female 47 Absent  Absent  Absent  Absent  Absent  
70,98 Afrikaner Female 47 Absent  Absent  Absent  Absent  Absent  
71,00 Afrikaner Male 55 Absent  Absent  Absent  Absent  Absent  
71,37 Afrikaner Female 58 Absent  Absent  Absent  Absent  Absent  
71,38 Afrikaner Male 72 Absent  Absent  Absent  Absent  Absent  
71,39 Afrikaner Female 41 Absent  Absent  Absent  Absent  Absent  
71,40 Afrikaner Male 52 Absent  Absent  Absent  Absent  Absent  
71,48 Afrikaner Female 37 Absent  Absent  Absent  Absent  Absent  
71,83 Afrikaner Female 43 Absent  Absent  Absent  Absent  Absent  
72,46 Afrikaner Male 69 Absent  Absent  Absent  Absent  Absent  
72,50 Afrikaner Male 56 Absent  Absent  Absent  Absent  Absent  
73,01 Afrikaner Male 61 Absent  Absent  Absent  Absent  Absent  
73,12 Afrikaner Male 65 Absent  Absent  Absent  Absent  Absent  
73,32 Afrikaner Male 57 Absent  Absent  Absent  Absent  Absent  
73,34 Afrikaner Male 39 Absent  Absent  Absent  Absent  Absent  
73,41 Afrikaner Male 43 Absent  Absent  Absent  Absent  Absent  
73,46 Afrikaner Male 55 Absent  Absent  Absent  Absent  Absent  
74,15 Afrikaner Male 43 Absent  Absent  Absent  Absent  Absent  
74,20 Afrikaner Female 73 Absent  Absent  Absent  Absent  Absent  
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Control Information HRM Screening Result 
Lab 
ID 
Ethnicity Gender 
Age 
in 
2018 
Gene 
CFAP65 
c.A3151G 
RFT1 
c.C1450G 
NRXN2 
c.G3008A 
TEP1 
c.A1276G 
CCNF 
c.G1176C 
74,23 Afrikaner Male 64 Absent  Absent  Absent  Absent  Absent  
74,38 Afrikaner Female 51 Absent  Absent  Absent  Absent  Absent  
75,77 Afrikaner Male 38 Absent  Absent  Absent  Absent  Absent  
75,81 Afrikaner Male 55 Absent  Absent  Absent  Absent  Absent  
76,21 Afrikaner Male 61 Absent  Absent  Absent  Absent  Absent  
76,26 Afrikaner Male 68 Absent  Absent  Absent  Absent  Absent  
77,12 Afrikaner Male 61 Absent  Absent  Absent  Absent  Absent  
77,39 Afrikaner Female 73 Absent  Absent  Absent  Absent  Absent  
77,40 Afrikaner Male 59 Absent  Absent  Absent  Absent  Absent  
78,30 Afrikaner Male 28 Absent  Absent  Absent  Absent  Absent  
78,34 Afrikaner Male 52 Absent  Absent  Absent  Absent  Absent  
78,40 Afrikaner Male 34 Absent  Absent  Absent  Absent  Absent  
86,89 Afrikaner Male 68 Absent  Absent  Absent  Absent  Absent  
86,92 Afrikaner Male 54 Absent  Absent  Absent  Absent  Absent  
86,95 Afrikaner Male 28 Absent  Absent  Absent  Absent  Absent  
86,99 Afrikaner Female 30 Absent  Absent  Absent  Absent  Absent  
87,03 Afrikaner Female 43 Absent  Absent  Absent  Absent  Absent  
Absent, Sanger sequence verified HRM result. 
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2. Appendix II 
2. Supplementary Figures 
Figure 1 Full pedigree of family ZA253. Circles denote females and squares depict males. The filled in symbols indicate affected individuals. The intersecting 
diagonal lines indicate that the person is deceased. The numbers below each individual is the laboratory ID number. For readability and confidentiality, the 
pedigree is greatly simplified. Branches without medically confirmed PD or without DNA samples were omitted. AAO, Age at onset, the black arrow shows 
the proband.  
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Figure 2 Ethics certificate. The researcher was granted ethical approval and permission to conduct this study by the Health Research Ethics Committee 
(Stellenbosch University). 
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